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Abstract 
Joanna R. Thomas; Exploring integrin and growth factor receptor crosstalk mechanisms. 
The pro-invasive integrin αvβ6 is upregulated in a range of carcinomas, from normally very 
low levels, and is associated with poor prognosis. Therapeutic targeting of αvβ6 with 
inhibitory antibodies has produced promising results in breast cancer models in vivo. 
Preclinical evidence has suggested that αvβ6 and EGFR expression correlate in disease, and 
that a co-operative relationship between αvβ6 and EGFR may exist in vivo. This study aimed 
to determine if αvβ6 and EGFR are functionally integrated, and to investigate wider 
mechanisms of integrin and growth factor receptor crosstalk.  
Immunofluorescent imaging, under steady-state conditions, demonstrated co-localisation 
between αvβ6 and EGFR in MDA-MB-468 cells in protrusive structures and endosomes. In 
addition, imaging and integrin-associated complex (IAC) enrichment approaches revealed 
that EGFR was recruited to sites of αvβ6 engagement on the αvβ6-selective ligand, latency-
associated peptide (LAP). Importantly, reciprocal EGF or LAP stimulation increased EGFR 
and αvβ6 co-localisation with early endosomes, indicative of co-internalisation. Together, 
these data suggest a co-regulatory relationship between αvβ6 integrin and EGFR that 
impacts receptor trafficking mechanisms. Stimulation with LAP caused the phosphorylation 
of ERK, indicating αvβ6 positively regulates MAPK pathway signalling, and that signalling 
crosstalk may also exist between αvβ6 and EGFR. 
Bioinformatic interrogation of αvβ6-IACs revealed αvβ6-medated adhesions are conducive 
sites of EGFR signalling. The identification of proteins associated with endocytosis and 
receptor trafficking highlighted liprin α1 as an important potential mediator of αvβ6 and 
EGFR crosstalk. The over-representation of Hippo pathway regulators at αvβ6-IACs led to 
on-going work that has identified αvβ6 as a regulator of YAP nuclear localisation and 
suggests that αvβ6-EGFR crosstalk is a determinant of this function.  
Proteomic analysis of EGF regulated IAC components led to the identification of the adaptor 
protein Eps8 as a novel mediator of integrin and EGFR crosstalk. Eps8 functions to constrain 
endocytosis of α5β1 and EGFR and is required for adhesion organisation. These functions 
have direct consequences for adhesion and cytoskeletal dynamics. 
On-going analysis of candidates identified from αvβ6-IAC proteomics will elucidate how 
αvβ6 and EGFR signalling networks and trafficking are integrated. In the future we aim to 
determine how these mechanisms contribute to αvβ6-dependent breast cancer cell 
invasion, and how αvβ6-EGFR receptor crosstalk understanding may contribute to the 
success of αvβ6-targeted therapeutics.  
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1. Introduction 
This thesis project studies mechanisms of crosstalk between integrins and growth factor 
receptors (GFRs). Receptor crosstalk can impact the function of both receptor families and 
must be fully understood to aid the development of targeted therapies, as unanticipated 
crosstalk mechanisms can hinder therapeutic efficacy. To put this into context, the canonical 
functions of the receptor families, modes by which they are regulated, and current targeted 
therapeutics are outlined. Known mechanisms of crosstalk between integrins and growth 
factor receptors are discussed. Particular focus has been given to the pro-invasive integrin 
αVβ6 and the ErbB family GFR EGFR in the context of triple-negative breast cancer (TNBC), 
as these receptors and their crosstalk represents novel and clinically relevant targets for the 
TNBC sub-type of breast cancer which currently has no targeted therapies (Andreopoulou et 
al., 2017). 
1.1 Extracellular Matrix 
Integrins are the main extracellular matrix (ECM) engaging surface receptors and function to 
integrate signals between cells and their microenvironment (Hynes, 2014). The ECM is the 
non-cellular component of tissues and organs that, in addition to physical support, can also 
regulate the behaviour of cells within, through biochemical and biophysical cues. The 
properties of the ECM can vary greatly between tissues (e.g. calcified bone vs the cornea) 
dependent on function, and in different physiological states (e.g. fibrotic or cancerous) 
(Frantz et al., 2010). The ECM is secreted and locally assembled primarily by fibroblasts. The 
three major classes of macromolecules that comprise the ECM are glycosaminoglycan (GAG)-
associated proteoglycans, fibrous proteins and glycoproteins (Frantz et al., 2010).  
GAGs and proteoglycans are strongly hydrophilic and adopt highly extended conformations. 
Consequently they form hydrogels that occupy a large volume relative to their mass, and are 
able to withstand compressive forces (Schaefer and Schaefer, 2010). Collagens are the major 
family of fibrous proteins, that constitute the main structural integrity of the ECM. Collagens 
can assemble into collagen fibrils, which often aggregate forming fibres that resist tensile 
force (Rozario and DeSimone, 2010). Inelastic collagen fibrils can be associated with elastin-
rich elastic fibres to limit the extent of stretching, preventing tearing of elastic tissues (Frantz 
et al., 2010). Glycoproteins such as fibronectin (FN) and laminins typically contain multiple 
domains with binding sites for ECM macromolecules and cell surface receptors (Frantz et al., 
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2010). These proteins are therefore able to contribute to the organisation of the ECM, 
cellular signalling and mechanochemical stimuli. 
The ECM is dynamic, constantly being synthesised, remodelled and degraded. Some self-
assembly of ECM fibrils can occur in vitro, however cell driven organisation of fibrils is the 
predominant mechanism (Humphrey et al., 2014; Hynes, 2014). The ability of cells to apply 
force to ECM macromolecules via ECM binding receptors linked to the actin cytoskeleton is 
crucial to this process (Wolanska and Morgan, 2015). Force application to ECM proteins, such 
as FN, can cause conformational changes revealing cryptic binding sites (Smith et al., 2007; 
Vogel, 2006). Fibres within the ECM may also be cross-linked by enzymes such as Lysyl 
oxidase (LOX) and transglutaminase 2, resulting in matrix stiffening (Griffin et al., 2002; 
Levental et al., 2009). Proteolytic degradation of ECM is primarily mediated by matrix 
metalloproteinases (MMPs) and serine proteases (Frantz et al., 2010). 
The ECM binds a range of growth factors, essentially acting as a reservoir, with a role in 
establishing stable gradients. Growth factors can function as soluble ligands released as a 
consequence of ECM degradation, or as bound ligands with proteoglycan involvement as a 
co-factor (Hynes, 2009). Many ECM proteins also contain domains that can act as ligands for 
growth factor receptors (GFRs), allowing the establishment of concentration gradients. 
Consequently, GFRs and ECM receptors in the cell plasma membrane can be bound 
simultaneously, to spatially localise and constrain initiation of multiple signalling mechanisms 
(Hynes, 2009).  
1.2 Integrin Family 
Cellular binding to the ECM is mediated primarily by the integrin family of receptors. 
Additional ECM binding receptors include the syndecan family of membrane spanning 
proteoglycans that can bind a wide range of ligands, and the discoidin domain receptor family 
of receptor tyrosine kinases (RTKs) that bind collagens (Couchman et al., 2001; Valiathan et 
al., 2012). All metazoan express at least one β and two α integrin subunits (Whittaker and 
Hynes, 2002). Evolutionary expansion of the family has produced the complete mammalian 
set of integrins comprised of 8 β- and 18 α-subunits that are known to assemble into 24 
distinct heterodimers (Figure 1.1) (Hynes, 2002). The family is further diversified by 
alternative spicing variants and post-translational modifications that may affect ligand 
binding (van der Flier and Sonnenberg, 2001). Integrin α- and β-subunits associate non-
covalently, and both span the plasma membrane with small intracellular C-terminal 
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cytoplasmic domains, and large extracellular N-terminal extracellular domains (Alberts et al., 
2015). 
Integrin heterodimers have specific non-redundant functions, as evidenced by their distinct 
knock-out mouse phenotypes, ranging from a block in pre-implantation development (β1 
knock-out) (Fassler and Meyer, 1995), to different developmental defects and post-natal 
phenotypes (Hynes, 2002). Ligand specificity is mediated by both the α- and β-subunits, 
contributing to an array of binding capabilities and affinities. Integrin binding to ECM 
macromolecules is normally mediated by a short motif, such as the Arg-Gly-Asp (RGD) motif 
(Hynes, 2002), that interacts with a divalent-cation-binding site within the integrin 
(Humphries et al., 2003b). Integrin heterodimers can be subcategorised by their structure 
and ligand binding profiles (Figure 1.1). The two most evolutionarily ancient sub-categories 
are the RGD-binding and laminin-binding integrins. The insertion of an A-domain in the α-
subunit created a collagen binding subgroup. α4β1 and α9β1 recognise an acidic Leu-Asp-Val 
(LDV) motif that is related to the RGD motif (Hynes, 2002). Vertebrates also express leukocyte 
specific integrins (αL, αM, αX, and αD that dimerise with β2, and αEβ7) that mediate cell-cell 
adhesion through immunoglobulin family cell surface receptors, such as ICAM (intercellular 
adhesion molecule) (Hynes, 2002).  
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Figure 1.1 The integrin receptor family. Heterodimers formed by integrin α- and β-subunits, omitting 
the leukocyte-specific β2, β7, αL, αM, αX, and αD (Hynes, 2002). Subfamilies based on ligand 
specificities are depicted (colouring of α-subunits). All five αV heterodimers, α5β1, α8β1, and αIIbβ3 
recognise the RGD tripeptide sequence (purple) in ligands such as fibronectin and vitronectin. α4β1 
and α9β1 recognise an acidic LDV motif (blue) that is functionally related to the RGD motif. α1, α2, 
α10 and α11 that pair with β1 contain an inserted A domain, forming a subfamily that can bind 
collagens and laminins (yellow). α3, α6 and α7 paired with β1, and α6β4 selectively bind laminins 
(green), however do not contain an A domain in the α-subunits. β-subunits with grey hatching can 
bind latency associated peptide (LAP) when paired with αV. The ligands fibronectin, LAP-TGFβ, 
collagen and laminin are depicted proximal to the integrins that they are engaged by (Humphries et 
al., 2006). 
1.2.1 Integrin Structure 
Integrins have large extracellular domains (>1,600 amino acids) and typically short 
cytoplasmic domains (20 – 50 amino acids) (Hynes, 2002) (Figure 1.2). The β4 subunit is a 
notable exception to this, as its cytoplasmic domain is larger (~1,000 amino acids), allowing 
it to connect to intermediate filaments instead of actin, as is the case for all other integrin β-
subunits  (Hynes, 2002). The first crystal structure of an integrin dimer was reported for the 
extracellular region of αVβ3 in (Xiong et al., 2001), followed by the structure in complex with 
an RGD ligand (Xiong et al., 2002). 
The extracellular domain contains a head, followed by the leg domain of each subunit, single 
pass transmembrane helices, ending a cytoplasmic domain (Figure 1.2). The major ligand 
binding site is formed by contact between the α-subunit β propeller, the β subunit A-domain, 
and the α-subunit A-domain if present (Humphries et al., 2003b). The A-domain contains a 
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metal ion-dependent adhesion site (MIDAS) site that binds cations and is responsible for the 
cation dependency of integrin ligand binding (Humphries et al., 2003a). 
 
 
Figure 1.2 Integrin structure and conformation. Integrin heterodimers are formed from an α (red) and 
a β subunit (blue). The α-subunit has a β propeller domain comprised of seven blades, followed by 
three β-sandwich domains termed thigh, calf-1 and calf-2 domains (Campbell and Humphries, 2011).  
If present, the αA domain is inserted between β propeller blades. The β-subunit head domain contains 
a βA-domain and hybrid domain, followed by a leg with a plexin-semaphorin-integrin (PSI) domain, 
followed by 4 EGF repeats and a β-tail domain. The head region is the primary site for ligand binding. 
The membrane-proximal regions of the cytoplasmic domains of both subunits contains an α helix. The 
C-terminal residues of the α-subunit cytoplasmic domain loop back to contact the membrane-proximal 
region. The terminal residues of the β-subunit cytoplasmic domain are disorganised and contain a 
NPxY motif responsible for interacting with talin (Travis et al., 2003).  Integrins can broadly form three 
different structures, a bent-closed with low ligand affinity, extended-closed primed structure with low 
ligand affinity, and an extended-open conformation with separated leg and cytoplasmic domains, 
which is active and has a high affinity for ligands (Askari et al., 2009). 
The α-subunit cytoplasmic domain has three β-sandwiches, termed thigh, calf-1 and calf-2 
domains. A flexible region between the thigh and calf-1 is termed the knee, which can adopt 
a 135° bend (Humphries et al., 2003a). The β-subunit has a ‘hybrid’ domain in the head 
region, that can move to promote a conformational changes that create high affinity binding 
sites in the integrin head and cytoplasmic regions (Liddington, 2014). The β-subunit leg 
domain contains a plexin-semaphorin-integrin (PSI) domain, four epidermal growth factor 
(EGF)-like repeats and a β-tail domain with a cystatin-like fold (Humphries et al., 2003a). 
The first 10 amino acids of the α- and 20 amino acids of the β-subunit cytoplasmic regions 
form α-helices. The remaining C-terminal residues of the α-subunit loop back to contact the 
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membrane-proximal region of its cytoplasmic domain. The final residues of the β-subunit 
cytoplasmic domain are disordered and contain a NPxY motif that mediates binding to talin 
via its four-point-one, ezrin, radixin, moesin (FERM) domain. The degree of conservation 
between β cytoplasmic domains is higher than between α-subunits, leading to the theory 
that the β-subunit is the principal binding site for cytoplasmic interactors, and the α-subunit 
may have a more regulatory role (Humphries et al., 2003a). 
1.3 Regulation of Integrins 
Integrin activity is tightly regulated for the spatial and temporal control of adhesion 
formation and detachment, which is essential to processes such as cell migration and 
vascular extravasation of leukocytes. Integrin structural conformation can be separated into 
three states; an inactive bent low ligand affinity conformation with inhibitory contact 
between the cytoplasmic domains, a primed extended low affinity conformation, and an 
active high affinity conformation with separated legs and cytoplasmic domains (Figure 1.2) 
(Liddington, 2014). Integrins exist in an equilibrium between these three states, that can be 
influenced to favour either direction (Pouwels et al., 2012). Cytoplasmic domain truncated 
mutants result in a constitutively high affinity state integrin, highlighting the important 
regulatory role of the cytoplasmic domains (Mehta et al., 1998). The inactive bent state of 
integrins is maintained by non-covalent interactions between α- and β-subunits in the 
transmembrane and cytoplasmic domains (Shattil et al., 2010). A salt bridge is formed 
between the membrane-proximal cytoplasmic domains of α- and β-subunits, which if 
disrupted results in integrin activation (Hughes et al., 1996). A conserved GFFKR motif within 
the α-subunit cytoplasmic domain is required for the formation of the salt bridge, and 
therefore for maintaining the inactive integrin conformation (O'Toole et al., 1991). 
1.3.1 Positive Regulation 
The extracellular microenvironment critically influences integrin activity. Integrin binding is 
affected by the extracellular concentration of Ca2+ and Mg2+, due to the MIDAS divalent 
cation binding domains in integrins. Divalent cations can affect the affinity and specificity of 
integrin ligand binding (Humphries et al., 2003a). Binding to extracellular multi-valent  ligands 
triggers the clustering of integrins, which increases their ligand avidity (Shattil et al., 2010). 
ECM rigidity is important for the response to intracellular force applied to integrins by 
actomyosin-dependent contractility, which increases binding strength (Friedland et al., 2009; 
Kong et al., 2009). 
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Talin binding to the integrin β cytoplasmic domain is a crucial step in integrin activation. The 
head domain of talin binds via its FERM domain to the NPxY motif of the β cytoplasmic 
domain, whilst the talin rod domain has multiple actin-binding sites. Talin exists in an 
autoinhibited conformation, which must be released to allow integrin binding (Moser et al., 
2009). Talin binding to the β-cytoplasmic domain disrupts the salt bridge connecting the 
cytoplasmic α- and β-subunits, resulting in a change in position of the β transmembrane helix, 
consequently activating the integrin by separating the cytoplasmic domains (Figure 1.2) 
(Banno and Ginsberg, 2008). The small guanosine triphosphatase (GTPase) Rap1 and its 
adaptor Rap1 GTP–interacting adaptor molecule (RIAM) are drive recruitment of talin to 
integrin β-subunit cytoplasmic domains (Lee et al., 2009). Kindlin is able to bind the integrin 
β-subunit cytoplasmic domain at sites distinct from talin, and functions to co-activate 
integrins potentially in a subunit specific manner (Ye et al., 2014). 
1.3.2 Negative Regulation 
Interference of talin or kindlin binding to the β cytoplasmic domain is a major inhibitory 
mechanism. Proteins containing a phosphotyrosine-binding (PTB) domain, such as tensins 1 
– 4,  bind to the NPxY motif and compete with talin  (Pouwels et al., 2012). Phosphorylation 
of the NPxY motif is required for PTB domain binding (Forman-Kay and Pawson, 1999), and 
inhibits talin binding (Anthis et al., 2009). Integrin cytoplasmic domain-associated protein-1 
(ICAP-1) also competes with talin binding, however does not require tyrosine 
phosphorylation of the NPxY motif for its interaction (Bouvard et al., 2003). Filamins also 
inhibit talin binding, by engaging with a filamin binding site that overlaps with the talin 
binding site on the β cytoplasmic domain (Kiema et al., 2006). 
Integrin α-subunit cytoplasmic domain binding negative regulators of integrin activity can 
bind to a conserved membrane-proximal region, or to poorly conserved membrane distal 
regions with potential to regulate integrin activity in a heterodimer specific manner (Pouwels 
et al., 2012). SHARPIN (SHANK associated RH domain interactor) binds the conserved 
WKxGFFKR motif in the α-subunit and has been shown to inhibit β1 activity by inhibiting talin 
and kindlin binding to the β-subunit (Rantala et al., 2011). Mammary-derived growth 
inhibitor (MDGI) binds several α-subunits and inhibits integrin activity in breast cancer cells, 
most likely by reducing the association between active β1 and kindlin (Nevo et al., 2010). The 
existence of negative regulators of integrin activity that exhibit specificity for specific α-
subunits is less clear (Pouwels et al., 2012).  
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In addition to direct integrin binding, integrin activity can be regulation by sequestration of 
integrin regulators. For example, the actin cytoskeletal regulators SHANK 1 (SH3 and multiple 
ankyrin repeat domains) and SHANK 3 indirectly inhibit integrins by sequestering integrin 
activators (Atherton and Ballestrem, 2017). SHANK interacts with active GTP-bound Rap1, 
and sequesters it limiting its bioavailability for activating integrins at the plasma membrane 
(Lilja et al., 2017). 
1.3.3 Integrin Trafficking 
The control of integrin bioavailability at the plasma membrane is key to regulating their 
function. Integrins are internalised in a constitutive and often ligand-independent manner 
via clathrin-dependent or clathrin-independent endocytosis (Bridgewater et al., 2012). 
Recruitment of endocytic regulators to integrins can influence and drive internalisation 
(Bridgewater et al., 2012). Cargo usually associates with clathrin-coated structures via an 
adaptor protein. HCLS-1-associated protein X1 (HAX1) is involved in clathrin-mediated 
endocytosis, and directly binds the cytoplasmic domain of β6 integrin. The interaction 
between HAX1 and β6 is essential for the clathrin-mediated endocytosis ofαVβ6 (Ramsay et 
al., 2007). The binding of protein kinase C α (PKCα) to β1 via the NPxY motif promotes 
caveolin dependent internalisation of β1 (Ng et al., 1999; Parsons et al., 2002). Active and 
inactive integrins can be trafficked differentially (Arjonen et al., 2012). One example of this 
is that efficient internalisation of active α5β1 requires the transmembrane glycoprotein 
neuropillin-1 (Nrp1), whereas inactive α5β1 internalisation is unaffected by Nrp1 silencing 
(Valdembri et al., 2009). Recruitment factors can also bind the α-subunit mediating 
heterodimer specific trafficking, for example p120RasGAP (RASA1) is able to bind α 
cytoplasmic domains, compete with Rab21 binding, facilitating integrin recycling (Mai et al., 
2011). 
Integrins rapidly traffic to early endosomes, where cargos are sorted either for degradation 
or recycling back to the plasma membrane (Figure 1.3) (Caswell and Norman, 2006; Sorkin 
and von Zastrow, 2009). Degradation of integrins is influenced by their level of ubiquitination 
(Caswell et al., 2009), however integrins can be retrieved from lysosomal degradation 
pathways by sorting nexin SNX17, and subsequently recycled (Steinberg et al., 2012).  
Proteins that predominantly localise to specific trafficking compartments can be used to 
identify different endosomal sub-types such as EEA1 (early endosomal antigen 1) which is 
present on early endosomes, HRS (hepatocyte growth factor-regulated tyrosine kinase 
substrate) which is a component of ESCRT that localises predominantly to the MVB, and 
LAMP2 (lysosome-associated membrane protein 2) which is present on lysosomes (Figure 
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1.3) (Braulke and Bonifacino, 2009; Goh and Sorkin, 2013). These markers will be utilised to 
investigate receptor trafficking in this thesis.  
The majority of integrins are sorted for recycling (Bretscher, 1989; Bretscher, 1992), either 
through a fast ‘short-loop’ or slow ‘long-loop’ pathway (Figure 1.3) (Bridgewater et al., 2012). 
The short-loop pathway recycles cargo from early endosomes, and is controlled by Rab4 and 
Rab35 (Grant and Donaldson, 2009). The long-loop pathway recycles cargo that have 
transited from early endosomes to the perinuclear recycling compartment and is Rab11 
and/or Arf6 (Figure 1.3) (ADP-ribosylation factor 6) dependent (Grant and Donaldson, 2009; 
Stenmark, 2009). The rate of integrin recycling can be affected by switching between the 
pathways. Stimulation with platelet derived growth factor (PDGF) switches αVβ3 from the 
long-loop Rab11 dependent recycling pathway, to the short-loop Rab4 dependent pathway 
(Roberts et al., 2001). 
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Figure 1.3 Integrin trafficking. Integrins can be endocytosed via clathrin-dependent (shown) and 
clathrin-independent routes, and traffic to the early endosome (EE). Integrins are predominantly 
recycled rather than degraded (De Franceschi et al., 2015). Integrin recycling is broadly associated with 
a fast short-loop pathway from the EE which is dependent on Rab4 and Rab35, or a slower long-loop 
pathway from the perinuclear recycling compartment (PNRC) which is dependent on Rab11 and Arf6 
(Bridgewater et al., 2012). Integrins trafficked to the late endosome (LE) or lysosome can also be 
recycled, and the ECM ligand is degraded. This process has been shown to be mediated by CLIC3 for 
α5β1 (Dozynkiewicz et al., 2012). 
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1.4 Integrin Function 
1.4.1 Bidirectional Signalling 
Integrins are so named for their ability to ‘integrate’ signals from the extracellular and 
intracellular environments. Central to this is their ability to transduce signals from the ECM 
to the cell, termed ‘outside-in signalling’, and the converse transmission of signals from the 
cell to the ECM termed ‘inside-out signalling’. ‘Outside-in’ signalling relies on ligand binding 
by the integrin extracellular head domain, to induce conformational changes that propagate 
down the structure and induce reorganisation of the cytoplasmic domains (Figure 1.2). The 
reverse is true for ‘inside-out’ signalling whereby cytosolic proteins alter the cytoplasmic 
regions to induce conformational changes in the extracellular domain of the integrin that 
affect ligand binding capabilities (Liddington, 2014). Outside-in signalling results in the 
dynamic recruitment of cytosolic proteins to integrin adhesions, that relay diverse 
intracellular signals mediating core processes such as cell survival, proliferation, spreading 
and migration (Harburger and Calderwood, 2009). Integrins lack intrinsic enzymatic activity 
and therefore initiate signalling through the dynamic recruitment of signalling moieties 
(Caswell et al., 2009). Inside-out signalling is able to modulate adhesion strength, transmit 
force required for cell migration and influence ECM assembly and remodelling (Shattil et al., 
2010). 
1.4.2 Mechanotransduction 
A key feature of integrin adhesions is their ability to sense mechanical force externally from 
the ECM, or internally from actomyosin contractility and respond with biochemical signals. 
The cytoplasmic domains of integrins do not contain actin-binding sites, therefore they are 
linked via proteins such as talin and vinculin to the actin cytoskeleton and its associated 
actomyosin contractility (Sun et al., 2016).  Integrin mechanotransduction is essential for the 
mechanical homeostasis of the ECM to maintain tissue structural integrity (Humphrey et al., 
2014). The ability of cells to generate traction forces is also essential for membrane 
protrusions and cell migration.  
Polymerisation of actin filaments perpendicular to the plasma membrane can cause 
distention and protrusion formation. In a situation where the actin cytoskeleton is not 
coupled to integrin adhesions, the polymerising end of the actin filament cannot distend the 
plasma membrane, and instead results in actin retrograde flow, where the actin filament is 
pushed backwards towards the cell body with the addition of new monomers (Sun et al., 
2016). When filamentous actin (F-actin) is linked to integrin adhesions, actin polymerisation 
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and actomyosin contractility can be converted into traction forces, which push the plasma 
membrane forward and apply force to the ECM (Sun et al., 2016). 
Integrin-mediated adhesion to the ECM is required for the generation of traction force, and 
the bond strength between integrins and ligands is regulated by force (Kong et al., 2009). The 
interaction is an example of a force-stabilised ‘catch bond’, where the application of force 
allosterically activates protein-protein interactions resulting in increased bond lifetime (Sun 
et al., 2016). Repeated cycles of force application and release was shown to strengthen the 
bond between α5β1 and FN, using atomic force microscopy (AFM) and a biomembrane force 
probe (BFP) (Kong et al., 2013).  
Proteins recruited to integrin-mediated adhesions can be regulated by mechanical force. 
Talin is a mechanosensitive protein, which undergoes force-dependent conformational 
changes (Jansen et al., 2017). Cytoplasmic talin is present in an inactive autoinhibited 
conformation, that can be relieved by Kank2 or RIAM binding (Sun et al., 2016). Actomyosin 
contractility is able to stretch talin that is simultaneously bound to integrins and actin (Sun 
et al., 2016). The talin rod domain contains 13 subunits (R1-13) which can be unfolded 
through application of force, with differential kinetics (Yao et al., 2016). The R3 domain is the 
most mechanically weak and is therefore considered to be the first mechanosensor. 
Unfolding of talin disrupts binding sites for proteins that bind its folded form and exposes 
new cryptic binding sites for proteins such as vinculin. The number of exposed vinculin 
binding sites increases with talin stretch, consequently increasing vinculin binding (Yao et al., 
2016). Vinculin binds talin and F-actin, strengthening the linkage and further recruiting F-
actin, thus re-enforcing coupling of the integrin-mediated adhesion to the cytoskeleton (Sun 
et al., 2016). Talin and vinculin are able to mediate the recruitment of other proteins at 
integrin adhesions depending on their activation states and structures (Jansen et al., 2017). 
Proteins involved in integrin adhesion signalling and actin regulation can be differentially 
recruited and activated in a force-dependent manner, demonstrated collectively through a 
meta-analysis of adhesion enriched mass spectrometry (MS) datasets sensitive to the myosin 
II inhibitor blebbistatin (Horton et al., 2016a). Focal adhesion kinase (FAK) and paxillin can 
both be phosphorylated in response to mechanical stimuli (Jansen et al., 2017). FAK-null 
fibroblasts have impaired migration and lose the ability to migrate preferentially towards 
stiffer substrates in a mechanosensitive process termed ‘durotaxis’ (Wang et al., 2001). 
Paxillin phosphorylation status is also important in durotaxis, and may be involved in vinculin 
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recruitment (Plotnikov et al., 2012). Mechano-regulated proteins recruited to integrin-
mediated adhesions are required for mediating downstream responses to mechanical force.  
Sensation of force at adhesions can result in transcriptional changes. Stem cell differentiation 
is influenced by ECM rigidity, demonstrated by mesenchymal stem cells cultured on soft 
substrates differentiating towards neurogenic lineages, intermediate substrates producing 
myogenic linages, and stiff substrates inducing osteoid phenotypes (Engler et al., 2006). YAP 
(Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif) were 
identified as key force sensitive transcription factors, that translocate to the nucleus in 
response to ECM stiffness (Dupont et al., 2011). Mechanical force application at integrin-
mediated adhesions is therefore important in regulating the function and composition of 
adhesions and can mediate long-term transcriptional changes that impact on cellular 
function and differentiation.  
1.5 Adhesion Dynamics 
Integrin-mediated adhesions are traditionally thought to exist in three major forms (nascent, 
focal and fibrillar adhesions) that develop sequentially and can co-exist simultaneously in the 
same cell. Nascent adhesions are initial contacts formed in lamellipodial protrusions. They 
consist of a small number of integrins, and are independent of myosin contractility 
(Wolfenson et al., 2013). Integrins are activated and cluster in nascent adhesions. Integrin 
clustering can be positively regulated by multi-valent ECM ligands, intracellular adhesion 
components, and the glycocalyx (Iwamoto and Calderwood, 2015; Paszek et al., 2014). 
Nascent adhesions can progress to form adhesion complexes, through actomyosin 
contractility strengthening the adhesions and recruiting cytosolic proteins to adhesion sites 
(Wolfenson et al., 2013). 
Nascent adhesions can either disassemble or mature to form focal adhesions in a force-
dependent process. The transition involves reinforcement with increased mechanical force 
and the formation of anchored actomyosin-containing stress fibres (Byron et al., 2010). Focal 
adhesions have a longer lifetime than nascent (~20 minutes compared to ~1 minute), and are 
key in supporting forward protrusions (Wolfenson et al., 2013). Controlled assembly and 
disassembly of focal adhesions is required for coordinated cell migration. Focal adhesions are 
disassembled predominantly at the rear of the migrating cell, primarily by microtubule-
mediated destabilisation (Kaverina et al., 1999; Wolfenson et al., 2013). 
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Focal adhesions can mature into fibrillar adhesions, that are more elongated and located 
centrally in the cell (Wolanska and Morgan, 2015). Fibrillar adhesions are the main sites of 
fibronectin deposition and fibrillogenesis (Byron et al., 2010). The formation of fibrillar 
adhesions is actomyosin force-dependent, however the maintenance of fibrillar adhesions is 
less sensitive to force than focal adhesions (Wolfenson et al., 2013). 
The coordination of adhesion formation and turnover is tightly regulated and intrinsically 
related to mechanical force. The Rho GTPases are central to the regulation of actin 
polymerisation and generation of intracellular contractility and force (Byron et al., 2010).  
Rac1 (Rac family small GTPase 1) and Cdc42 (cell division cycle 42) promote the formation of 
focal complexes, whereas RhoA is implicated in maturation into focal adhesions. RhoA 
promotes myosin activity through myosin light chain phosphorylation via Rho-associated 
Kinase (ROCK) and induces the formation of bundled actin stress fibres (Byron et al., 2010; 
Wolfenson et al., 2013). RhoA is also involved in generating fibrillar adhesions, by promoting 
the translocation of ligated α5β1 integrin (Pankov et al., 2000). The regulation of integrin-
mediated adhesion formation and maturation is required for the control of adhesion-related 
functions such as coordinated cell migration and ECM production and remodelling. 
1.5.1 The Adhesome 
Integrin adhesions recruit large associated cytosolic multiprotein complexes, termed the 
integrin ‘adhesome’. Advances in adhesion isolation techniques and proteomics have 
enabled the unbiased identification of thousands of associated proteins, compared with 
previous literature-curated databases estimating over 200 (Winograd-Katz et al., 2014). 3D 
super-resolution microscopy demonstrates the adhesome is a stratified and highly organised 
structure (Kanchanawong et al., 2010).  The adhesome can be categorised into three 
functionally distinct layers: a membrane-proximal integrin signalling layer containing integrin 
cytoplasmic domains, FAK and paxillin; an intermediate force transduction layer of 
predominantly talin and vinculin; and a distal actin regulatory layer composed of zyxin, VASP 
(vasodilator-stimulated phosphoprotein) and α-actinin. Talin spans all three layers in a highly 
polarised orientation, with its head domain bound to integrin cytoplasmic domains, and the 
tail spanning to actin and overlapping with actin regulatory layer components 
(Kanchanawong et al., 2010).  
The integrated proteomic analysis of seven adhesome proteomic datasets generated a 2,412 
protein meta-adhesome (Horton et al., 2015a). The datasets were generated by different 
laboratories with varying methods and a range of cells, using the ligand fibronectin. A core 
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‘consensus’ adhesome of 60 proteins identified in at least five of the datasets was produced, 
which broadly clustered into four theoretical protein-protein interaction axes comprising α-
actinin, zyxin and VASP; talin and vinculin; FAK and paxillin; and integrin-linked kinase (ILK) 
and kindlin. 29 of the 60 consensus proteins were not present in the literature-curated 
adhesome, and had varying degrees of known protein interactions with canonical adhesome 
components (Horton et al., 2015a). 
Temporal changes in adhesome composition were examined during adhesion assembly and 
disassembly, which supported the theory of a hierarchical distribution of components 
(Horton et al., 2015a). Integrins remained most stable compared to other proteins at the 
adhesion site throughout disassembly, and integrin-actin links were also disrupted late in the 
disassembly process. Adaptor proteins were lost earlier and faster in disassembly, indicating 
they may be primary targets for the initiation of this process. Components displayed different 
kinetics in adhesion assembly and disassembly, indicating that these processes are 
differentially regulated and not reciprocal (Horton et al., 2015a). Myosin II dependent 
adhesomes were highly enriched in LIM (Lin-11, Isl1, and Mec-3) domain containing proteins 
(Horton et al., 2016a; Horton et al., 2015a), demonstrating their force dependency as LIM 
domains are biosensors of mechanical tension (Schiller et al., 2011). 
Integrin adhesions are highly dynamic and exhibit constant turnover, enabling rapid and 
sensitive responses to external cues (Wolfenson et al., 2013). In addition to varying adhesion 
composition, protein interactions can be modulated in response to adhesion turnover. 
Differing interaction combinations can greatly influence the composition of the adhesome, 
particularly if centred on a core component. Conformational changes can produce open 
active or closed inactive protein forms, that if force regulated can have roles in 
mechanosensation (Zaidel-Bar and Geiger, 2010). Adhesion components can also be highly 
phosphorylated, which may create docking sites for interacting proteins or illicit a 
conformational change (Zaidel-Bar and Geiger, 2010). Rho GTPases at adhesions are 
activated by guanine nucleotide exchange factors (GEFs) and inactivated by GTPase-
activating proteins (GAPs), and primarily alter adhesion composition indirectly through actin 
cytoskeleton regulation (Zaidel-Bar and Geiger, 2010). 
Whilst proteomic approaches have greatly advanced the understanding of the complexity of 
integrin adhesions, many questions remain. The composition of adhesions on different 
ligands, engaging different integrin heterodimers, and in different cell types remains to be 
elucidated (Horton et al., 2015a). Analysis of adhesions on cells in more complex 
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microenvironments such as cell-derived ECM matrices and pliable 3D substrates will also be 
key to informing knowledge of adhesome components that may be functional in vivo. 
1.6 Integrins in Cancer 
Integrin-mediated regulation of biological processes such as proliferation, gene expression, 
cell survival and cell motility are exploited by tumour cells to promote cancer progression 
and invasion (Hamidi et al., 2016). Expression of integrins αVβ3, α5β1, αVβ5, α6β4, αVβ1 and 
αVβ6 correlate with tumour progression of various types (Desgrosellier and Cheresh, 2010). 
Integrins αVβ3, α5β1 and αVβ6 are usually expressed at very low or undetectable levels in 
normal epithelia, but are greatly upregulated in some cancers, and their expression 
correlates with a poor prognosis (Desgrosellier and Cheresh, 2010). Integrins have therefore 
been recognised as clinically relevant targets for cancer therapeutics. 
Normal non-circulating cells typically exhibit anchorage-dependent survival as a mechanism 
to prevent inappropriate proliferation. In such instances, loss of cell adhesion triggers anoikis 
(detachment induced apoptosis). Ligand-engaged integrin-mediated signalling promotes cell 
survival primarily by promoting the phosphoinositide 3-kinase (PI3K)-Akt pathway activity 
(Hager et al., 2013). Integrins can also control the expression of key cell cycle proteins, such 
as cyclin D1 (Fournier et al., 2008). Integrins have been shown to continue signalling within 
endosomes, conferring a resistance to anoikis (Alanko et al., 2015). Cancer cells typically 
exhibit anchorage-independent growth, whereby suppression of anoikis enables tumours to 
survive in circulation and therefore metastasise to distant sites.  
The tumour stromal microenvironment is recognised as a key mediator of tumour 
progression, and can actively promote malignant conversion (Micke and Ostman, 2004). The 
tumour stroma consists of fibroblasts, inflammatory cells, blood vessels, and ECM (Dvorak, 
2015). Increased matrix stiffness within tumours is linked to a more invasive tumour 
phenotype. Increased ECM rigidity due to collagen cross-linking enhances integrin signalling 
and induces a more invasive tumour phenotype (Levental et al., 2009). Increased collagen 
deposition in desmoplasia (the growth of fibrous or connective tissue) is able to promote 
tumour cell survival and proliferation through integrin signalling (Desgrosellier and Cheresh, 
2010). Integrins also have a well-established role in promoting tumour angiogenesis. Integrin 
αVβ3 and α5β1 expression on endothelial cells promotes tumour vascularisation, by allowing 
endothelial cells to engage initial matrix proteins such as vitronectin and fibrinogen, that are 
deposited at tumour sites (Desgrosellier and Cheresh, 2010). 
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Metastasis is responsible for up to 90% of cancer-related mortality (Chaffer and Weinberg, 
2011). For metastasis to occur, tumour cells must be able to invade local tissue, intravasate, 
survive in the circulation, extravasate, then colonise and proliferate at a metastatic site. Cell 
motility and protrusions are intrinsically related to invasion as this process is dependent on 
cell migration. Local invasion can be collective, where cells maintain cell-cell contacts that 
are cadherin and integrin-mediated (Hager et al., 2013); however single cell detachment is 
often considered to be required for distant metastases. Epithelial-to-mesenchymal transition 
(EMT) is key in this process, as it involves the downregulation of cell-cell adhesions and 
induces scattering. The loss of epithelial morphology results in an invasive phenotype that is 
more likely to induce metastasis (Hager et al., 2013). Invasion into the microenvironment can 
require the degradation of the ECM if it is a physical barrier. This process is primarily 
mediated by MMPs that are secreted or surface bound in the case of membrane-type 1 MMP 
(MT1-MMP) (Page-McCaw et al., 2007). Integrins can affect the localisation and activity of 
MMPs, promoting invasion (Gonzalo et al., 2010; Morgan et al., 2004).  
Integrins are important for the colonisation of and proliferation in a new metastatic site. The 
combination of integrins expressed by a tumour cell dictate tumour cell binding abilities, 
potentially to very different ECM compositions at metastatic sites compared to the primary 
tumour (Seguin et al., 2015).  Integrins may also be involved in priming pre-metastatic niche 
formation. Exosomes secreted by the primary tumour can be sequestered by cells at 
metastatic destinations. Distinct integrin expression patterns within exosomes were 
identified directing metastases for tissue/organ specific colonisation, such as α6β4 and α6β1 
directing metastases to the lung, and αVβ5 to the liver (Hoshino et al., 2015). 
Integrins therefore have roles in many of the hallmarks of cancer, including adhesion-
independent growth, invasion, angiogenesis and metastasis. Integrin-targeted therapeutics 
could therefore be used to target multiple aspects of cancer biology. 
1.6.1 Integrin Targeted Therapies 
Integrins have been identified as potential therapeutic targets since the discovery that they 
may promote pathogenic processes, such as cancer. Integrins are amenable to 
pharmacological inhibitors, as their binding sites and some regulatory sites are extracellular 
and therefore accessible. Integrin inhibitory antibodies are mostly either competitive 
inhibitors obstructing the ligand binding site, or allosteric inhibitors that can, for example, 
prevent activating conformational changes (Byron et al., 2009). 
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Nineteen of the 24 integrin heterodimers have been targets for therapeutic drugs, either 
alone or as multi-chain families (e.g. αVβx), with 480 integrin targeting drugs identified (July 
2017 survey cut-off) (Raab-Westphal et al., 2017).  Seven drugs targeting integrins have 
reached clinical market: abciximab (anti-β3), tirofiban (anti-αIIbβ3), eptifibatide (anti-
αIIbβ3), natalizumab (anti-α4), vedolizumab (anti-α4β7) and lifitegrast (anti-αLβ2), with 
efalizumab (anti-αLβ2) having been withdrawn (Millard et al., 2011; Raab-Westphal et al., 
2017). Integrins are also in development for use in diagnostic imaging, and as a mechanism 
for drug delivery (Raab-Westphal et al., 2017). 
The four β1 collagen binding integrins have been targeted, with the focus on α1β1 for 
rheumatoid arthritis (SAN-300 Valent, Quebec, QC, Canada) and α2β1 as an anti-thrombotic 
and potentially a cancer therapeutic; with phase two clinical trials active for both (Raab-
Westphal et al., 2017). Fibronectin binding integrins β1 (α4, α5, α8) and αV (β1, β3 and β6) 
have been prominent targets for drug design, as they are extensively linked to cancer, 
fibrosis, inflammation and autoimmune diseases (Raab-Westphal et al., 2017). α4β1 binds 
VCAM-1 (vascular cell adhesion molecule 1) and is involved in homing activated T-cells to 
sites of inflammation. The pan-α4 inhibitor natalizumab (Tysabri®) is used clinically for the 
treatment of multiple sclerosis and Crohn’s disease (Raab-Westphal et al., 2017). 
αV integrins are interesting as cancer therapeutics, as they are involved in angiogenesis, 
tumour growth, immunomodulation and metastases. Two pan αV inhibitors abituzumab 
(Merck KGaA (Darmstadt, Germany) and intetumumab (Centocor (Malvern, PA, USA) have 
been evaluated in late-stage clinical trials, for colorectal cancer and melanoma respectively 
(Raab-Westphal et al., 2017). No drugs specifically targeting laminin-binding integrins have 
reached clinical trials (Raab-Westphal et al., 2017). 
Targeting of leukocyte specific integrins that mediate cell-cell adhesion have produced three 
therapeutics that have made it to market. The β2 inhibitor Lifitegrast (Xiidra®) is a licenced 
local inflammation suppressant for the treatment of dry-eye disease. The αLβ2 inhibitor 
efalizumab (Raptiva®) was launched in 2003 for the treatment of psoriasis, but was 
associated with 3 cases of progressive multifocal leukoencephalopathy (PML), and 
subsequently withdrawn in 2009 after treatment of 45,000 patients (Raab-Westphal et al., 
2017). Vedolizumab (Entyvivo®) was launched in 2014 after clinical trials in Crohn’s disease 
and ulcerative colitis. Vedolizumab inhibits the interaction between α4β7 and Mad-CAM-1 
(mucosal vascular addressin cell adhesion molecule 1), blocking homing of activated T-cells 
to Peyer’s patches in the gut (Wagner et al., 1996). 
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The majority of successful integrin therapeutics are anti-thrombotics, targeting αIIbβ3 
expressed on platelets. αIIbβ3 has a low affinity for fibrinogen on resting platelets, but is 
converted to a high-affinity form upon platelet activation, and induces platelet aggregation 
during blood clotting (Coller and Shattil, 2008). The pan β3 inhibitor abciximab (Reopro®) was 
the first integrin inhibitor to reach therapeutic market, in 1995 (Goodman and Picard, 2012). 
The success of abciximab in clinic prompted the development of tirofiban (Aggrastat®) and 
eptifibatide (Integrilin®) which were both launched in 1998 for the treatment of acute 
coronary syndrome (Raab-Westphal et al., 2017). 
The development of integrin targeting drugs has not been very successful, with only 7 of the 
480 that entered clinical trials reaching market, compared to the 10% average for drugs that 
have entered phase one clinical trials (Raab-Westphal et al., 2017).  Animal models have been 
particularly misleading for integrins, hindered by inherent difficulties with models such as 
xenografts that cannot accurately represent the clinical scenario; although these can be 
improved using patient-derived explant models (Yada et al., 2018).  
Success has also been restricted by a lack of knowledge regarding the complexities of integrin 
biology. This issue is exemplified by the αVβ3- and αVβ5-specific inhibitor Cilengitide (Merck 
KGaA) which was identified as a promising anti-angiogenic and anti-tumour therapeutic in 
phase one and two preclinical studies. Cilengitide failed phase three clinical trials for the 
treatment of glioblastoma, showing no clinical benefit (Stupp et al., 2014). Crosstalk between 
αVβ3 and vascular endothelial growth factor (VEGF) is a potential contributor to the failure 
of cilengitide. Mice deficient in αVβ3 have enhanced tumour growth and angiogenesis, likely 
due to a compensatory upregulation of VEGF receptor, which promotes angiogenesis in 
response to VEGF (Reynolds et al., 2002). Nanomolar concentrations of cilengitide were 
shown to promote VEGF receptor-mediated angiogenesis, and increased recycling of αVβ3 
and VEGF receptor to the plasma membrane (Reynolds et al., 2009). The failure of cilengitide 
is a direct example of integrin and GFR mediated crosstalk resulting in an unanticipated 
biological outcome that resulted in failure of the drug to meet clinical trial outcomes. This 
highlights the importance of understanding and considering integrin and GFR crosstalk in the 
development of integrin-targeted therapeutics.  
Despite disappointing outcomes in clinical trials, patient stratification can determine clinical 
contexts where integrin-targeting therapies may yet become effective therapies. 
Natalizumab was withdrawn a year after launch after three patients developed PML. This was 
found to be an on-target side-effect due to T-cell immunosuppression leading to the 
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induction of John Cunningham polyoma virus (JC-virus). Screening patients for JC-virus 
antibodies allowed the renewed use of natalizumab (Raab-Westphal et al., 2017). The pan-
αV inhibitor abituzumab was evaluated compared to standard of care in a phase two clinical 
trial for metastatic colorectal cancer (Elez et al., 2015). Whilst the progression-free survival 
endpoint was not met, overall survival was longer in patients with high integrin αVβ6 
expression. These patients represent a subgroup for cohort-stratification that abtituzumab 
could benefit (Elez et al., 2015). Patient-stratification is likely to be important in identifying 
sub-groups of patients where integrin-targeted therapeutics may be clinically successful. The 
potential target αVβ6 will be discussed further in section 1.7.5. 
1.7 Integrin αVβ6 
Integrin αVβ6 was identified in epithelial cells as an RGD-binding integrin (Busk et al., 1992). 
with an expression pattern exclusive to epithelia (Breuss et al., 1995). The β6 subunit can 
only associate with αV, whereas αV can additionally associate with β1, β3, β5 and β8 (Figure 
1.1) (Hynes, 2002). Under homeostatic conditions αVβ6 is expressed at very low, or 
undetectable, levels in most tissues, except secretory glands in the endometrium and the 
luminal surface in colon epithelia (Breuss et al., 1995). αVβ6 is upregulated, however, during 
epithelial remodelling in circumstances such as embryogenesis, wound healing and 
tumourigenesis (Breuss et al., 1995; Haapasalmi et al., 1996). αVβ6 is upregulated in a range 
of cancers including breast, oral squamous, pancreatic, colon, cervical and non-small cell lung 
carcinomas; and this upregulation is usually associated with poor prognosis and survival 
(Bates et al., 2005; Elayadi et al., 2007; Hazelbag et al., 2007; Moore et al., 2014; Thomas et 
al., 2001b).  
Little is known about the control of αVβ6 expression levels. High cell density is known to 
enhance αVβ6 expression levels in colon cancer cells mediated via protein kinase C (PKC) 
activity (Niu et al., 2001). TGFβ and tumour necrosis factor alpha (TNFα) have both been 
shown to upregulate αVβ6 expression (Scott et al., 2004; Zambruno et al., 1995), potentially 
synergistically through upregulating the transcription factor Ets-1 (eukaryotic translation 
initiation factor) (Bates et al., 2005). These mechanisms may be important in stimulating the 
upregulation of αVβ6 expression that is observed in cancer. 
Trafficking is an important mechanism of regulation of αVβ6 and has been shown to influence 
αVβ6 biological function. Integrin αVβ6 is internalised via clathrin-dependent endocytosis 
(Berryman et al., 2005; Ramsay et al., 2007). HS1-associated protein X-1 (HAX-1) was 
identified in a yeast-two hybrid screen for novel interactors of the β6 cytoplasmic domain 
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and is required for αVβ6 dependent migration and invasion (Ramsay et al., 2007). HAX-1 and 
clathrin heavy chain are both required for αVβ6 internalisation, and HAX-1 is hypothesised 
to regulate clathrin-mediated endocytosis of αVβ6, which is required for coordinated 
receptor turnover crucial to cellular migration and invasion (Ramsay et al., 2007). Activation 
of PKC with phorbol 12-myristate 13-acetate (PMA) increases αVβ6 internalisation and 
recycling rates, which theoretically could also enhance αVβ6 receptor redistribution and 
promote motility, although this has not been assessed (Wang et al., 2011a). 
Knock-out mouse phenotypes provided initial information regarding the physiological 
functions of αVβ6. The αVβ6-null mouse phenotype has inflammation of the skin and airways 
(Huang et al., 1996), and is protected from pulmonary fibrosis (Munger et al., 1999). 
Similarities between the phenotypes of αVβ6- and TGFβ-null mice led to the observation that 
αVβ6 can function through promoting TGFβ activity (Munger et al., 1999). Constitutive over-
expression of αVβ6 in epithelium also resulted in a mouse phenotype with increased TGFβ 
activity and spontaneous chronic fibrotic lesions, supporting these conclusions (Hakkinen et 
al., 2004). Regulation of TGFβ activity is therefore considered to be the primary physiological 
function of αVβ6. 
1.7.1 TGFβ Signalling 
TGFβ is a pleotropic cytokine that exists in three isoforms, TGFβ1, TGFβ2 and TGFβ3, which 
are widely expressed and conserved, with different functions demonstrated by unique knock-
out mouse phenotypes (Khan and Marshall, 2016). TGFβ is important during development 
for body patterning, ECM production, cell proliferation, differentiation and apoptosis. In the 
adult, TGFβ primarily functions during tissue repair and is involved in immune regulation 
(Massague, 2008). TGFβ binding to its receptor stimulates serine/threonine kinase domain 
activity of the receptor, which then phosphorylates Smad2/Smad3. Phosphorylated Smad2/3 
dissociates from the receptor, and associates with the co-smad Smad4, to form a complex 
that translocates to the nucleus to associate with other transcriptional regulators, and 
control the transcription of target genes (Alberts et al., 2015). TGFβ signalling is dynamically 
regulated at multiple levels. Partner proteins in the nucleus which vary depending on cell 
type and state, can affect which genes are influenced by TGFβ (Alberts et al., 2015).  
Different routes of TGFβ receptor trafficking can either further activate or inactivate the 
signalling pathway. Smad shuttling in and out of the nucleus also allows for differential 
responses depending on TGFβ concentration and signal duration. Inhibitory Smads -6 and -7 
can inhibit signalling through competitive binding. TGFβ signalling can also stimulate 
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mitogen-activated protein kinase (MAPK) and PI3K signalling pathways in addition to its 
canonical Smad cascade (Alberts et al., 2015). Dysregulated TGFβ signalling can lead to 
chronic fibrosis, which is an inappropriate response to organ injury resulting in excessive ECM 
deposition, ultimately leading to organ failure (Margadant and Sonnenberg, 2010). 
1.7.2 TGFβ Activation  
Control of TGFβ activity is a key regulatory mechanism, as TGFβ is always produced in an 
inactive form. TGFβ genes encode a 25 kDa latency associated peptide (LAP) and a 12.5 kDa 
TGFβ moiety, forming a propeptide complex. LAP and TGFβ are cleaved in the Golgi, but 
remain non-covalently associated upon secretion in a conformation that renders TGFβ 
inactive (Worthington et al., 2011). The LAP- TGFβ small latent complex (SLC) can associate 
with the latent TGFβ binding protein (LTBP) to form the large latent complex (LLC), which can 
be anchored to the ECM through LTBP binding fibronectin (Worthington et al., 2011). TGFβ 
can be activated by pH, reactive oxygen species, proteases and the glycoprotein 
thrombospondin-1 (Annes et al., 2003). More recently however, integrins have been 
identified as key activators of TGFβ. 
LAP associated with TGFβ contains an RGD motif theoretically bound by all RGD-binding 
integrins, and demonstrably can be bound by αVβ3, αVβ5, αVβ6 and αVβ8 (Humphries et al., 
2006; Worthington et al., 2011). A point mutation in the TGFβ1 LAP RGD motif to RGE 
produces a mouse phenotype seemingly identical to TGFβ1 knockout, strongly suggesting 
integrin-mediated activation of TGFβ1 is key for its function, as defects occur despite the 
availability of non-integrin-mediated activation mechanisms (Yang et al., 2007). The integrin 
αV knockout mouse develops abnormalities in vasculogenesis and cleft palate, in common 
with TGFβ1 and -3 knockout mice (Bader et al., 1998; Dickson et al., 1995; Kaartinen et al., 
1995). The presence of the RGD motif within LAP and the overlap between TGFβ-null and 
integrin-null mouse phenotypes provided initial evidence of a link between integrins and the 
regulation of TGFβ activity. 
Integrins αVβ3 and αVβ5 are unlikely to have crucial roles in TGFβ activation, as neither of 
their knockout mouse phenotypes exhibit pathology associated with TGFβ deficiency 
(Worthington et al., 2011). αVβ8 and αVβ6 are considered the most important integrins for 
mediating TGFβ activation (Aluwihare et al., 2009).  αVβ8 is required for TGFβ activation 
controlling neurovascular development and stability (Mu et al., 2008). αVβ6 is important for 
the localised activation of TGFβ in epithelium, and has a role in immune cell control at 
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epithelial barriers. (Worthington et al., 2011). This indicates integrin heterodimer specificity 
in controlling different functions related to TGFβ activity. 
Integrin αVβ6 activates TGFβ by binding LAP and applying tension-mediated force to produce 
a conformational change, releasing TGFβ from its inactive complex (Worthington et al., 
2011). Protease inhibitors do not prevent αVβ6-mediated activation of TGFβ, indicating the 
process is not cleavage mediated (Munger et al., 1999). Traction force microscopy of 
pancreatic cancer cell lines on LAP-coated substrates demonstrated increased Rho activity 
promoted force application on LAP, which correlated with TGFβ activity levels (Tod et al., 
2017). Integrin αVβ8 activation of TGFβ is mediated by proteolytic cleavage of LAP by MT1-
MMP (Mu et al., 2002). This indicates αVβ6 has specialised mechanism for the activation of 
TGFβ, that is not common to αVβ8. 
TGFβ has differential effects in cancer and can function as a tumour suppressor or promoter. 
TGFβ inhibits cell proliferation mainly by blocking cell cycle progression in the G1 growth 
phase, therefore suppressing tumour growth (Massague, 2008). TGFβ promotes EMT in part 
by activating the transcription of Snail and Slug, which are key mediators of the EMT process 
(Naber et al., 2013). TGFβ-mediated EMT has been linked to increased tumour cell invasion 
and metastases, and modulation of the tumour stroma promoting a myofibroblast rich 
environment involved in promoting an invasive and fibrotic tumour phenotype (Khan and 
Marshall, 2016; Naber et al., 2013). TGFβ tumour suppressor functions are thought to 
predominate in the early stages of tumour progression, and then become pro-oncogenic in 
later stages, as the cancer becomes less responsive to external control over its proliferation 
(Thomas et al., 2006). 
1.7.3 αVβ6 in cancer  
Wound healing and carcinogenesis have many biological processes in common, to the extent 
that tumours have been described as wounds that cannot heal (Dvorak, 2015). Commonality 
exists between the advancing edge of a wound, and the invasive edge of a carcinoma, both 
requiring tissue remodelling. Tumours are thought to hijack these physiological mechanisms 
to aid their progression. An important differential between the two processes for αVβ6 is a 
permanent ‘on’ state in tumours, rather than the temporal regulation observed in wound 
healing (Thomas et al., 2006). αVβ6 is elevated in one third of carcinomas and correlates with 
poor survival (Raab-Westphal et al., 2017). Higher levels of αVβ6 are commonly observed at 
the invasive edge of the tumour, indicating a relationship with tumour invasiveness (Niu and 
Li, 2017). 
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Integrin αVβ6 has been extensively studied in colon cancer, with early observations showing 
αVβ6 enhances cell proliferation (Agrez et al., 1994). αVβ6 is upregulated in 34 – 37% of colon 
cancer patient samples, and in 70% of patients with liver metastases (Yang et al., 2008). 
Colorectal cancer patients with high αVβ6 levels have statistically significantly reduced 
median survival times (Bates et al., 2005). αVβ6 expression is increased during adenoma-to-
carcinoma progression, indicating a role in this process and implying potential for αVβ6-
targeted therapeutics in inhibiting this process (Brunton et al., 2001). 
High levels of αVβ6 have been observed in 15 – 16% of invasive ductal breast carcinomas and 
is associated with a poor prognosis (Moore et al., 2014). αVβ6 has been identified as a marker 
of ductal carcinoma in situ (DCIS) progression, as it is associated with progression to invasive 
cancer (Allen et al., 2014a).  αVβ6 promotes tumour cell invasion in vitro and growth in vivo, 
through modulation of the microenvironment  (Allen et al., 2014b). αVβ6 is statistically 
significantly associated with the incidence of distant metastases (Moore et al., 2014) and 
lymph node positive tumours (Desai et al., 2016). 
Integrin αVβ6 is expressed in the majority of oral squamous cell carcinomas (OSCC) (Jones et 
al., 1997a), and is associated with malignant transformation (Thomas et al., 2006). αVβ6 
promotes migration and invasion of squamous carcinoma cells in vitro (Thomas et al., 2001b) 
and tumour growth in vivo (Ramos et al., 2002).  αVβ6 is expressed at moderate to high levels 
in 45% of pancreatic ductal carcinomas (PDAC) and correlates with a more advanced state 
and lymph node metastases (Li et al., 2016). αVβ6 promotes PDAC cell proliferation and 
invasion, and tumour growth in vivo (Li et al., 2016). The role of αVβ6 in pancreatic cancer is 
complicated however by the TGFβ paradox, as TGFβ activation can also suppress tumour 
progression if TGFβ is functioning as a tumour suppressor (Hezel et al., 2012). Integrin αVβ6 
expression is therefore associated with a poor prognosis in a range of cancers, where it has 
been shown to mediate cancer-related processes such as cellular invasion, malignant 
transformation and metastases. 
1.7.4 αVβ6 is a Pro-Invasive Integrin 
Integrin αVβ6 enhances cell invasion in a range of models, and therefore is widely considered 
to be a pro-invasive integrin. αVβ6 upregulates the expression of proteinases such as MMPs 
and urokinase plasminogen activator (uPa), which mediate degradation of the ECM that can 
be a physical barrier to cell invasion. αVβ6 positive ovarian cancer cells express elevated 
levels of pro-MMP-9 and uPa, which results in increased plasminogen-dependent ECM 
degradation (Ahmed et al., 2002b). αVβ6 expression in oral keratinocytes increases MMP-2 
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and MMP-9 expression and enhances cellular migration and invasion in an MMP-9 
dependent manner (Thomas et al., 2001a; Thomas et al., 2001c).  αVβ6 is also implicated in 
the regulation of MMP-3, which is associated with increased invasion (Ramos et al., 2002). A 
region of the β6 cytoplasmic domain was demonstrated to mediate the pro-invasive effects 
mediated by MMP-2 and MMP-9 (Morgan et al., 2004). 
Local activation of TGFβ by αVβ6 can also increase cell invasion, due to TGFβ-mediated EMT 
which promotes single cell motility and invasion (Li et al., 2014). Interestingly, predominantly 
local and reversible rather than constitutive activation of TGFβ appears to mediate the switch 
from collective to single cell motility in breast cancer (Giampieri et al., 2009). αVβ6 activation 
of TGFβ also has a role in regulating the tumour microenvironment, modulating the stroma 
to enhance tumour invasive capacity (Khan and Marshall, 2016). Key known mechanisms by 
which αVβ6 facilitates cellular invasion are therefore regulating the expression and activity 
levels of proteases and TGFβ. 
Rac1 activity is associated with increased invasion of αVβ6 positive oral squamous and 
pancreatic cancer cells (Nystrom et al., 2006; Tod et al., 2017). A switch between Rac1 activity 
and RhoA activity regulated by Eps8 (epidermal growth factor receptor kinase substrate 8) 
differentially regulates the pro-migratory and TGFβ-activating functions of αVβ6 in PDAC cell 
lines (Tod et al., 2017). Eps8 activates Rac1 when in complex with Abi1 and the Rac1 GEF Sos1 
(Di Fiore and Scita, 2002).  Down-regulation of Eps8, Sos1 or Rac1 inhibited αVβ6-mediated 
cell motility, and promoted αVβ6-mediated TGFβ activation which corresponded with 
increased RhoA activity (Tod et al., 2017). Rac1 is reported to antagonise RhoA activity 
directly (Sander et al., 1999), and mathematical modelling has predicted inhibition of Eps8-
mediated Rac1 activation promotes RhoA activation (Hetmanski et al., 2016). This 
demonstrates the pro-migratory and TGFβ-activating functions of αVβ6 are distinct, and are 
regulated by Eps8. 
1.7.5 αVβ6 Targeting for Imaging and Therapy 
αVβ6 meets requirements for an imaging and therapeutic target, as it is expressed on the cell 
surface, at low levels normally, but at higher levels in tumours compared to the surrounding 
areas (Thomas et al., 2006). αVβ6 has been targeted in two clinical trials for the treatment of 
idiopathic pulmonary fibrosis. The antibody BG00011 (STX-100) from Biogen-Idec completed 
phase 2 trials in March 2017 (NCT01371305) for idiopathic pulmonary fibrosis and 
nephropathy, however no results have been released to date (Raab-Westphal et al., 2017). 
The αVβ6 positron emission tomography (PET) imaging agent GSK3008348 (GSK (Brentford, 
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UK)) is in phase 1 clinical trials (NCT03069989) for the therapy of idiopathic pulmonary 
fibrosis (Raab-Westphal et al., 2017). 
Additional inhibitors of αVβ6 are also in development. The selective αVβ6 inhibitor 6.3G9 
inhibited tumour growth and TGFβ activation in Detroit 562 pharyngeal carcinoma cell 
xenografts in vivo (Van Aarsen et al., 2008; Weinreb et al., 2004). The humanised monoclonal 
antibody 264RAD, developed by Astra Zeneca, has also produced promising results in in vivo 
xenograft models. 264RAD is a potent inhibitor of αVβ6 with some additional inhibitory 
activity against αVβ8 (Eberlein et al., 2013). 264RAD treatment reduced the rate of tumour 
growth in a dose-dependent manner in Detroit 562 xenografts, and caused a regression of 
tumour size at the highest dose of 20 mg/kg (Eberlein et al., 2013). 264RAD treatment slowed 
tumour growth and statistically significantly reduced the number of lung metastases of 4T1 
breast tumour xenografts, which metastasise to the lung (Eberlein et al., 2013). 264RAD also 
successfully inhibited tumour growth in HER2 positive breast cancer xenografts as a 
monotherapy, and effectively prevented tumour growth when in combination with the HER2 
inhibitor trastuzumab even in trastuzumab resistant MCF-7/HER2-18 xenografts (Moore et 
al., 2014). 264RAD continued to be effective in a long term (six week) treatment (Moore et 
al., 2014). 
A20FMDV2 peptide derived from foot and mouth virus is in development for PET imaging of 
αVβ6 positive tumours using a radiolabelled form (Slack et al., 2016). Specific binding to αVβ6 
can also be utilised for drug delivery if the peptide or antibody is internalised (Man et al., 
2018). An antibody-drug conjugate (15H3, Seattle Genetics (Bothell, USA)) is in early 
development for this purpose (Raab-Westphal et al., 2017). 
Targeting αVβ6 as a therapeutic is complicated by its role in TGFβ activation (Hezel et al., 
2012). The αVβ6 inhibitor 3G9 was assessed in KRas driven pancreatic ductal 
adenocarcinoma (PDAC) mouse model. αVβ6 and TGFβ inhibition promoted the progression 
of premalignant pancreatic intraepithelial neoplasia (PanIN) lesions into PDAC and a decrease 
in ‘survival’, defined as the point at which signs of illness facilitated euthanasia (Hezel et al., 
2012). αVβ6 inhibition was repeated in a Smad4-null version of the mouse model, and had 
no effect on ‘survival’, suggesting the tumour promoting effects of αVβ6 were due to its 
activation of TGFβ (Hezel et al., 2012). This highlights the importance of TGFβ tumour 
sensitivity in the response to αVβ6 therapeutics and suggests Smad4 status could be 
important patient stratification criteria for future clinical trials. 
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The targeting of αVβ6 represents an exciting clinical therapeutic for the treatment of a range 
of different cancers, however the development of αVβ6 therapeutics is likely to require 
careful consideration of patient stratification criteria to identify sub-sets of patients where 
the therapy is most likely to be clinically effective or could be contraindicated. Utilisation of 
αVβ6 as a clinical imaging target also represents an interesting avenue for αVβ6 in cancer 
treatment. 
1.8 The ErbB Growth Factor Receptor Family 
The ErbB growth factor receptor family (originally named for homology to the 
erythroblastoma viral gene product, v-erbB), are RTKs that are activated upon ligand binding, 
and stimulate intracellular signalling pathways to promote cell growth, survival, proliferation 
and differentiation into different cell subtypes (Alberts et al., 2015). There are four members 
of family; EGFR (ErbB1; HER1, human EGFR 1), ErbB2 (HER2; Neu), ErbB3 (HER3) and ErbB4 
(HER4). The ligands for the ErbB receptors are the 11 ligands of the EGF-family, which can be 
grouped into three according to receptor affinity. Specific EGFR binding ligands are EGF, 
tumour transforming growth factor α (TGFα), amphiregulin and epigen; ligands with dual 
specificity for EGFR and ErbB4 are betacellulin, heparin-binding EGF and epiregulin, and the 
final group neuregulins (NRGs) (also termed heregulins) bind both ErbB3 and ErbB4 (NRG-1 
and NRG-2) or ErbB4 only (NRG-3 and NRG-4) (Hynes and MacDonald, 2009). 
The ErbB family receptors have an extracellular domain with a ligand-binding cleft and 
dimerisation loop, a helical transmembrane domain, and a cytoplasmic region with a tyrosine 
kinase domain and ATP (adenosine triphosphate) binding site, and a c-terminal tail with 
phosphorylatable tyrosines  (Yarden and Pines, 2012). ErbB receptors exist in either a 
unliganded autoinhibited ‘closed’ formation, where the loop that mediates receptor 
dimerisation is occluded, or an ‘open’ form that results from the structural rearrangement of 
the extracellular domains upon ligand binding (Cho et al., 2003). ErbB receptors function as 
homodimers or heterodimers, for which ErbB2 is a preferential binding partner (Hynes and 
MacDonald, 2009). Each dimer exhibits distinct functional properties such as ligand binding 
affinities, receptor trafficking routes, and effector activation (Citri and Yarden, 2006). 
ErbB2 is a notable exception to the ErbB family, as it has no identified high affinity ligands, 
and exists in a fixed conformation resembling a ligand-activated state, and consequently 
ErbB2 is readily able to function as a co-receptor for ErbB binding partners that may become 
available (Cho et al., 2003). ErbB3 is also atypical as it has low kinase activity (~1,000 fold less 
than EGFR) (Shi et al., 2010). Despite their respective lack of ligands and kinase activity, the 
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ErbB2 ErbB3 heterodimer is one of the most potent for promoting cell growth and 
differentiation (Citri et al., 2003). 
1.8.1 EGFR Activation 
EGFR can function as a homodimer, or as a heterodimer with ErbB2, ErbB3 or ErbB4 (Citri and 
Yarden, 2006). EGFR homodimers and heterodimers with ErbB2 form with similar affinities, 
however heterodimers formed with ErbB3 or ErbB4 are much weaker (Graus-Porta et al., 
1997; Hendriks et al., 2003). The ErbB1 knockout mouse is lethal mid-gestation or at 
postnatal day 20, dependent on genetic background (Miettinen et al., 1995; Sibilia and 
Wagner, 1995; Threadgill et al., 1995). The phenotypes of multi-organ failure revealed the 
importance of EGFR in epithelial cell proliferation, migration and differentiation (Citri and 
Yarden, 2006). EGFR ligand knockout mouse phenotypes were milder and did not phenocopy 
ErbB1 knockout, indicating redundancy between ligands despite distinct functions (Luetteke 
et al., 1999; Mann et al., 1993; Sweeney et al., 2001). 
EGFR is activated upon ligand binding, resulting in activation of its kinase domain and 
consequent autophosphorylation. Ligand binding does not act as a physical bridge between 
the two monomers, as the ligand binding clefts are distal to the dimerisation loop, resulting 
in a ‘back-to-back’ conformation (Figure 1.4) (Garrett et al., 2002; Ogiso et al., 2002). In the 
classical model of EGFR activation, ligand binding to EGFR monomers at the plasma 
membrane results in a conformational change in the extracellular domain, releasing the 
dimerisation loop motif from an inactive tethered state (Alberts et al., 2015; Ferguson et al., 
2003). EGFR then forms a dimer with another ligand bound monomer, where the interaction 
is primarily mediated by the dimerisation loop with stabilisation facilitated by other regions 
such as the transmembrane domain (Mendrola et al., 2002).  
Receptor dimerisation orients the intracellular domains, forming an asymmetric structure 
where one kinase domain is termed the ‘activator’, and the other the ‘receiver’ (Figure 1.4). 
Activation of the kinase domains depends on an intermolecular interaction, as opposed to 
trans-autophosphorylation exhibited by other RTKs (Alberts et al., 2015). The C-lobe of the 
‘activator’ kinases interfaces with the N-lobe of the ‘receiver’ kinase and stabilises it in an 
active conformation (Zhang et al., 2006). The active ‘receiver’ then phosphorylates multiple 
tyrosine residues on the C-terminal tails of both receptors (Alberts et al., 2015). 
More recent evidence has suggested EGFR dimers can be present in a preformed state, prior 
to ligand-engagement (Tao and Maruyama, 2008). Ligand-induced activation is still required 
for receptor activation however and can additionally result in further aggregation of dimers 
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into oligomers forming competent signalling platforms (Bessman et al., 2014; Needham et 
al., 2016). Discrepancies in the literature are likely the result of a wide range of experimental 
techniques with varying cellular contexts, confounded by a potential context dependent 
equilibrium. The essential role of EGFR is reflected in the multi-modal regulation of its 
activity, indicating the importance of fine control over its function.   
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Figure 1.4 EGFR signalling and trafficking. Active ligand bound EGFR is a back-to-back homodimer, 
interacting primarily through the trans- and juxta-membrane domains. EGFR activation induces an 
asymmetrical orientation of the tyrosine kinase domains (visualisation aided by monomers as different 
colours), which triggers autophosphorylation (Lemmon, 2009). Signalling effectors are recruited to 
phosphorylated tyrosines, and mediate downstream signalling (PI3K-Akt and MAPK pathways shown 
in purple and green, respectively) (Yarden and Shilo, 2007). EGFR activation stimulates receptor 
internalisation via clathrin-dependent and independent routes (Sorkin and Goh, 2009). Ubiquitin 
moieties on EGFR are detected by the ESCRT complex which sorts EGFR for lysosomal degradation 
(Raiborg and Stenmark, 2009). 
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1.8.2 EGFR Signalling 
Phosphorylated tyrosine residues primarily on the C-terminal tail of EGFR are docking sites 
for proteins that contain Src homology 2 (SH2) or PTB domains, that recognise peptide motifs 
containing phosphorylated tyrosines (Guo et al., 2003). Proteins can either be recruited 
directly to phosphorylated tyrosines on EGFR, or indirectly via phosphorylated docked 
proteins or adaptors. Many of the proteins recruited are signalling effectors, that become 
activated by docking either through phosphorylation or an induced conformational change 
(Alberts et al., 2015). 
EGFR activates the Ras-MAPK signalling pathway which stimulates cell proliferation (Figure 
1.4). The adaptor protein Grb2 (growth factor receptor-bound protein 2) binds EGFR directly 
at Y1068 (Rojas et al., 1996), or via the adaptor Shc which docks to EGFR at Y1148 and Y1173 
(Zwick et al., 1999). Grb2 recruits the Ras-GEF Sos (son-of-sevenless), which activates Ras.  
Active Ras results in the sequential recruitment and phosphorylation of the kinases Raf 
(MAPKKK), Mek (MAPKK), and finally Erk (MAPK). Erk then translocates to the nucleus and 
phosphorylates transcription regulators that promote proliferation and cell cycle progression 
(Yarden and Shilo, 2007). The Ras-MAPK pathway is tightly regulated, and usually only 
transiently activated. Tyrosine specific phosphatases reverse phosphorylation at multiple 
levels in the cascade. Ras activation is terminated by Ras-GAPs that inactivate Ras. MAPK 
activates a negative feedback loop by increasing transcription and inhibiting degradation of 
MAPK phosphatases, that inactivate MAPKs (Alberts et al., 2015; Caunt and Keyse, 2013). 
There are multiple parallel MAPK pathways with different MAPKs involved, that can be 
differentially regulated and constrained by scaffold proteins that spatially restrict their 
signalling (Alberts et al., 2015). 
The PI3K-Akt pathway is also stimulated by EGFR and promotes cell survival by inhibiting 
apoptosis (Figure 1.4). The membrane bound enzyme PI3K is activated by EGFR, and 
phosphorylates PIP2 (phosphatidylinositol (4,5)-bisphosphate), producing PIP3 
(phosphatidylinositol (3,4,5)-trisphosphate) (Alberts et al., 2015). PIP3 recruits PDK1 
(phosphoinositide-dependent protein kinase 1), which phosphorylates Akt. Akt 
phosphorylates multiple proteins, including pro-apoptotic Bcl-2-associated death promoter 
(Bad). Phosphorylation of Bad creates a binding site for 14-3-3, which then sequesters Bad 
preventing its action thereby evading apoptosis (Avraham and Yarden, 2011). The PI3K-Akt 
pathway is also able to promote cell growth, through the indirect activation of mTOR 
(mammalian target of rapamycin). The phosphoinositide phosphatase PTEN (phosphatase 
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and tensin homolog) inhibits the conversion of PIP2 to PIP3 and therefore all Akt downstream 
signalling. 
Phospholipase C γ (PLCγ) becomes activated after docking to EGFR. PLCγ converts PIP2 into 
inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) (Alberts et al., 2015). IP3 raises 
intracellular calcium levels, and DAG activates PKC (Oda et al., 2005). Both of these signalling 
pathways have downstream effects on cell motility (Yarden and Shilo, 2007). EGFR signalling 
can therefore function to promote cellular proliferation, survival and motility. 
1.8.3 EGFR Trafficking 
Un-ligated EGFR is constitutively endocytosed slowly, and rapidly recycled to maintain 
predominant membrane localisation (Sorkin and Goh, 2008). The rate of EGFR endocytosis is 
increased following ligand stimulation, and EGFR is efficiently targeted for lysosomal 
degradation (Figure 1.4) (Sorkin and Goh, 2008; Wiley et al., 1991). This ligand-mediated 
downregulation of EGFR levels is an important negative feedback mechanism for attenuating 
signalling. The majority of EGFR signalling occurs at the plasma membrane (Brankatschk et 
al., 2012; Sousa et al., 2012), however it can continue from endosomal vesicles and is 
required for some specific signalling pathways and optimal activation of subsets of 
transducers at intracellular sites (Vieira et al., 1996). EGFR internalisation can therefore have 
both negative and positive effects on signalling. 
EGFR is internalised predominantly via clathrin-mediated endocytosis, however when this 
pathway is saturated due to high ligand or receptor concentrations, slower clathrin-
independent routes are additionally employed (Sigismund et al., 2005). Grb2 binding to 
pY1068 and pY1086 on EGFR promotes its internalisation and is involved in its recruitment 
to clathrin-coated pits (Fortian and Sorkin, 2014; Jiang et al., 2003). The E3 ubiquitin ligase 
Cbl (Casitas B-lineage lymphoma proto-oncogene) recruited to EGFR via pY1045 or indirectly 
through GRB2 is also involved in EGFR internalisation (Waterman et al., 2002) is, however 
this is independent of EGFR ubiquitination (Huang et al., 2007; Huang et al., 2006). 
After internalisation EGFR containing clathrin coated vesicles fuse with early endosomes. 
EGFR is then either rapidly recycled to the plasma membrane, or remains in the endosomes 
as they fuse with each other and mature into multivesicular bodies (MVBs) and late 
endosomes (Sorkin and von Zastrow, 2009). EGFR can be recycled through tubular extensions 
of the MVB, or via a Rab11 pathway from late endosomes (Tomas et al., 2014). Ligands 
dissociate from EGFR with different pH sensitivities, for example TGFα dissociates at 
endosomal pH, whereas EGF remains bound until lysosomal acidification (French et al., 
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1995). Ligand release leads to receptor dephosphorylation and deubiquitination, and 
consequent receptor recycling influencing EGFR trafficking fates. Ligand release is not a pre-
requisite for recycling however, demonstrated by the recycling of EGF bound EGFR (Sorkin et 
al., 1991). 
Ubiquitinated EGFR interacts with ubiquitin binding domains of ESCRT-0 (Endosomal Sorting 
Complex Required for Transport) (primarily comprised of HRS (hepatocyte growth factor-
regulated tyrosine kinase substrate) and STAM (signal-transducing adaptor molecule)), which 
triggers its incorporation into internal vesicles within the MVB (Eden et al., 2012). The MVB 
then fuses with lysosomes, resulting in the degradation of EGF and EGFR. c-Cbl is recruited 
to active EGFR promoting its ubiquitination and subsequent degradation (Waterman et al., 
2002); therefore linking ubiquitination to EGFR activation status and mediating termination 
of active signalling  (Lemmon and Schlessinger, 2010).   
EGFR degradation is also influenced by deubiquitinating enzymes (DUBs) that remove 
ubiquitin from proteins (Clague et al., 2012). An example of this is the DUB AMSH (associated 
molecule with the SH3 domain of STAM) that deubiquitinates EGFR, opposing its ubiquitin-
dependent sorting for lysosomal degradation (McCullough et al., 2004). Proteasomal 
degradation is also implicated for EGFR (Longva et al., 2002), however this is potentially an 
indirect mechanism influencing protein levels of the ESCRT complex (Sorkin and von Zastrow, 
2009). Trafficking of EGFR is therefore an important mechanism for regulating its surface 
bioavailability and total protein levels, which has direct consequences for its function.  
1.8.4 EGFR in Cancer 
EGFR signalling can be dysregulated in cancer, contributing to uncontrolled cell growth and 
evasion of apoptosis. Overexpression of EGFR due to gene amplification is reported in a wide 
range of cancers including lung and breast, where it can correlate as an indicator of 
recurrence or shorter survival (Yarden and Pines, 2012). EGFR can also be mutated primarily 
in the extracellular and kinase domains, resulting in enhanced signalling. Signalling effectors 
and mediators are also frequently mutated in cancer, for example pro-oncogenic active Ras 
mutations, and PTEN deficiencies (Alberts et al., 2015). 
The most common EGFR mutant is the truncated EGFR vIII (deletion of residues 6-273) that 
lacks a proportion of the extracellular ligand binding domain (Pedersen et al., 2001). This 
mutant is constitutively phosphorylated independent of ligands, and is pro-tumourigenic 
(Pedersen et al., 2001). EGFR vIII hypophosphorylation at the c-Cbl docking site Y1048 
reduces receptor ubiquitination, allowing degradation evasion (Grandal et al., 2007; Han et 
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al., 2006). The most frequent mutation in the kinase domain is an L858R point mutation 
(Sigismund et al., 2017). L858R EGFR has impaired c-Cbl-mediated ubiquitination, slower 
internalisation rates and enhanced heterodimerisation with ErbB2 (Shtiegman et al., 2007). 
EGFR targeted therapies are in clinical use for a range of cancers, primarily non-small-cell 
lung carcinoma (NSCLC), head and neck squamous cell carcinoma and colorectal cancer 
(Yarden and Pines, 2012). EGFR therapeutics can be divided into antibodies and small 
molecule kinase inhibitors. Cetuximab (Erbitux®, Bristol-Myers Squibb) and panitumumab 
(Vectibix®, Genentech) are the most commonly used antibodies (Sigismund et al., 2017). 
Cetuximab was licensed in 2004 for the treatment of wild type KRAS colorectal cancer and 
head and neck cancer (Roskoski, 2014). Panitumumab was licensed in 2006 as a second line 
treatment for metastatic colorectal cancer (Roskoski, 2014). 
First generation small molecule tyrosine kinase inhibitors gefitinib (Iressa®, AstraZeneca) and 
erlotinib (Tarceva®, OSI/Genentech) were approved in 2003 and 2004, respectively (Cohen 
et al., 2005; Cohen et al., 2003). Gefitinib is a second line treatment for NSCLC, and erlotinib 
is licensed for NSCLC and as a combination therapy for pancreatic cancer (Roskoski, 2014). 
EGFR therapies are often hindered by the development of resistance. The most common 
mechanism of EGFR kinase inhibitors is a T790M point mutation in the EGFR kinase domain 
(Mazza and Cappuzzo, 2017). The third generation EGFR kinase inhibitor Osimertinib 
(Tagrisso®, Astra Zeneca) was licensed in 2017 for the treatment of metastatic NSCLC with 
the T790M mutation (AURA3 clinical trial NCT012151981) (Mazza and Cappuzzo, 2017). 
Resistance-causing mutations are also implicated in downstream effectors of EGFR in KRAS, 
BRAF, PI3K and PTEN (Yarden and Pines, 2012). Combination therapies with non-overlapping 
targets are a potential means of more effectively targeting EGFR and delaying resistance 
(Sigismund et al., 2017). 
In conclusion, EGFR is frequently mutated or overexpressed in cancer, which results in a poor 
prognosis due to the dysregulation of EGFR functions such as mitogenic signalling, protection 
from apoptosis and promotion of cell motility. EGFR has been successfully targeted by 
antibodies and small molecule inhibitors in a range of cancers and has been particularly 
successful in NSCLC, head and neck squamous cell carcinoma and colorectal cancer. EGFR 
therefore represents a clinical relevant and therapeutically amenable target that is relevant 
to a wide range of cancers. 
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1.9 Integrin and Growth Factor Receptor Crosstalk 
Crosstalk between cell-ECM adhesions and GFRs has long been evident in the phenomenon 
of cell survival anchorage dependence. Detachment from solid substrates initiates anoikis 
(detachment-induced apoptosis) in adherent cell types, due to impaired growth factor and 
cytokine signalling (Alberts et al., 2015). Attachment-independent survival is a hallmark of 
metastatic cancer, and is required for distant spread via circulation (Liotta and Kohn, 2004). 
GFRs signal inefficiently without integrin-mediated adhesions, and signalling is cell-type and 
matrix specific (Ivaska and Heino, 2011). Crosstalk between integrins and GFRs affects the 
activity, expression level, signalling and trafficking of both. 
1.9.1 Regulation of Receptor Activity 
Integrins and GFRs often co-localise at the cell surface, however few examples of direct 
binding exist (Ivaska and Heino, 2011). Aggregation of integrins causes GFR co-clustering, 
creating a permissive environment by bringing GFR monomers into proximity with each other 
and common downstream signalling effectors (Figure 1.5) (Yamada and Even-Ram, 2002). 
GFRs may also influence integrin clustering, for example knockdown of EGFR results in 
increased membrane diffusion and decreased clustering of Drosophila orthologs of integrin 
β1 (Arora et al., 2012).  Lipid raft plasma membrane microdomains have been implicated as 
specialised regions that gather integrins and GFRs into signalling platforms (Decker et al., 
2004). Other transmembrane receptors such as tetraspanins and syndecans may act as 
physical bridges between integrins and GFRs (Charrin et al., 2014; Morgan et al., 2007; Streuli 
and Akhtar, 2009). Some ECM components can be engaged both by integrins and by GFRs, 
for example tenascin-C can be bound by both EGFR and αVβ3, and therefore function as 
linkers (Jones et al., 1997b; Swindle et al., 2001). Integrins can also regulate the activity of 
GFRs by mechanisms that are more direct that creating a permissive environment. 
Integrins are reported to activate GFRs in a ligand-independent manner. Cell adhesion to FN 
or collagen, has been shown to stimulate EGFR phosphorylation under serum free conditions 
(Moro et al., 1998). This effect was recapitulated by binding antibodies against integrin αV 
and β1 indicating an integrin-dependent mechanism. Activation of the adaptor p130cas and 
kinase Src was also required, indicating the mechanism may not be solely receptor mediated 
(Moro et al., 2002). Interestingly ligand-independent activation of EGFR produces a different 
pattern of receptor tyrosine phosphorylation, omitting Y1148 which is phosphorylated with 
EGF (Moro et al., 2002). Phosphorylated Y1148 is a docking site for Shc which is important 
for Ras-MAPK signalling (Zwick et al., 1999). Integrin-mediated activation may therefore have 
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unique signalling consequences compared to canonical ligand stimulation. Integrin-mediated 
ligand-independent activation of GFRs has been demonstrated for multiple other integrin 
subtypes and GFRs including hepatocyte growth factor receptor (Met) and platelet-derived 
growth factor receptor (PDGFR) (Ivaska and Heino, 2011; Veevers-Lowe et al., 2011). 
Adhesion stimulated activation of GFRs does not appear to be a universal phenomenon and 
may be ligand and cell type specific. Adherence to laminin-332 is demonstrated to have no 
effect on EGFR phosphorylation status, however it enhances EGFR phosphorylation following 
EGF stimulation, compared to cells in suspension or adhered to poly-L-lysine (Alexi et al., 
2011). The amount of receptor at the cell surface also appears to be an important 
determinant (Moro et al., 2002).   
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Figure 1.5 Integrin and growth factor receptor crosstalk. Examples of mechanisms of crosstalk, with 
published examples where appropriate that have are detailed in the text of section 1.9 (Ivaska and 
Heino, 2011). Green arrows represent signalling. (A) Integrins and growth factors can co-cluster which 
positively regulates their signalling. (B) Integrins and GFRs can be bridges by ECM proteins. (C) Integrins 
can stimulate EGFR signalling in an EGFR ligand-independent manner. (D) Integrins and GFRs can 
activate common signalling pathways. (E) Integrins can negatively regulate GFR signalling. (F) Integrins 
can upregulate the expression of GFRs. (G) Integrins and GFRs can be co-internalised (H) and co-
recycled.  
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Integrins also negatively regulate GFR activity, by mechanisms such as recruiting 
phosphatases. One example of this is the recruitment of the phosphatase TCPTP (T-cell 
protein tyrosine phosphatase) by integrin α1β1 (Mattila et al., 2005). Binding to collagen 
promotes an interaction between the integrin α1 cytoplasmic domain and TCPTP, activating 
TCPTP potentially by interfering with autoinhibitory interactions. TCPTP dephosphorylates 
EGFR, resulting in reduced EGFR phosphorylation after EGF stimulation, inhibiting EGF 
induced cell proliferation (Mattila et al., 2005). TCPTP has also been shown to 
dephosphorylate VEGF receptor 2, which is the receptor type primarily responsive to VEGF 
(Mattila et al., 2008). 
Integrins and GFRs can affect the expression and surface levels of one another (Ivaska and 
Heino, 2011). For example overexpression of αVβ3 upregulates EGFR expression (Lossner et 
al., 2008), and sustained stimulation with HGF increases integrin α2 levels. Integrins can also 
indirectly affect GFR activity through interacting with their ligands. The best characterised 
example of this is integrin-mediated activation of the growth factor TGFβ through mechanical 
force or proteases (Worthington et al., 2011). Integrins are also able to bind some growth 
factors, such as αVβ3 which can bind insulin-like growth factor-1 (IGF-1) and angiopoietin-2 
(Saegusa et al., 2009; Thomas et al., 2010). Integrin binding to growth factors can promote 
the signalling of the corresponding GFR, suggesting integrins could be involved in introducing 
the growth factor to the GFR (Ivaska and Heino, 2011).  
Integrin and GFR mediated crosstalk therefore has important consequences for regulating 
the activity of both receptor families, in a positive or negative manner. Crosstalk can be 
mediated indirectly of both receptors for example by a divalent ECM ligand, through 
permissive mechanisms such as influencing receptor expression and clustering, and by direct 
mechanisms such as the recruitment of phosphatases to directly control receptor activity.  
1.9.2 Concomitant Signalling 
In addition to promoting GFR signalling in a collaborative manner integrins can independently 
activate common signalling pathways, enhancing signalling concomitantly (Ivaska and Heino, 
2011). Key shared pathways are Ras-MAPK, PI3K-Akt, and the downstream regulation of Rho 
family GTPases. 
Integrin-mediated adhesion recruits FAK to adhesion sites, where it is then phosphorylated 
on multiple residues. FAK binds to β integrin cytoplasmic domains indirectly via paxillin and 
talin (Mitra et al., 2005). FAK autophosphorylation at Y397 (either in cis or trans) produces a 
binding site for SH2 domain containing proteins, including Src family kinases, Shc, 
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p120RasGAP and PI3K (Mitra et al., 2005). Phosphorylated Src Y397 is a high-affinity binding 
site for Src, and the ‘FAK-Src’ complex phosphorylates itself and a range of other signalling 
proteins, many of which are RTK signalling effectors (Mitra and Schlaepfer, 2006). FAK 
phosphorylation of bound PI3K stimulates PI3K-Akt survival pathway signalling (Xia et al., 
2004). Src phosphorylation of FAK Y925 creates an SH2 binding site for Grb2, connecting FAK 
to Ras activation and the MAPK cascade (Mitra et al., 2005). Overexpression of FAK facilitates 
competitive sequestering of p120RasGAP away from active Ras, resulting in elevated Ras 
activity (Hecker et al., 2004). GFRs can activate FAK directly or indirectly via Src, and both are 
central nodes downstream of both integrin and GFR signalling (Ivaska and Heino, 2011). 
Recently a role for EGFR and ErbB2 directly participating in integrin-mediated force sensation 
has been discovered (Saxena et al., 2017). During cell attachment and spreading cells produce 
actomyosin based ‘contractile units’ to sense ECM rigidity. Cells attached to rigid matrices 
(17.2 kPa) of FN coated pillars generate a greater number of contractile units than those on 
soft matrices (7.2 kPa). Inhibition of EGFR kinase activity under serum-free and EGF-free 
conditions, statistically significantly decreased cell area spreading and formation of 
contractile units on rigid substrates (Saxena et al., 2017). Inhibition of ErbB2 had no effect, 
however ErbB2 overexpression rescued the EGFR knockdown phenotype indicating potential 
compensation. The number of contractile units peaks 20 minutes after attachment, 
diminishing 10-fold after 5 hours. Stimulation with EGF after 6 hours of attachment 
stimulated lamellipodial protrusion and the formation of contractile units in extensions. An 
inhibitor of myosin-II ROCK-mediated activity (ROCK phosphorylates myosin-regulatory light 
chain, which promotes myosin-II contractility) abrogated the effects of EGF stimulation, 
indicating EGFR exerts its contractile function via myosin-II. EGFR has previously been shown 
to activate myosin-II contractility (Schneider et al., 2009), potentially indirectly via PKC (Chen 
et al., 2017). 
Src is recruited to active EGFR, and both can phosphorylate each other stimulating their 
activity and signalling (Alberts et al., 2015). Src-mediated phosphorylation of EGFR was 
required for EGFR localisation to early adhesions, in a rigidity dependent manner (Saxena et 
al., 2017). Src is not recruited to adhesions in a force-dependent manner however, so is 
unlikely to be directly involved in recruiting EGFR (Chen et al., 2017). One likely candidate for 
this role is p130cas, which can be mechanically unfolded (Sawada et al., 2006) and is involved 
in EGFR localisation (Kang et al., 2011; Moro et al., 2002). 
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Shared signalling effectors downstream of integrins and GFRs results in collaborative 
signalling whereby both receptors independently activate the same pathways. Integrins and 
GFRs can additionally regulate downstream signalling of the reciprocal receptor family, 
controlling their associated functions. 
1.9.3 Trafficking Crosstalk 
Crosstalk between integrins and GFRs affects the endosomal trafficking of both receptor 
types. The receptor families have shared trafficking routes including those for internalisation, 
and recycling (Ivaska and Heino, 2011). Both demonstrate constitutive endocytosis with 
predominant membrane localisations (Bridgewater et al., 2012; Sorkin and Goh, 2008). They 
differ however in their ligand stimulated trafficking fates, with the traditional view being 
integrins are predominantly recycled, whereas GFRs are degraded (Wiley et al., 1991). 
Integrins and GFRs can affect each other’s internalisation. Expression of the constitutively 
active EGFR vIII mutant reduced surface levels of integrin α2 and cell spreading, which was 
reversed through inhibition of EGFR catalytic activity (Ning et al., 2007). EGF stimulation 
triggered internalisation of both EGFR and α2 through distinct pathways with different 
trafficking fates (Ning et al., 2007). HGF stimulation promotes co-internalisation and co-
trafficking of Met and β1, promoting sustained signalling from internalised Met (Barrow-
McGee et al., 2016). Integrin β1 may also co-internalise with bone morphogenic protein 
receptor 1A, as the receptors colocalised in internal compartments when β1 internalisation 
was triggered by culturing bone marrow mesenchymal stem cells on soft substrates 
(Bridgewater et al., 2012; Du et al., 2011). Co-internalisation of surface receptors is an 
important mechanism by which receptor surface bioavailability can be regulated in a co-
ordinated and linked manner. 
Receptor recycling is an important determinant of spatial and temporal control of 
bioavailability at the plasma membrane, which can be regulated by integrins and GFRs. Under 
serum-starved conditions integrin αVβ3 traffics through Rab4 positive early endosomes to 
Rab11 positive endosomes in the perinuclear recycling compartment and is recycled in a 
long-loop Rab11 dependent manner. PDGF stimulation diverts αVβ3 recycling to short-loop 
Rab4 dependent recycling, and directs αVβ3 to small puncta which later develop into focal 
complexes, implicating a role for PDGF in promoting cell-matrix adhesions (Roberts et al., 
2001). Protein kinase D (PKD) signalling downstream of PDGF is potentially the mechanism 
behind this switch, promoting an interaction between the Rab5 effector rabaptin-5 and Rab4 
(Christoforides et al., 2012). Integrins and GFRs can also directly associate and recycle in a 
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coordinated manner together. Inhibition of αVβ3 promotes the coordinated recycling of 
α5β1 and EGFR (Caswell et al., 2008; White et al., 2007). Rab-coupling protein (RCP) binds to 
β1 and EGFR, physically linking them. This results in fast rapid motility associated with α5β1, 
and elevated EGFR autophosphorylation and Akt signalling (Caswell et al., 2008). Regulation 
of receptor recycling has direct consequences for receptor surface bioavailability dynamics 
and levels, which influences receptor function.  
The small GTP binding protein Arf6 has been implicated in controlling the recycling of both 
integrins and GFRs (Caswell et al., 2009). The Arf family regulate endocytic trafficking by 
recruiting cargo-sorting coat proteins, and modifying membrane lipid composition through 
recruiting phosphatidylinositol kinases, and interacting with the cytoskeleton (Donaldson 
and Jackson, 2011). The Arf family are activated by GEFs, and inactivated by GAPs that 
hydrolyse GTP which is crucial as Arfs have negligible intrinsic capacity to hydrolyse GTP 
(Donaldson and Jackson, 2011).  EGFR signalling activates Arf6 through recruiting the Arf GEF 
GEP100 to phosphorylated EGFR Y1068 (Morishige et al., 2008). Activation of Arf6 in 
conjunction with a downstream effector AMAP1 promotes recycling of integrin β1, through 
indirect binding of AMAP1 to β1 via PKD (Onodera et al., 2012). HGF stimulation is also able 
to stimulate the recycling of β1, via a mechanism that requires Arf6 (Hongu et al., 2015). The 
Arf family GTPases therefore represent important regulators of integrin and GFR recycling 
and trafficking crosstalk.  
1.10 Crosstalk between αVβ6 and EGFR 
Integrin αVβ6 is involved in downstream signalling associated with EGFR. Treatment of 
Detroit 562 pharyngeal carcinoma cell xenografts with the clinical αVβ6 inhibitor 264RAD 
resulted in a dose-dependent inhibition of ERK phosphorylation levels, detected 
histologically (Eberlein et al., 2013). αVβ6 levels were also reduced, indicating these 
phenomena could be linked (Eberlein et al., 2013). Stimulation of OSCC cells with FN 
stimulated the activity of the Src family kinase Fyn. This effect was abrogated with αVβ6 
inhibition, and Fyn was co-immunoprecipitated with αVβ6 indicating proximity and therefore 
a potentially direct mechanism (Li et al., 2003). Stimulation of Fyn activity could indirectly 
couple αVβ6 to the Ras-MAPK activity, through activity of a Fyn-FAK complex activating Shc 
(Li et al., 2003). The αVβ6 may associate with ERK2 via the β6 subunit and promote its activity, 
demonstrating a direct link between αVβ6 and Ras-MAPK pathway signalling (Ahmed et al., 
2002a). The mechanisms by which αVβ6 effects GFR signalling is undefined and therefore 
requires further studying. 
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Crosstalk between αVβ6 and EGFR has been demonstrated to have global cellular 
consequences on migration and force application. Stimulation of three pancreatic cancer cell 
lines (Capan1, BxPC3 and Panc0403) with EGF statistically significantly increased migration 
towards the αVβ6 ligand LAP. This effect was abrogated with inhibition of αVβ6, 
demonstrating the migration induced by EGF was αVβ6 dependent (Tod et al., 2017). EGF 
stimulation promoted Rac1 activity, which was also dependent on αVβ6 (Tod et al., 2017). 
Unpublished data from our laboratory (Stephanie Mo, University of Liverpool) demonstrated 
EGF stimulation reduced the capacity of MDA-MB-468 cells to apply force to LAP coated 
matrices, measured by traction force microscopy (TFM). Modulating the ability of αVβ6 to 
transduce force would have physiological consequences as this is the mechanism by which 
αVβ6 activates TGFβ (Worthington et al., 2011). These data imply EGF stimulation may alter 
the composition of αVβ6 adhesions or downregulate αVβ6 at the plasma membrane by 
stimulating internalisation.  
1.11 Thesis Aims 
Integrin αVβ6 has been implicated as an attractive therapeutic target for a range of cancers, 
with inhibitory antibodies in clinical development. Unanticipated crosstalk mechanisms are 
a major concern behind integrin therapy failures. Preliminary evidence indicates crosstalk 
exists between integrin αVβ6 and EGFR, which may have implications for the therapeutic 
potential of these receptors. 
The primary aim of this thesis was to elucidate αVβ6 crosstalk mechanisms with EGFR and 
generate a greater understanding of αVβ6.  Trafficking crosstalk was investigated through 
stimulating receptor endocytosis and analysing changes in endosomal localisation and 
internalisation rates. Collaborative signalling was assessed by analysing downstream 
receptor signalling target activations statuses following receptor activation. Isolation and 
proteomic analysis of αVβ6-specific adhesions contributed to the characterisation of the 
αVβ6 adhesome and identify novel regulators. The adhesion isolation technique was adapted 
to identify novel regulators of integrin GFR crosstalk and led to the investigation into the 
function of the adaptor protein Eps8.  
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2. Materials and Methods 
All reagents were obtained from Sigma-Aldrich (Poole,UK) unless otherwise stated.  
2.1 General Buffers 
DMEM 5: Dulbecco’s Modified Eagle’s Medium with 25 mM Hepes 
Heat denatured BSA: 10 mg/ml > 98% pure BSA in PBS (-), heated to 85°C for 13 minutes, 
cooled, filtered through 0.45 μm pore Millex filter unit (Millipore) 
Krebs Buffer: 118 mM NaCl, 25 mM NaHCO3, 11 mM glucose, 4.8 mM KCl, 1.5 mM CaCl2, 1.5 
mM sodium pyruvate, 1.2 mM KH2PO4, 1.2 mM MgSO4 
PBS (-): Dulbecco’s phosphate buffered saline without divalent cations (136.9 mM NaCl, 1.5 
mM KH2PO4, 8.1 mM Na2HPO4, 2.7 mM KCl; pH 7.1 – 7.5) 
PBS (+): Dulbecco’s phosphate buffered saline with divalent cations Mg2+ [0.1 g/L] and Ca2+ 
[0.133 g/L] 
PBST: PBS (-) containing 0.1% (v/v) Tween-20 
5 x Sodium dodecyl sulfate (SDS) Sample Buffer: 50% (v/v) glycerol, 10% (w/v) SDS, 0.01% 
(w/v) bromophenol blue, 250 mM pH 6.8 Tris HCl; 15% (v/v) β-mercaptoethanol added fresh 
TBST: 20 mM Tris base (Fisher Scientific), 150 mM NaCl (Fisher Scientific), 0.1% Tween-20 
(v/v), pH 7.6 
0.1/0.1 Buffer: 0.1% BSA (w/v), 0.1% sodium azide (v/v) in PBS (-) 
2.2 Extracellular Matrix Proteins 
All extracellular matrix proteins used as 2D coated ligands were diluted in PBS (+). Fibronectin 
(from bovine plasma) at 10 μg/ml, Collagen I (rat tail) (Corning) at 10 μg/ml and LAP at 0.5 
μg/ml. Surfaces for coating were incubated with the protein solution rocking overnight at 
4°C, washed three times with PBS (-) then blocked with heat denatured BSA for 30 minutes 
at room temperature.  Surfaces were washed in PBS (-) followed by the appropriate media, 
and allowed to equilibrate. Coated surfaces were used for experiments immediately after 
equilibration.  
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2.3 Growth Factors and Ligands 
Recombinant human EGF was reconstituted in molecular biology grade water to 0.1 mg/ml 
stock, and used at 10 ng/ml in DMEM with 25 mM Hepes (DMEM5). LAP was reconstituted 
in 0.22 µm-filtered PBS (-) containing 0.1% (w/v) >99% purity BSA, to 25 µg/ml stock, and 
used at 0.5 μg/ml in DMEM5. 
2.4 Oligonucleotides 
siRNA oligonucleotides were obtained from Dharmacon (GE healthcare). The siRNA 
lyophilised powder was reconstituted in siRNA buffer (Dharmacon) (75 mM KCl, 7.5  mM 
HEPES-pH 7.5, 0.25 mM MgCl2) in RNAse-free water, and stored at – 20° C. 
 Target sequences are detailed below in table 2.1. AllStars negative control siRNA (Qiagen) 
was used as a negative control for all siRNA knockdown experiments. The negative control 
siRNA lyophilised powder was reconstituted in RNAse-free water (Qiagen) for a 20 µM 
solution, and stored at - 20° C.  
Target Target sequence Catalogue number Stock  
Mouse Eps8 ACGACUUUGUGGCGAGGAA J-045154-11-0050 50 μM 
Mouse Eps8L2 UCGACUAUCUGUACGACAU J-062758-10-0010 40 μM 
Table 2.1: List of siRNA oligonucleotide target sequences 
2.5 Antibodies 
2.5.1 Immunoblotting Antibodies 
Immunoblotting antibodies were diluted in either 1 x casein blocking buffer solution with 
0.1% (v/v) Tween-20, 5% non-fat dry milk (Marvel) in PBST, or 5% BSA in TBST. Alexa fluor 
conjugated 680 and 790 secondary antibodies (Molecular Probes Invitrogen) were diluted to 
1:10,000 in the same buffer as the corresponding primary antibody used.  
Primary 
Antibody 
Clone Host 
Species 
Supplier Catalogue 
Number 
Dilution kDa Buffer 
α-actinin BM-75.2, Mouse 
mAb 
Sigma 
Aldrich 
A5044 1:1000 100 5% BSA 
(TBST) 
Actin AC-40 Mouse 
mAb 
Sigma 
Aldrich 
A3853 1:1000 42 1 x 
casein 
Akt (pan) C67E7 Rabbit 
mAb 
CST 4691 1:1000 60 5% BSA 
(TBST) 
Phospho-Akt 
(Ser473) 
D9E Rabbit 
mAb 
CST 4060 1:1000 60 5% BSA 
(TBST) 
BAK D4E4 Rabbit pAb CST 12105 1:1000 25 1 x 
casein 
Clathrin heavy 
chain 
23 Mouse 
mAb 
BD 
Biosciences 
610499 1:1000 180 5% BSA 
(TBST) 
EGFR D38B1 Rabbit 
mAb 
CST 4267 1:1000 175 5% BSA 
(TBST) 
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Primary 
Antibody 
Clone Host 
Species 
Supplier Catalogue 
Number 
Dilution kDa Buffer 
EGFR (1005)-G Goat pAb Santa Cruz sc-03-G 1:1000 170 5% milk 
(PBST) 
EGFR (pY1068) D7A5 Rabbit 
mAb 
CST 3777 1:1000 175 5% BSA 
(TBST) 
Eps8 15/Eps8 Mouse 
mAb 
BD 
Biosciences 
610144 1:500 97 5% BSA 
(TBST) 
Eps8L2 
 
Rabbit pAb Protein tech 20461-1-
AP 
1:500 81 5% BSA 
(TBST) 
FAK 77/FAK Mouse 
mAb 
BD 
Biosciences 
610088 1:1000 116-
125 
5% BSA 
(TBST) 
Phospho-FAK 
pTyr397 
 
Rabbit pAb Invitrogen 44-624G 1:1000 125 5% BSA 
(TBST) 
GAPDH mAbcam 
9484 
Mouse 
mAb 
Abcam ab9484 1:1000 36 1 x 
casein 
GEF-H1  Rabbit 
pAb 
Fisher 
Scientific 
PA5-32213 1:1000 111 5% BSA 
(TBST) 
HER2/ErbB2 29D8 Rabbit 
mAb 
CST 2165 1:1000 185 1 x 
casein 
HSP70 JG1 Mouse 
mAb 
Invitrogen MA3-028 1:1000 70 1 x 
casein 
HSP90α CA1023 Mouse 
mAb 
Merck 
Millipore 
EMD17E7 1:1000 90 1 x 
casein 
Integrin α5 
 
Rabbit pAb CST 4705 1:1000 150 1 x 
casein 
Integrin αV EPR16800 Rabbit 
mAb 
Abcam ab179475 1:1000 125, 
135 
1 x 
casein 
Integrin αVβ6 c-19 Goat pAb Santa Cruz sc-6632 1:300 97 5% milk 
(PBST) 
Integrin β1 EP1041Y Rabbit 
mAb 
Abcam ab52971 1:1000 140-
150 
1 x 
casein 
Integrin β3 D7X3P Rabbit 
mAb 
CST 13166 1:1000 100 1 x 
casein 
Liprin α1 A-5 Mouse 
mAb 
Santa Cruz sc-376141 1:1000 134-
136 
5% BSA 
(TBST) 
p44/42 MAPK 
(Erk1/2) 
137f5 Rabbit 
mAb 
CST 4695 1:1000 42, 
44 
5% BSA 
(TBST) 
p44/42 MAPK 
(Erk1/2) 
(pT202/pY204
) 
 Rabbit pAb CST 9101 1:1000 42, 
44 
5% BSA 
(TBST) 
Paxillin 349/ 
Paxillin 
Mouse 
mAb 
BD 
Biosciences 
610051 1:500 68 5% BSA 
(TBST) 
Paxillin 
(pY118) 
 
Rabbit pAb CST 2541 1:500 68 5% BSA 
(TBST) 
Paxillin (pY31) 19/ 
Paxillin 
(Y31)  
Mouse 
mAb 
BD 
Biosciences 
558356 1:500 68 5% BSA 
(TBST) 
Rab8A EPR14873 Rabbit 
mAb 
Abcam ab188574 1:2000 24 5% BSA 
(TBST) 
Rap1A/Rap1B  Rabbit 
pAb 
CST 4938 1:500 21 5% BSA 
(TBST) 
Src 
 
Rabbit pAb CST 2108 1:1000 60 1 x 
casein 
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Primary 
Antibody 
Clone Host 
Species 
Supplier Catalogue 
Number 
Dilution kDa Buffer 
Src GD11 Mouse 
mAb 
Merck 
Millipore 
05-184 1:1000 60 5% BSA 
(TBST) 
Src Family 
Kinase (pY416)  
 
Rabbit pAb CST 2101 1:1000 60 5% BSA 
(TBST) 
Src (pY527) 
 
Rabbit pAb CST 2105 1:500 60 5% BSA 
(TBST) 
Talin c-20 Goat pAb Santa Cruz sc-7534 1:1000 230 1 x 
casein 
Tubulin DM1A Mouse 
mAb 
Sigma 
Aldrich 
T9026 1:1000 50 5% BSA 
(TBST) 
Vinculin hVIN-1 Mouse 
mAb 
Abcam ab11194 1:1000 123 1 x 
casein 
Table 2.2 Primary antibodies used for immunoblotting. Antibody details, dilution factor, molecular 
weight of the protein recognised (kDa) and the appropriate blocking buffer. The supplier Cell 
Signalling Technologies is abbreviated to CST. 
2.5.2 Immunofluorescence Antibodies 
Immunofluorescence antibodies were diluted in 0.1/0.1 buffer. All fluorophore conjugated 
secondary antibodies (Alexa 488, Alexa 594 and Alexa 647) were obtained from Jackson 
ImmunoResearch (Philadelphia, USA) and conjugated Phalloidin from Molecular Probes 
Invitrogen. Secondary antibodies and Phalloidin stains were diluted 1:400 in 0.1/0.1 buffer. 
Primary 
Antibody 
Clone Host Species Supplier Catalogue 
Number 
Dilution 
Caveolin 
 
Rabbit pAb BD Biosciences 610060 1:25 
Clathrin Heavy 
Chain 
23/Clathrin 
Heavy  
Mouse mAb BD Biosciences 610499 1:100 
EEA1 14/EEA1 Mouse mAb BD Biosciences 610456 1:500 
EGFR D38B1 Rabbit mAb CST 4267 1:1000 
EGFR R-1 Mouse mAb CRUK n/a 1:2000 
HRS 958/3 Rabbit pAb Sylvie Urbé n/a 1:1000 
Integrin αVβ6 53A2 Rat pAb John Marshall n/a 1:137 
LAMP2 H4B4 Mouse mAb Abcam ab119124 1:100 
Table 2.3 Primary antibodies used in immunofluorescence. Anti-HRS 958/3 (Sachse et al., 2002), anti-
integrin αVβ6 (Marsh et al., 2008). 
 
2.5.3 Flow Cytometry Antibodies 
Flow Cytometry antibodies were diluted in 0.1/0.1 buffer to 5 μg/μl. Fluorophore conjugated 
secondary antibodies (Alexa 488) were obtained from Jackson ImmunoResearch 
(Philadelphia, USA), and used diluted 1:400 in 0.1/0.1 buffer. 
Primary 
Antibody 
Clone Host Species Supplier Catalogue 
Number 
Concentration 
Integrin α5 VC5 Mouse mAb BD Biosciences 555651 5μg/μl 
Integrin αV 272-17E6 Mouse mAb Abcam ab16821 5μg/μl 
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Primary 
Antibody 
Clone Host Species Supplier Catalogue 
Number 
Concentration 
Integrin αVβ3 LM609 Mouse mAb Merck 
Millipore 
MAB1976 5μg/μl 
Integrin αVβ5 P1F6 Mouse mAb Merck 
Millipore 
MAB1961Z 5μg/μl 
Integrin αVβ6 E7P6 Mouse mAb Merck 
Millipore 
MAB2074Z 5μg/μl 
Integrin β1 K-20 Mouse mAb Santa Cruz sc-18887 5μg/μl 
IgG1 kappa 11711 Mouse mAb R&D Systems MAB002 5μg/μl 
Table 2.4 Primary antibodies used in flow cytometry 
2.6 Immunoblotting 
2.6.1 Sample Preparation 
Cells ready for lysis were placed on ice and washed once in ice cold PBS (-). Cells were lysed 
in a modified RIPA lysis buffer (500 mM NaCl, 50 mM pH 7.2 Tris, 10 mM MgCl2, 5 mM EGTA, 
1% (v/v) Triton X-100, 0.5% (v/v) Igepal, 0.1% (v/v) SDS; protease inhibitors added fresh: 20 
mM NaF, 2 mM Na3VO4, 50 µg/µl leupeptin, 50 µg/µl apoprotein, 0.5 mM AEBSF), and 
adherent cells were scraped off and transferred to a pre-cooled Eppendorf tube. Lysed cell 
suspensions were centrifuged at 13,000 x g for 10 minutes at 4°C. Supernatants were 
harvested and stored at – 20°C. 
Sample protein concentration was measured using the Pierce™ BCA Protein Assay Kit 
(ThermoFisher), per the manufacturer’s microplate procedure instructions (User guide 
MAN0011430 Rev. A). Samples were diluted for the assay 1:5 or 1:10, and all sample and 
standard curve samples were made in triplicate.  Sample absorbance was measured at 562 
nm on the Promega Golmax Multi Detection System. 
Reducing 5 x SDS sample buffer was added to samples for a final 1 x concentration. Samples 
were heated at 95°C for 5 minutes to denature the protein. 
2.6.2 Electrophoresis 
Sample protein concentrations typically loaded ranged between 5 – 30 μg depending on the 
sample concentration and volume. Equal amounts of protein were used for samples 
electrophoresed on the same gel. Samples were electrophoresed and separated in 1 or 1.5 
mm 4 – 12% Novex® NuPAGE™ gels (Invitrogen), in the Novex® Mini-cell XCell SureLock™ 
Electrophoresis tanks (Invitrogen). A constant 200 V for 45 minutes was used to resolve the 
samples. Precision Plus Protein™ All Blue Prestained Protein Standards (Bio-Rad) was used as 
the molecular weight marker. Novex® NuPAGE™ MES-SDS running buffer (Invitrogen) was 
used.  
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2.6.3 Transfer and Detection of Proteins 
Proteins were transferred using the semi-dry XCell SureLock™ XCell II™ Blot Module (Fisher 
Scientific) onto Amersham™ Protran® Premium Western blotting nitrocellulose membrane 
(pore size 0.45 µm). The transfer buffer was 20% (v/v) methanol, 200 mM glycine, 25 mM tris 
base, 350 µM SDS. A constant 35 V for 90 minutes was used to transfer the protein. 
Membranes were incubated in the appropriate blocking buffer corresponding to the primary 
antibody used (5% BSA in TBST, 5% non-fat dry milk in PBST or 1 x casein), for half an hour at 
room temperature on a rocker. Membranes were incubated with primary antibody solution 
overnight at 4°C on a rocker. 
Membranes were washed three times in TBST for five minutes on a shaker (120 RPM), before 
incubation with the secondary antibody (Alexa fluor 680 or 790 conjugated, Molecular 
Probes Invitrogen) diluted to 1: 10,000 in the corresponding blocking solution that was used. 
Membranes were washed again in TBST as before, then visualised on the LI-COR Odyssey Sa 
imaging system. Band pixel intensities were quantified using the Image Studio Version 3.1 
software.  
2.7 Immunofluorescence 
Cells were fixed with 4% (w/v) paraformaldehyde (PBS (-), pH 6.9) for 20 minutes at room 
temperature, then washed three times in PBS (-). Cells were then permeabilized for 3 – 4 
minutes with 0.1% (v/v) Triton X-100 at room temperature followed by three 0.1/0.1 buffer 
washes. Primary antibody incubations were for 45 minutes at room temperature, followed 
by three washes in 0.1/0.1 buffer. Samples were incubated with secondary antibody, with or 
without phalloidin (1:400 in 0.1/0.1 buffer), for 45 minutes at room temperature protected 
from light. Samples were then washed twice in PBS (-) and once in Milli-Q water, before 
mounting with Prolong Gold anti-fade mountant (Molecular Probes Invitrogen) on glass 
Superfrost® Plus glass slides (Thermo Scientific). 
Samples were imaged using the Zeiss 3i Marianas spinning disk confocal system using a 
63x/1.4 oil objective. Downstream image processing was performed using Image J FIJI. Co-
localisation analysis was assessed visually by eye.  
2.8 Flow Cytometry 
Cells were washed three times in PBS (-) and detached with trypsin. Cells were centrifuged 
at 280 x g for four minutes, then washed three times in cold 0.1/0.1 buffer. Cells were 
centrifuged again at 4°C and re-suspended in 100 µl primary antibody or isotype control (5 
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µg/ml in 0.1/0.1). Three negative controls were included: unstained cells re-suspended in 
0.1/0.1 buffer only, secondary antibody only control re-suspended in 0.1/0.1 buffer only at 
this stage, and an IgG isotype control. Only one isotype control was required as all the primary 
antibodies used were mouse. Cells were incubated in primary antibody for 30 minutes on ice. 
Cells were washed three times in 0.1/0.1 buffer, centrifuged (280 x g, 4 minutes, 4°C) and re-
suspended in 100 µl secondary antibody (1:200 in 0.1/0.1) (Donkey anti-mouse 488, Jackson 
ImmunoResearch), excluding the unstained control that was re-suspended in 0.1/0.1 buffer. 
Cells were incubated with the secondary antibody for 30 minutes on ice. Cells were washed 
three times in 0.1/0.1 buffer, centrifuged and re-suspended in 1 ml of cold PBS (-) and kept 
on ice.  
Cell surface fluorescence was measured using the FACSCanto II flow cytometer (BD 
Biosciences), with technical assistance from Carolyn Rainer from the University of Liverpool 
Technology Directorate Cell Sorting facility. Results were analysed using FlowJo® software.  
2.9 Mammalian Cell Culture 
The breast cancer cell lines MDA-MB-468, MCF-7, HER2-18, BT-474, pancreatic 
adenocarcinoma cell line BxPC3 (Tan et al., 1986), and fibroblast cell line TIFs (Telomerase-
immortalised fibroblasts) were maintained in Dulbecco’s Modified Eagle’s Medium (high 
glucose), supplemented with 10% (v/v) fetal calf serum (FCS) (Gibco) at 37°C, 5% CO2. The 
breast cancer cell line BT-20 (Lasfargues and Ozzello, 1958) was maintained in Minimum 
Essential Medium Eagle supplemented with 10% (v/v) fetal calf serum (FCS) (Gibco), at 37°C, 
5% CO2. Immortalised mouse embryonic fibroblasts (Im+ MEFs) (Jat et al., 1991) were 
maintained in Dulbecco’s Modified Eagle’s Medium (high glucose), supplemented with 10% 
(v/v) fetal calf serum (FCS) (Gibco) and 20 ng/ml interferon gamma (PeproTech, London, UK) 
at 33°C, 5% CO2. MDA-MB-468 (Cailleau et al., 1978), BT-20 and HER2-18 (Benz et al., 1992)  
were a gift from John Marshall (Barts Cancer Institute), MCF-7 (Soule et al., 1973) from Viki 
Allan (University of Manchester), BT-474 (Lasfargues et al., 1978) from Ian MacDonald 
(University of Nottingham), and TIFs (Bodnar et al., 1998) from Jim Norman (The Beatson 
Institute). 
2.9.1 Sub-cultivation 
Cells were washed three times with PBS (-) and detached from the culture flask using trypsin-
EDTA (0.5 g/l porcine trypsin, 0.2 g/l EDTA•4Na in Hank's Balanced Salt Solution (5.4 mM KCl, 
4.4 mM KH2PO4, 4.3 mM NaHCO3, 136.9 mM NaCl, 335.7 µM Na2HPO4 · 7H2O, 5.6 mM 
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C6H12O6, 28.2 µM Phenol red sodium salt (C₁₉H₁₃NaO₅S))) at 37°C. Cell suspensions were 
centrifuged at 280 x g for 4 minutes, before re-suspension in medium and re-plating 
appropriately. 
2.9.2 Cryopreservation 
Cells were washed three times with PBS (-) and detached from the culture flask using trypsin-
EDTA at 37°C. Cell suspensions were centrifuged at 280 x g for 4 minutes, before washing 
once in PBS (-), then re-suspending in FCS with 10% (v/v) DMSO. Cell suspensions in cryovials 
were frozen at -80°C before transferral to liquid nitrogen for long term storage. 
2.10 siRNA Transfection 
Im+ MEFs were transfected using the Lonza MEF 2 Nucleofector® Kit using the A-023 
programme on the Amaxa biostystems Nucleofector™ II (Lonza) machine, per the 
manufacturer’s instructions. Cells were 50 – 60% density before nucleofection. 2 x 106 cells 
and 3 μg of the oligonucleotide were used per reaction. A second round of transfection was 
performed 48 hours later, and the cells were used for the assay 48 hours after this. 
2.11 Generation of Cell-derived Matrices 
Cell-derived matrices were produced by stimulating TIF fibroblasts to produce extracellular 
matrix, and subsequently removing the cellular material leaving the intact structure 
(Beacham et al., 2007). Fibroblasts were cultured over time on pre-treated 13 mm coverslips 
(VWR) in a 24 well plate format. 
Coverslips were washed three times in PBS (-) then incubated with 0.2% sterile gelatin (from 
porcine skin) for one hour at 37°C. Coverslips were again washed in PBS (-), cross linked with 
1% (v/v) sterile glutaralydehyde in PBS (-) for 30 minutes at room temperature. After another 
PBS (-) wash, the crosslinker was then quenched with 1 M sterile glycine in PBS (-) for 20 
minutes at room temperature. The coverslips were then washed with PBS (-) and left to 
equilibrate in the appropriate culture medium (DMEM, 10% (v/v) FCS) at 37°C, prior to cell 
seeding. 
TIFs were detached with 1 x trypsin-EDTA as described and seeded at a concentration of 5 x 
104 cells per well on the pre-treated coverslips. Cells were then cultured overnight at 37°C 
8% CO2. If cells were sub-confluent at this stage, they were cultured longer until they reached 
confluence. The medium on confluent cells was changed to the same medium, supplemented 
with 50 µg/ml ascorbic acid. The ascorbic acid supplemented media was replaced every other 
day, until denudation. Ascorbic acid stimulates collagen production and stabilises the matrix. 
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Cells were cultured at 37°C, 8% CO2 for 8 days from the first ascorbic acid stimulation, prior 
to denudation. 
On the day of denudation, medium was removed and cells were washed with PBS (-), before 
adding pre-warmed (37°C) extraction buffer (20 mM NH4OH, 0.5% (v/v) Triton X-100 in PBS 
(-)). Cells were lysed for 2 minutes, by which point no intact cells were visible. Extraction 
buffer was removed, and cells washed in PBS (+). Residual DNA was digested with 10 µg/ml 
DNase I (Roche) in PBS (+) for 30 minutes at 37°C, 5% CO2. The DNase solution was removed, 
followed by two PBS (+) washes. At this point the cell-derived matrices were ready for use or 
stored at 4°C in PBS (+) supplemented with 1 x antibiotic antimycotic solution (100 x stock: 
10,000 units penicillin, 10 mg streptomycin, 25 µg/ml amphotericin B, Sigma), for up to a 
month.  
Prior to use, cell-derived matrices were washed twice in PBS (+) before blocking in heat-
denatured BSA for 30 minutes at room temperature. Matrices were then washed in PBS (+) 
and equilibrated in the appropriate medium for the assay.  
2.12 Cell Protrusion Assay 
Im+ MEFs were transfected with control, Eps8 or Eps8L2 siRNA, as detailed in section 2.10. 
The second transfection however was a co-transfection, containing 4 µg of LifeAct-GFP 
(Thistle Scientific) in addition to the siRNA oligonucleotides. LifeAct stains filamentous (F-
actin) without interfering with actin dynamics (Riedl et al., 2008). 
The next day cell-derived matrices were washed in PBS (-), then blocked in heat denatured 
BSA for 30 minutes at room temperature. Matrices were then washed again in PBS (-), then 
in phenol red free reduced serum Opti-MEM™ (Fisher Scientific) and left to equilibrate at 
37°C. Transfected Im+ MEFs were seeded at a density of 5 x 103 per compartment in a 35mm 
diameter 4 compartment CELLview™ glass bottom cell culture dish (Greiner Bio-One). 
16 hours later the media in each compartment was replenished, and cells were imaged using 
a Zeiss 3i Spinning disk confocal microscope Marianas™ SDC live cell imaging system, using a 
63x/1.4 aperture oil objective. Images were captured at 40 second intervals. After an hour of 
imaging, cells were stimulated with EGF (10 ng/ml), and then imaged after a brief interval (2 
– 3 minutes) required for capture focusing, for another hour.  
Cellular protrusive activity and motility was quantified using the QuimP software set of plug-
ins for ImageJ (Till Bretschneider, University of Warwick) (Dormann et al., 2002). 
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2.13 Growth Factor Stimulation 
Prior to growth factor stimulation cells were washed twice in PBS (-) and twice in DMEM5. 
Cells were then serum starved in DMEM5 at 37°C, 5% CO2 for a minimum of four hours. 
Growth factor was added diluted in pre-equilibrated DMEM5 in a bolus 10% of the volume 
of DMEM5 on the cells.  
2.13.1 Inhibition of EGFR 
Cells were pre-incubated with gefitinib at 1 µM for one hour to inhibit EGFR prior to assays. 
Gefitinib stock concentration (20 mg/ml) was in DMSO, so a corresponding fold diluted DMSO 
vehicle control condition was included in all assays. Gefitinib is a potent selective inhibitor of 
EGFR that binds to the kinase domain of the receptor.  
2.14 Inhibition of Protein Degradation 
Folimycin (Calbiochem) was used as a lysosomal inhibitor, as it is a potent and selective 
inhibitor of the vacuolar-type H+-ATPase that prevents acidification of the lysosome. 
Epoxomicin (Calbiochem) was used as a proteasomal inhibitor, as it is a potent and selective 
inhibitor of the peptide hydrolysing activities of the proteasome. Serum starved cells were 
incubated in 100 nM concentrations of both folimycin and epoxomicin for 6 hours, before 
EGF or LAP stimulation (Eccles et al., 2016). Inhibitor stocks were reconstituted in DMSO (1 
mg/ml) therefore control conditions included a DMSO vehicle control.  
2.15 Surface Receptor Internalisation Assay 
Cells were seeded at a 60% density in 10 cm dishes (three per condition) for 8 hours, before 
serum starvation overnight, by washing three times in PBS (-) then incubating in DMEM5 
solution. High binding half area 96 well ELISA (Enzyme Linked Immunosorbent Assay) 
immunoassay plates (Corning) were coated overnight at 4°C on a rocker with 5 μg/ml primary 
antibody (620W7 anti-integrin αVβ6, rat polyclonal, in-house supplied by John Marshall, 
Barts Cancer Institute, London (Morgan et al., 2011); or EGFR.1 anti-EGFR, mouse polyclonal 
(BD Biosciences, cat# 555996)) diluted in 0.05 M NaCO3 pH 9.6. The 96 well plates were 
washed four times in PBST, then blocked in 5% BSA at room temperature for a minimum of 
1 hour. All wash steps with cells during the assay were done on ice with ice cold buffers, 
unless otherwise stated. 
Cells were washed twice in Krebs, before labelling with EZ-Link™ Sulfo-NHS-SS-Biotin 
(Thermo Scientific) (220 μM in PBS (-)) at 4°C on a gentle rocker (7 RPM). Unbound biotin was 
removed by washing three times in Krebs. ‘Total’ positive control cell plates were returned 
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to 4°C to show maximal surface biotinylated receptor signal. ‘Blank’ negative control plates 
were also returned to 4°C to show the efficiency of surface biotin removal without 
internalisation. Equilibrated warm medium alone or with LAP (0.5 μg/ml) or EGF (10 ng/ml) 
was added to plates, before immediate transferral to 37°C to allow surface receptor 
internalisation for either 4, 7, 15 or 30 minutes. 
After internalisation plates were immediately returned to ice and washed twice with PBS (-) 
and once with pH 8.6 buffer (100 mM NaCl, 50 mM Tris pH 7.5, pH 8.6 at 4°C). pH 8.6 buffer 
supplemented with 22.84 mM Sodium 2-mercaptoethanesulfonate (MesNa) (Fluka 
Analytical) and 0.22 mM NaOH was then added to the blank and internalised plates, before 
incubation for 30 minutes at 4°C on a gentle rocker. The incubation with the reducing agent 
MesNa removes surface biotin by cleaving the reducible disulphide bond in the biotin 
reagent. Biotin bound to internalised surface receptors is unaffected, as MesNa is cell-
impermeant (Rainero et al., 2013). 
Plates are then washed twice in PBS (-) then lysed in lysis buffer (200 mM NaCl, 75 mM Tris, 
7.5 mM EDTA, 7.5 mM EGTA, 1.5% (v/v) Triton X-100, 0.75% (v/v) Igepal CA-630, 15 mM NaF, 
1.5 mM Na3VO4, 50 µg/µl leupeptin, 50 µg/µl apoprotein, 1 mM AEBSF). Lysates were spun 
at 13,000 x g for 10 minutes at 4°C. The blocking buffer was removed from the 96 well plate 
which was washed four times in PBST, before the lysate supernatant was added into each 
corresponding well.  Plates were incubated with the lysate overnight at 4°C.  
Unbound material was removed with four PBST washes. Wells were then incubated with 
streptavidin-conjugated horseradish peroxidase (1:500) in PBST containing 1% BSA, for 1 
hour at room temperature. The plate was then washed again four times in PBST, before 
incubation with an ABTS substrate solution (ABTS buffer: 0.1 M sodium acetate, 0.05 
NaH2PO4 pH 5, with 2 mM ABTS, 2.5 mM H2O2). The resultant colourimetric change was 
measured at 405 nm absorbance on a Thermo Labsystem Multiskan Spectrum plate reader. 
Readings were taken across multiple time points ranging from 30 minutes to 24 hours, 
depending on the rate of development.  
2.16 Isolation of 2D Cell-matrix Adhesions 
The protocol for isolating 2D cell-matrix adhesions is based on the published methodology 
with some outlined modifications (Jones et al., 2015). Tissue culture 10 cm dishes were 
coated with either fibronectin, LAP or collagen I ligands overnight at 4°C on a rocker. Dishes 
were then washed twice in PBS (-), blocked using heat inactivated BSA for 30 minutes at room 
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temperature on a rocker. Plates were then washed twice in PBS (-), once in DMEM5, then 
incubated with 9 ml of DMEM5 to equilibrate at 37°C, 5% CO2. 
Cells were washed in PBS (-), harvested by trypsinisation and centrifuged at 280 x g for 4 
minutes. Cell pellets were then re-suspended in DMEM5 and incubated in 40 ml DMEM5 at 
37°C for 30 minutes. The cell suspension was centrifuged and re-suspended in DMEM5 
sufficient to plate 1 ml of cell suspension per prepared 10 cm dish. Cells were seeded at 5 x 
106 per ml and allowed to adhere to ligand for 2 hours 30 minutes at 37°C, 5% CO2. 
Cells were then cross-linked with the cell-permeable crosslinker DTBP (dimethyl 3,3'-
dithiobispropionimidate, Thermo Fisher), which stabilises protein interactions. DMEM5 was 
then removed and replaced with 5 ml per plate of pre-warmed (37°C) 3 mM DTBP in DMEM5. 
Plates are incubated at 37°C for 30 minutes to permit cross-linking.  
Cells were then washed twice in ice cold PBS (-) and incubated with 20 mM pH 8.0 Tris for 5 
minutes at room temperature, to quench the crosslinker activity. Plates were then washed 
twice in ice cold PBS (-) and transferred to ice packs. 
Immediately prior to sonication, cells were washed once and filled with cold extraction buffer 
(20 mM NH4OH, 0.5% (v/v) Triton X-100 in PBS (-)). Cells were sonicated submerged in 
extraction buffer, using the SONICS Vibra cell™ sonicator at 20% amplitude for approximately 
2 minutes per plate. After sonication plates were washed three times in cold extraction 
buffer, and three times in cold PBS (-). 
PBS (-) was then thoroughly removed from the plates, and plates were dried. Remaining 
adhesion complexes were harvested by scraping in 2 x concentrated reducing Sodium 
dodecyl sulfate (SDS) sample buffer. Harvested material was collected in an Eppendorf and 
incubated at 95°C for 5 minutes. A proportion of the sample was then immunoblotted to 
assess the quality and specificity of the adhesion isolation. The remaining sample was then 
processed for MS.  
2.17 Mass Spectrometry 
2.17.1 Protein Gel Preparation 
Samples from 2D cell-matrix adhesion isolation preparation were resolved by polyacrylamide 
gel electrophoresis (PAGE), in 1.5 mm 10 well 4 – 12% Novex® NuPAGE™ gels (Invitrogen), in 
the Novex® Mini-cell XCell SureLock™ Electrophoresis tanks (Invitrogen). A constant 160 V 
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was used to resolve the samples. Novex® NuPAGE™ MES-SDS running buffer (Invitrogen) was 
used.  
Protein in the gels was stained by incubating the gel in Instant Blue™ (Expedion) colloidal 
Coomassie protein stain, for one hour at room temperature on the rocker. Gels were then 
de-stained with five five-minute washes in MilliQ water, on the rocker. Gels were then 
washed further in MilliQ for one hour on the rocker, before storing in MilliQ overnight at 4°C. 
2.17.2 Peptide Digestion 
Gel bands were excised with sterile scalpel blades on a clean tile. Gel bands were then cut 
into ~1 mm3 pieces and transferred into a single corresponding well of a 96-well perforated 
plate (Glygen Corp). The gel was kept moist throughout excision with MilliQ water. Gel pieces 
were then destained by incubation in 100 µl 50% (v/v) acetonitrile (ACN) / 50% (v/v) NH4HCO3 
for 30 minutes at room temperature, before removing the supernatant (wash) by 
centrifugation (96-well-plate rotor, 1,500 RPM, 2 minutes). This step was repeated until all 
the stain was removed from the gel pieces, leaving them transparent (usually four washes 
were required). 
Gel pieces were then dehydrated twice by incubating with 50 µl 100% ACN for 5 minutes, 
removing the supernatant following centrifugation each time. Gel pieces were then dried by 
vacuum centrifugation for 20 minutes using the Christ VWR RVC 2-25 Speed vacuum, then 
incubated in 50 µl 10 Mm Dithiothreitol (DTT) for one hour at 56°C, to reduce the proteins in 
the sample. DTT was then removed following centrifugation, and proteins then alkylated by 
incubating the gel pieces in 50 µl 55 mM Iodoacetamide (IA) for 45 minutes at room 
temperature, in the dark. 
IA was then removed, and gel pieces were then sequentially washed then dehydrated twice, 
by incubating in 50 µl 25 mM NH4HCO3 for 10 minutes, then 50 µl ACN for 5 minutes at room 
temperature, removing each solution after incubation following centrifugation. The gel 
pieces were then dried by vacuum centrifugation for 20 minutes. 
A fresh collection plate (microplate u-shaped well bottom, Thermo Scientific) was then 
placed under the perforated plate, for peptide collection. Gel pieces were then incubated 
with 1.25 ng/µl trypsin gold (Promega) in 25 mM NH4HCO3 for 45 minutes at 4°C to allow 
even penetration into the gel without proteolytic activity. Proteins in gel pieces were then 
incubated in the trypsin solution overnight at 37°C for protein digestion. 
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2.17.3 Peptide Extraction 
Tryptic peptides were collected by centrifugation. Additional peptides were extracted by 
incubating the gel pieces in 50 μl 99.8% (v/v) ACN/ 0.2% (v/v) formic acid (FA) for 30 minutes 
at room temperature, centrifugation, followed by incubating with 50 μl 50% (v/v) ACN/ 0.1% 
(v/v) FA for 30 minutes at room temperature. These additional extracted peptides were 
collected by centrifugation then pooled with the initial supernatant and evaporated to 
dryness in the collection plate by vacuum centrifugation for approximately two hours, 
monitoring every 20 minutes after the initial hour to ensure peptides were not over-dried.  
Dried peptides were then re-suspended in 20 µl 5% (v/v) ACN in 0.1% FA and transferred into 
12 x 32 mm glass screw neck vials (Waters). Peptides were then stored at –20°C until analysis. 
2.17.4 Mass Spectrometry 
5 µl of each digest was injected onto a Nanoacquity™ (Waters) Ultra Performance Liquid 
Chromatography (UPLC) column, coupled to an LTQ-Orbitrap XL (Thermo Fisher) equipped 
with a nanoelectrospray source (Proxeon). Samples were separated on a 1 – 85% ACN 
gradient, 0.300 µl/min flow rate, with an 80-minute retention time. Dynamic exclusion was 
enabled for a repeat count of 1 for a duration of 30.00 s. MS spectra were acquired by the 
LTQ-Orbitrap at a resolution of 30,000 and MS/MS was performed on the top 12 most intense 
ions in the LTQ ion trap.  
2.17.5 Peptide Identification 
Raw peptide MS data were converted into peak lists and searched against a reviewed H. 
Sapiens UniProt database (containing 149,633 sequences; 47,132,354 residues) using Mascot 
Daemon (version 2.3.2) software. The initial precursor and fragment ion maximum mass 
deviations in the database search were set to 5 ppm and 0.6 Da, respectively, which is optimal 
for linear ion trap data. One missed cleavage by the enzyme trypsin was allowed. Cysteine 
carbamidomethylation (C) was set as a fixed modification, whereas oxidation (M, K, P), and 
phosphorylation (S, T, Y) were considered as variable modifications. 
The database search results were processed and statistically evaluated within Scaffold 
(version 4) The false discovery rate (FDR) for the peptides and proteins were set to 0.01 and 
0.4 respectively, to ensure the worst peptide/protein identifications had a 1% or 4% 
probability of being a false identification, respectively.  The imported data was also searched 
with the X!Tandem (The Global Proteome Machine Organization), and the results from both 
were combined to increase protein identification confidence. 
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2.17.6 Proteomic Analysis 
Data was imported into Cytoscape (v3.4.0) for visualization of protein-protein interactions 
mapped using the Protein Interaction Network Analysis (PINA) interactome database (release 
date 21/05/2014) (Wu et al., 2009) supplemented with a literature curated database of IAC 
proteins (Robertson et al., 2015; Zaidel-Bar et al., 2007). Three proteins could not be mapped 
(E9PAV3, NACA; Q9BQ48, MRPL34; E9PRG8, c11orf98) as these were not present in the PPI 
database.  
Over-representation of gene ontology (GO) term analysis was performed using the Cytoscape 
plug-in ClueGO (version 2.3.3), with KEGG (Kyoto Encyclopedia of Genes and Genomes) and 
Reactome pathway terms. GO term grouping was used to combine related terms into groups, 
with a designated leading term. 
2.18 Statistics 
Pair-wise comparisons of continuous data were tested using Student’s two-tailed t-test for 
parametric data, or Rank sums test for non-parametric data where the equal variance test 
(Brown-Forsythe) failed. Comparisons between more than two groups were tested using the 
analysis of variance (ANOVA) with the appropriate post-hoc test for multiple test correction. 
Statistical tests were performed using either SigmaPlot 13.0 statistical software, or within the 
‘Quantitative Analysis’ section of Scaffold 4.8 (Proteome Software). 
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3. Crosstalk between αVβ6 and EGFR 
3.1 Introduction 
Integrin αVβ6 is normally expressed at very low or undetectable levels and is upregulated 
during processes that require epithelial remodelling such as wound healing (Breuss et al., 
1995). A key function of αVβ6 is the local activation of TGFβ, which is thought to be achieved 
through the application of mechanical force to LAP, releasing TGFβ from its inactive complex 
(Tod et al., 2017; Worthington et al., 2011). Integrin αVβ6 is therefore intimately linked with 
functions downstream of TGFβ signalling including epithelial repair, ECM deposition and 
EMT. Upregulation of αVβ6 is observed in a range of cancers such as breast, pancreatic, oral 
squamous cell and colon carcinomas, and usually correlates with poor survival (Bates et al., 
2005; Li et al., 2016; Moore et al., 2014; Thomas et al., 2001b). Expression of αVβ6 can be 
elevated at the invasive front of tumours and is associated with increased incidence of 
metastatic lesions (Cantor et al., 2015; Moore et al., 2014; Yang et al., 2008). These 
observations suggest αVβ6 promotes local invasion and distant metastases, linking it to 
higher mortality rates caused by metastases (Chaffer and Weinberg, 2011).  
Integrin αVβ6 is shown to drive cellular invasion, and therefore can be described as a pro-
invasive integrin. Knockout or inhibition of αVβ6 decreases cell invasion in vitro in transwell 
and organotypic assays (Moore et al., 2014; Morgan et al., 2011; Thomas et al., 2001b). Local 
invasion can be facilitated through αVβ6 promoted expression, secretion and activation of 
proteinases including uPa and MMPs which degrade ECM that can otherwise be a physical 
barrier to cell migration (Dalvi et al., 2004; Morgan et al., 2004). Invasion can also be 
increased through αVβ6 dependent induction of EMT via activation of TGFβ, which causes a 
switch from collective to single cell motility (Lee et al., 2014). 
Integrin αVβ6 is an independent predictor for breast cancer survival, with statistically 
significant lower survival rates in patients with high αVβ6 expression in cohort studies 
(Moore et al., 2014). Patients with ErbB2 positive breast cancer and high levels of αVβ6 also 
had a statistically significant worse survival prognosis compared to those with low αVβ6 
expression (Moore et al., 2014). Inhibition of αVβ6 abrogated ErbB2-dependent invasion in 
response to the ErbB2/ErbB3 ligand Heregulin β1 (HRGβ), suggesting ErbB2 invasion was 
αVβ6 dependent, leading to the study of the complex relationship between the two 
receptors (Moore et al., 2014). Monotherapy with the clinical αVβ6 inhibitor 264RAD or the 
ErbB2 inhibitor trastuzumab slowed tumour growth in ErbB2 positive breast cancer 
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xenografts, however a combination of the two therapies effectively stopped tumour growth 
even in a trastuzumab resistant xenograft model (Moore et al., 2014). These data 
demonstrated potential for 264RAD as either a mono or combination therapy in ErbB2 
positive breast cancer, and indicated crosstalk between αVβ6 and ErbB2 may be clinically 
important. 
High expression of αVβ6 is associated with very poor survival in triple-negative breast cancer 
(TNBC) (HR = 1.71, 95% CI = 1.06 to 2.77, P = 0.026) (personal correspondence, Louise Jones, 
Barts Cancer Institute QMUL). TNBC is a highly aggressive sub-category representing 15% of 
breast cancer, defined by the absence of the oestrogen receptor (ER), progesterone receptor 
(PG) and absence or lack of amplification or overexpression of ErbB2 (Andreopoulou et al., 
2017; Denkert et al., 2017). TNBC typically has a poor prognosis and rapid onset of metastasis 
(Denkert et al., 2017). There are no specific targeted therapies against TNBC, and 
chemotherapy is the mainline treatment (Harbeck and Gnant, 2017). Few therapeutic targets 
are identified in TNBC aside from the BRCA1/2 mutation and androgen receptor (Denkert et 
al., 2017; Harbeck and Gnant, 2017). EGFR is overexpressed in the majority of TNBC and 
associated with a worse prognosis (Livasy et al., 2006; Nielsen et al., 2004); however, despite 
this, anti-EGFR therapeutics have been unsuccessful in clinical trials (Andreopoulou et al., 
2017). There is therefore a great clinical need for identification of therapeutic targets for the 
treatment of TNBC. 
Unanticipated receptor crosstalk is an important feature behind clinical trial failures, which 
has been particularly problematic in the development of integrin targeting agents (Raab-
Westphal et al., 2017). The relationship between αVβ6 and ErbB2 has been demonstrated to 
be therapeutically relevant in ErbB2 positive breast cancer (Moore et al., 2014). This project 
aims to investigate crosstalk between αVβ6 and EGFR, which are both associated with poor 
prognosis in TNBC and have been reported to exhibit crosstalk (Ahmed et al., 2002a; Eberlein 
et al., 2013; Tod et al., 2017). 
An appropriate cell line model will be established, based on expression and sub-cellular 
distribution of αVβ6 and EGFR. Trafficking of the receptors will be examined with ligand-
induced stimulation, to determine if this can concomitantly affect the endocytosis and 
trafficking routes of the reciprocal receptor. Collaborative signalling downstream of the 
receptors will be assessed by investigating activation status of relevant signalling cascades 
following ligand stimulation of either receptor. 
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3.2 Results 
3.2.1 Cell line characterisation 
An appropriate cell line for use in this study needed to be established. The key criteria were 
expression of αVβ6 and EGFR without ErbB2 to allow the dissection of EGFR specific effects 
that do not rely on its dimerisation with ErbB2. The TIF fibroblast cell line was used as a 
negative control for αVβ6 expression, as αVβ6 expression is restricted to epidermal cells. The 
breast cancer cell lines MCF-7 and HER2-18 were used as negative and positive controls for 
αVβ6 respectively. The HER2-18 cell line was created by overexpressing ErbB2 in MCF-7 cells 
(Benz et al., 1992). HER2-18 cells exhibit de novo expression of αVβ6 (Moore et al., 2014), 
however it is unknown if this is a consequence of ErbB2 overexpression or a result of clonal 
selection. BT-474 were used as an additional positive control for αVβ6 and ErbB2 expression 
(Holliday and Speirs, 2011; Moore et al., 2014). The TNBC cell lines MDA-MB-468 and BT-20 
were identified as potentially relevant models as both have documented EGFR expression 
(Grigoriadis et al., 2012). The pancreatic cancer cell line BxPC3 was also assessed as a 
potential model as αVβ6 EGFR crosstalk may also be therapeutically relevant in pancreatic 
cancer (Li et al., 2016). 
Total expression levels of integrins, EGFR and HER2 were assessed by immunoblotting (Figure 
3.1 A). All cell lines were positive for integrin αV and β1, which can form heterodimers with 
multiple other subunits. HER2-18, BT-474, MDA-MB-468, BT-20 and BxPC3 cell lines were 
positive for β6 subunit expression. HER2-18, MCF-7, BxPC3 and TIF were positive for α5, 
which can dimerise with β1 and bind the RGD motif. All cell lines except MCF-7 expressed 
EGFR, with particularly high levels observed in MDA-MB-468. EGFR expressed in BT-474 cells 
is a slightly higher molecular weight than in the other cell lines, suggesting that the protein 
may have undergone post-translational modifications. The positive controls HER2-18 and BT-
474 expressed high levels of ErBb2, whereas TIF and BT-20 cells expressed low levels. Protein 
loading was not very equal in these experiments (see GAPDH in Figure 3.1 A) therefore only 
broad conclusions regarding protein expression levels can be made. 
Surface expression of a panel of integrins was assessed by flow cytometry for MDA-MB-468, 
BT-20 and BxPC3 cell lines (Figure 3.1 B). In agreement with the immunoblotting data, all cell 
lines were positive for αVβ6 (detected by a heterodimer specific antibody) and β1. BxPC3 
cells had low surface levels of β1 in contrast to the high total protein levels observed by 
immunoblotting, suggesting the cellular pool of β1 is not entirely at the cell surface. BT-20 
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and BxPC3 but not MDA-MB-468 were positive for α5. All cell lines were negative for αVβ3, 
and BT-20 was the only cell line positive for αVβ5.  
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Figure 3.1 Integrin, EGFR and ErbB2 expression in a panel of cell lines. (A) Western blotting of integrin, 
EGFR and ErbB2 protein expression levels in Her2-18, MCF-7, MDA-MB-468, BxPC3, BT-20, BT-474 and 
TIF total cell lysates. N=3 for integrin, and N=1 for EGFR and ErbB receptor immunoblotting (B) Flow 
cytometry surface expression of integrin αvβ3, αvβ5, αvβ6, α5, β1 in MDA-MB-468, BT-20 and BxPC3 
cell lines. N=1 
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MDA-MB-468, BT-20 and BxPC3 were all characterised as potentially suitable cell line models. 
This project aimed to investigate αVβ6-specific processes, using LAP as a key ligand, therefore 
a lack of alternative LAP binding integrins facilitates the use of LAP as an αVβ6-specific ligand. 
Integrins αVβ3 and αVβ5 bind the RGD motif present in ligands including LAP. MDA-MB-468s 
were chosen as the primary cell line model for study due to the high level of αVβ6 and EGFR 
expression. BT-20s were identified as a complementary cell line with a similar αVβ6 
expression profile but a lower level of EGFR. BT-20s have surface expression of αVβ5 and α5 
whereas MDA-MB-468s do not. Work was not continued with the BxPC3 cell line to 
concentrate focus on molecular processes associated with TNBC. 
Having identified MDA-MB-468s as the primary cell line model, the subcellular distribution 
of αVβ6 and EGFR was then investigated by co-staining for both receptors by 
immunofluorescence (Figure 3.2). Cells were plated either in the presence of 10% serum, or 
on coverslips coated with FN or LAP ligands in the absence of serum. Serum contains ECM 
molecules and therefore represents a mixed ligand environment (Zheng et al., 2006). Serum-
free conditions were used for FN and LAP ligand conditions to ensure cells specifically 
engaged the coated ligand rather than alternative serum-derived ligands, as FCS contains a 
mixture of ECM proteins and growth factors. 
Preliminary data showed cells plated in serum, or bound to FN, had αVβ6 positive adhesions 
and actin stress fibres, clearly visible in juxtamembrane z-sections (Figure 3.2). Few αVβ6 
adhesions were observable on LAP, and cells had a more rounded morphology without clear 
stress fibres. It is likely cells on LAP were not forming focal adhesions which are dependent 
on mechanical force application associated with actin stress fibres, as opposed to the 
alternative scenario that cells were forming focal adhesions lacking αVβ6. Integrin αVβ6 
present across the ventral surface of the cell is likely to be engaging ligands regardless of 
aggregation into mature adhesions, as it is at the site of the cell-matrix interface. EGFR was 
distributed throughout the cell at the surface and intracellularly (Figure 3.2). Integrin αVβ6 
and EGFR co-localised in the ventral cell surface plane proximal to αVβ6-dependent 
adhesions and at intracellular structures reminiscent of trafficking vesicles, most evident in 
juxtabasal z-sections towards the middle of the cell. Co-localisation between αVβ6 and EGFR 
was seen across all three ligand conditions at the membrane and in vesicles, although 
appeared most pronounced in the presence of serum (Figure 3.2). A key difference between 
the serum containing condition compared to the FN and LAP ligand conditions is that cells 
were serum-starved for 2.5 hours during adherence and spreading to facilitate engagement 
of specific ligands. The presence of soluble growth factors and ECM ligands in serum could 
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potentially engage both αVβ6 and EGFR and stimulate receptor internalisation, resulting in 
an altered subcellular distribution. 
 
Figure 3.2 β6 and EGFR subcellular distribution in MDA-MB-468 cells on different ligands. MDA-MB-
468 cells adhered and spread on glass coverslips in the presence of 10% FBS, or under serum free 
conditions on glass coverslips coated with FN or LAP, over the course of 2.5 hours. Single z sections 
are displayed for basal and juxtramembrane sections of the cell, 1 μm, 0.8 μm and 0.6μm above for 
serum, FN and LAP images, respectively.  β6; green and EGFR (R-1); red. Scale bar = 10μm. N=1 
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3.2.2 αVβ6 and EGFR traffic concomitantly 
Internal structures of overlapping αVβ6 and EGFR were reminiscent of endosomes. To 
determine the nature of these structures MDA-MB-468 cells were co-stained by 
immunofluorescence for αVβ6 and EGFR, and the trafficking compartment markers EEA1 
(early endosomal antigen 1), HRS (hepatocyte growth factor-regulated tyrosine kinase 
substrate) or LAMP2 (lysosome-associated membrane protein 2). EEA1 is a marker of early 
endosomes, and is recruited to their membrane during their formation shortly after 
endocytosis (Sorkin and von Zastrow, 2009). HRS is classed as a later trafficking marker, as it 
is a major component of ESCRT-0 which predominantly localises to MVBs (Raiborg and 
Stenmark, 2009). LAMP2 is a marker of the lysosome, which cargo can be trafficked to from 
the late endosome (Luzio et al., 2007).  
MDA-MB-468 cells were seeded onto coverslips in DMEM in the presence of 10% FBS and 
allowed to adhere and spread, then serum-starved prior to stimulation with EGF or LAP to 
promote the internalisation of αVβ6 and EGFR. LAP stimulation was hypothesised to trigger 
endocytosis of αVβ6, as ligand stimulation is known to trigger integrin internalisation 
(Bridgewater et al., 2012). For LAMP2 co-localisation assays, lysosomal and proteasomal 
inhibition was achieved by pre-incubating cells with the inhibitors folimycin and epoxomicin 
(Eccles et al., 2016). Co-localisation of αVβ6, EGFR and endosomal markers was analysed by 
eye. 
Under serum-starved conditions αVβ6 and EGFR colocalise with each other but not EEA1, 
HRS or LAMP2 (20/20 cells) (Figure 3.3 and Figure 3.4). The receptor distribution with respect 
to EEA1 is unchanged after 5 minutes EGF stimulation (17/17 cells) (Figure 3.3 A). After 10 
minutes cells exhibit one of three phenotypes; 1) αVβ6 and EGFR co-localisation with (6/18 
cells) or 2) without low levels of EEA1 overlap (6/18 cells), and 3) EGFR EEA1 co-localisation 
with little αVβ6 co-localisation (6/18 cells). The predominant subcellular distribution after 15 
minutes of EGF is weak co-localisation of αVβ6, EGFR and EEA1 (16/16 cells). This distribution 
persists until 30 minutes (9/13 cells), however there is a shift towards weak co-localisation 
between EGFR and EEA1 only in some cells (4/13 cells). This is followed by a return to αVβ6 
and EGFR co-localisation without EEA1 in vesicles at 60 minutes (10/15 cells), although some 
infrequent EGFR EEA1 colocalising cells persist (5/15 cells).  
EGF stimulation triggers endocytosis of EGFR, therefore it was expected that stimulation with 
EGF would increase co-localisation of EGFR with the early endosomal marker EEA1. EGF 
stimulation also causes αVβ6 to weakly colocalise with EEA1, proximal to EGFR. These data 
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demonstrate that EGF induces re-distribution of αVβ6 in a manner consistent with 
internalisation. This preliminary data showing weak co-localisation of αVβ6 and EGFR in the 
same EEA1 positive endosomes suggests these receptors could have co-internalised 
together.  
 
 
Figure 3.3 A EGF stimulation induces colocalisation of β6 and EGFR with EEA1. MDA-MB-468 cells, co-
stained for β6, EGFR (D38B1) and EEA1. Single z slice shown for a juxtamembrane section of the cell.  
EGF stimulation is shown in minutes. EGFR is shown at 50 – 15000 for 0, 5 and 15 minutes and 100 - 
2000 for 10, 30 and 60 minutes, intensity arbitrary units. Scale bar = 10 μm. N= 2, n= 13 - 20 cells per 
timepoint. 
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Figure 3.3 B  EGF stimulation induces colocalisation of β6 and EGFR with HRS. MDA-MB-468 cells, co-
stained for β6, EGFR (R-1) and HRS. Single z slice shown for a juxtamembrane section of the cell.  EGF 
stimulation shown in minutes. Scale bar = 10 μm. N= 2, n= 16 – 18 cells per timepoint.  
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Figure 3.3 C EGF stimulation induces colocalisation of EGFR with LAMP2. MDA-MB-468 cells, co-
stained for β6, EGFR (D38B1) and LAMP2. Cells were pre-incubated with the lysosomal and 
proteasomal inhibitors folimycin and epoxomicin, respectively. Single z-slice shown for a 
juxtamembrane section of the cell.  EGF stimulation shown in minutes. EGFR is shown at 100 - 19000 
for 0 - 10 minutes and 100 - 2600 for 15 - 90 minutes, intensity arbitary units. Scale bar = 10 μm. N=1, 
n= 15 - 20 cells per timepoint. 
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Figure 3.3 D: EGF stimulation induces colocalisation of EGFR with LAMP2. MDA-MB-468 cells, co-
stained for β6, EGFR (D38B1) and LAMP2. DMSO vehicle control for folimycin and epoxomicin 
lysosomal and proteasomal inhibitors. Single z slice shown for a juxtamembrane section of the cell.  
EGF stimulation shown in minutes. EGFR is shown at 100 - 19000 for 0 - 30 and 90 minutes and 100 - 
2600 for 60 minutes, intensity arbitrary units. Scale bar = 10 μm. N=1, n= 8 - 24 cells per timepoint. 
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All cells at 5 minutes (16/16 cells), and most cells at 10 minutes (10/16 cells) of EGF 
stimulation, had some weak co-localisation between EGFR and αVβ6 but not HRS (Figure 3.3 
B). Approximately one-third of cells (5/16 cells) at 10 minutes have some co-localisation 
between both αVβ6 and EGFR with HRS. After 15 minutes the majority of cells have some 
weak co-localisation between EGFR and αVβ6 in HRS positive endosomes (14/18 cells), whilst 
a remaining quarter of cells have EGFR and αVβ6 co-localisation without HRS overlap (4/18). 
Some punctae of co-localisation was observed between both receptors and HRS at 30 (11/16 
cells) and 60 minutes (18/18 cells) EGF stimulation. This preliminary data indicates some co-
localisation of EGFR and αVβ6 with HRS positive endosomes, which could suggest the 
receptors remain proximal whilst HRS is recruited to early endosomes and in the formation 
of the MVB. 
Without lysosomal and proteasomal inhibition, no co-localisation was observed between 
either αVβ6 or EGFR and LAMP2, except at 60 minutes where EGFR colocalised with LAMP2 
in approximately one-quarter of cells (6/23 cells) (Figure 3.3 D). In the presence of inhibitors, 
EGFR and LAMP2 co-localised initially after 15 minutes of EGF stimulation (8/17 cells), prior 
to which co-localisation was between EGFR and αVβ6 only (Figure 3.3 C). EGFR/LAMP2 co-
localisation increased further with EGF stimulation time (30 minutes 7/15, 60 minutes 13/20 
cells. Integrin αVβ6 is excluded from sites of EGFR and LAMP2 co-localisation. Preliminary 
data showing co-localisation of EGFR with LAMP2 indicates EGFR is trafficked to the lysosome 
for degradation. The absence of αVβ6 in LAMP2 positive structures indicates it may follow 
an alternative trafficking route following EGF stimulation, likely recycling. These fates for 
EGFR and αVβ6 agree with the canonical view that EGFR is targeted for lysosomal 
degradation, and integrins are predominantly recycled (Bridgewater et al., 2012; Wiley et al., 
1991). Increasing EGFR and LAMP2 co-localisation with EGF stimulation time is likely 
influenced by accumulation of EGFR in lysosomes, as the lysosomal inhibitor Folimycin 
inhibits lysosomal acidification therefore preventing enzymatic degradation of its contents. 
A reciprocal experiment with LAP stimulation was also performed to test the hypothesis that 
soluble LAP stimulates αVβ6 endocytosis, and if so, if αVβ6 internalisation affects the 
distribution of EGFR. Most cells show co-localisation between αVβ6 and EGFR after 5 minutes 
of stimulation, without co-localisation with EEA1 (4/7 cells). However, some cells exhibited 
weak co-localisation of αVβ6 and EGFR in EEA1 positive endosomes (3/7 cells) (Figure 3.4 A).  
All cells at 10 minutes LAP stimulation had a degree of co-localisation between αVβ6, EGFR 
and EEA1 (5/5 cells). No co-localisation was observed between αVβ6 and EEA1 between 15 
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to 60 minutes LAP stimulation. Cells at 60 minutes have αVβ6 positive focal adhesions 
indicating a large proportion of receptor at the cell membrane. 
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Figure 3.4 A LAP stimulation induces colocalisation of β6 and EGFR with EEA1. MDA-MB-468 cells, co-
stained for β6 (620W7), EGFR (D38B1) and EEA1. Single z slice shown for a juxtamembrane section of 
the cell.  LAP stimulation is shown in minutes. Scale bar = 10 μm. N=2, n= 13 - 20 cells per timepoint.
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Figure 3.4 B LAP stimulation induces colocalisation of β6 and EGFR with HRS. MDA-MB-468 cells, co-
stained for β6, EGFR (D38B1) and HRS.  Single z slice shown for a juxtamembrane section of the cell.  
LAP stimulation is shown in minutes. EGFR is shown at 100 - 14000 for 0, 5 and 10 minutes and 120 - 
500 for 15, 30 and- 60 minutes, intensity arbitrary units. Scale bar = 10 μm. N=2, n= 13 - 19 cells per 
condition. 
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Figure 3.4 C LAP stimulation induces colocalisation of EGFR with LAMP2. MDA-MB-468 cells, co-stained 
for β6, EGFR (D38B1) and LAMP2. Cells were pre-incubated with the lysosomal and proteasomal 
inhibitors folimycin and epoxomicin, respectively. Single z slice shown for a juxtamembrane section of 
the cell. LAP is stimulation shown in minutes. EGFR is shown at 160-3700 intensity arbitrary units. Scale 
bar = 10 μm. N=1, n =12 - 15 cells per condition. 
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Figure 3.4 D LAP stimulation induces colocalisation of EGFR with LAMP2. MDA-MB-468 cells, co-
stained for β6, EGFR (D38B1) and LAMP2. DMSO vehicle control for folimycin and epoxomicin 
lysosomal and proteasomal inhibitors. Single z slice shown for a juxtamembrane section of the cell.  
LAP stimulation shown in minutes. EGFR is shown at 160 - 47000 for 10 minutes and 160 - 3700 for 
15, 30, 60 and 90 minutes, intensity arbitrary units. Scale bar = 10 μm.  N=1, n= 15-17 cells per 
condition. 
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Preliminary data indicating an induction of αVβ6 co-localisation with EEA1 demonstrates 
stimulation with soluble LAP causes αVβ6 internalisation, supporting our earlier hypothesis. 
A change in EGFR distribution with αVβ6 to EEA1 positive endosomes following LAP 
stimulation, would suggest αVβ6 triggers co-internalisation of EGFR.  
Most cells had αVβ6 and EGFR co-localisation after 5 minutes LAP stimulation (11/15 cells), 
many of which also had HRS co-localisation (7/15 cells) (Figure 3.4 B). Co-localisation 
between αVβ6, EGFR and HRS was not observed between 10 and 60 minutes. Preliminary 
data suggests co-localisation between αVβ6, EGFR and HRS which, if proven, would indicate 
these receptors are proximal on early endosomes and the MVB. 
As with EGF stimulation, little co-localisation was observed between either receptor and 
LAMP2 without lysosomal and proteasomal inhibition, except after 60 minutes of LAP 
stimulation where EGFR colocalised with LAMP2 in approximately one-third of cells (7/17) 
(Figure 3.4 D). In the presence of lysosomal and proteasomal inhibitors, co-localisation of 
EGFR with LAMP2 was first observed after 30 minutes of LAP stimulation (4/15 cells) (Figure 
3.4 C). The highest co-localisation between EGFR and LAMP2 was at 60 minutes, with almost 
all cells (13/15 cells) displaying this phenotype. This was still the predominant phenotype at 
90 minutes (11/14 cells). In common with EGF stimulated trafficking, preliminary data shows 
αVβ6 did not colocalise with LAMP2 and is presumably targeted to alternative recycling 
trafficking routes. Co-localisation of EGFR and LAMP2 would indicate that despite αVβ6 
engagement during EGFR internalisation rather than EGF, EGFR was still targeted for 
lysosomal degradation in agreement with its canonical trafficking route.  
Together these preliminary data indicate that stimulation of MDA-MB-468 cells with EGF or 
LAP triggers the internalisation of αVβ6 and EGFR, which potentially traffic together to the 
MVB. Following this, EGFR is likely targeted for lysosomal degradation and αVβ6 potentially 
could be recycled. This suggests mutual and reciprocally-regulated trafficking mechanisms 
for αVβ6 and EGFR.  
Preliminary immunofluorescence data indicated stimulation with either EGF or LAP triggered 
the endocytosis of both EGFR and αVβ6. To confirm this result, the rate of receptor 
internalisation was measured using a biotinylation receptor internalisation assay.  
The rate of EGFR internalisation was unaffected by either EGF or LAP stimulation (Figure 3.5 
A). This was unexpected as EGF stimulation canonically stimulates EGFR endocytosis. The 
unstimulated rate of EGFR internalisation was quite high however, suggesting any further 
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increase may not be measurable. Conclusions therefore cannot be made on the effect of LAP 
on EGFR internalisation in this experiment. Internalisation of αVβ6 was statistically 
significantly increased with EGF stimulation compared to the control (4 minutes: EGF mean= 
4.06, SD= 2.63; control mean= 0.532, SD = 2.41; p= 0.021. 30 minutes: EGF mean= 12.84, SD= 
6.97; control mean= 5.04, SD= 3.87; p= 0.016) (Figure 3.5 B), confirming the 
immunofluorescence trafficking results. By contrast, LAP stimulation had no effect on αVβ6 
internalisation rates. 
 
Figure 3.5 EGF increases rate of αvβ6 internalisation. Surface receptor internalisation assay 
percentage receptor internalisation of (A) EGFR (EGFR.1) and (B) αvβ6 (620W7) at 4, 7, 15 and 30 
minutes with EGF (10 ng/ml) or LAP (0.5 μg/ml) stimulation. Receptor internalisation is expressed as a 
percentage of the total surface levels from unstimulated cells. Mean and SEM of data points is plotted. 
One-way ANOVA * = p< 0.05 EGF Vs control,  **  = p< 0.01 EGF Vs LAP. N = 3. 
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Concomitant trafficking observed between EGFR and αVβ6 by immunofluorescence 
prompted the study of receptor dynamics with the anti-β6 clinical inhibitory antibody 
264RAD (Eberlein et al., 2013). Inhibitory anti-αVβ6 antibodies can differentially affect its 
trafficking, for example constraining it at the cell surface, or stimulating endocytosis 
(Weinreb et al., 2004). BT-20 cells were seeded onto glass dishes in DMEM in the presence 
of 10% FBS and allowed to adhere and spread for four hours. Cells were then serum-starved 
for four-hours, prior to incubation with 10 µg/ml 264RAD. Cells were co-stained for αVβ6 
and EGFR by immunofluorescence.  
Receptor distribution was assessed using an arbitrary visual scale (Figure 3.6 A) of 
predominantly surface to internal distributions. Images were blinded for analysis, and αVβ6 
and EGFR distribution was defined a value 0 – 4 using the scale for each cell. 264RAD 
incubation caused a more internal receptor distribution of both αVβ6 and EGFR (Figure 3.6B, 
C). This preliminary data suggests 264RAD stimulates the internalisation of both receptors, 
which could be an important consideration in its development as a αVβ6-targeting 
therapeutic.  
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Figure 3.6 264RAD promotes a more intracellular subcellular distribution of integrin β6 and EGFR 
(D38B1) in BT-20s. (A) Arbitrary scale of predominantly surface to internal receptor distributions for 
β6 and EGFR (D38B1). (B) Representative images of β6 and EGFR with β6 inhibitor 264RAD incubation. 
Scale bar = 10μm. (C) Quantitation of distribution scale score for β6 and EGFR with 264RAD incubation. 
N=1, n= 10 - 15 cells per timepoint. 
Results I 
96 
 
3.2.3 Collaborative signalling crosstalk 
Response to the ligand EGF and the EGFR tyrosine kinase inhibitor gefitinib was assessed by 
measuring EGFR and ERK phosphorylation, to determine the appropriate concentrations to 
use experimentally. EGFR phosphorylation at tyrosine residue 1068 (Y1068) increased with 
EGF concentration (Figure 3.7 A). The residue Y1068 is auto-phosphorylated by EGFR upon 
ligand stimulated activation in a concentration dependent manner, below saturation (Tanaka 
et al., 2018). EGFR Y1068 phosphorylation does not plateau, indicating the saturation point 
is either between 30 – 100 ng/ml EGF or greater than 100 ng/ml EGF. EGFR Y1068 was 
phosphorylated post-serum starvation in the absence of EGF (Figure 3.7 A). Basal activation 
of EGFR occurs in ligand-independent activation mutants, however the cell line MDA-MB-468 
has no documented mutations in EGFR (Forbes et al., 2017; Purba et al., 2017). ERK 
phosphorylation was increased with EGF stimulation in a concentration dependent manner 
(Figure 3.7 A). ERK is phosphorylated as part of the MAPK cascade that is activated 
downstream of EGFR phosphorylation. The optimal concentration of EGF concluded to use 
was 10 ng/ml, as this was below the point of EGFR and ERK phosphorylation saturation and 
is frequently used in the literature (Waterman and Yarden, 2001). 
Gefitinib is a potent and selective EGFR inhibitor (Ki = 0.4 nM, www.kinasenet.ca) produced 
by AstraZeneca. Gefitinib suppressed EGFR Y1068 phosphorylation in a concentration 
dependent manner in the presence of EGF (Figure 3.7 B). Phosphorylation of ERK was not 
notably reduced at the concentrations trialled however. The maximum concentration 
AstraZeneca recommend gefitinib in vitro use is 1 µM, above which off-target effects due to 
inhibition of other tyrosine kinases may occur. The optimal concentration of gefitinib chosen 
based on data in figure 3.7 and commercial recommendations was 1 µM, to achieve maximal 
inhibition of EGFR and its downstream signalling. 
Integrins and GFRs can signal collaboratively, activating common signalling pathways (Ivaska 
and Heino, 2011). To investigate if a signalling crosstalk mechanism exists between EGFR and 
αVβ6, both receptors were stimulated individually, and a panel of downstream signalling 
proteins were assessed for activation status.  
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Figure 3.7 EGF and Gefitinib concentration titration. (A) Stimulation of serum starved MDA-MB-468 
cells with 0.3 - 100 ng/ml EGF for 10 minutes. (B) Stimulation of serum starved MDA-MB-468 cells with 
10 ng/ml EGF for 10 minutes after one-hour pre-incubation with a DMSO vehicle control or 2 - 250 nM 
of the EGFR kinase inhibitor gefitinib. Western blot of EGFR and ERK1/2 phosphorylation with 
accompanying quantification. N=1. 
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Signalling associated with EGFR stimulation was assessed by phosphorylation of EGFR, ERK, 
and Akt. ERK and Akt are phosphorylated and activated in the MAPK and PI3K-Akt signalling 
pathways respectively, which are canonically activated downstream of EGFR. Preliminary 
data showed stimulation with EGF triggered phosphorylation of EGFR, ERK and Akt (Figure 
3.8 A, B). Stimulation with LAP triggered phosphorylation of ERK, however EGFR and Akt were 
unaffected (Figure 3.8 A, C). EGFR inhibition with gefitinib may partially inhibit LAP-mediated 
ERK phosphorylation however this is unclear due to variability. 
Signalling associated with integrin adhesions was assessed by phosphorylation of paxillin, 
FAK and Src. The adaptor protein paxillin, and the kinases FAK and Src are canonical adhesion 
components, that are recruited to and phosphorylated at sites of integrin-mediated 
adhesions (Horton et al., 2015a). Their phosphorylation status can also be regulated by 
growth factor stimulation, including EGF (Eberwein et al., 2015). LAP is an endogenous ligand 
for αVβ6 and is likely to engage with primed integrin at the surface and stimulate the 
formation of adhesions. Preliminary data showed differences in paxillin, Src or FAK 
phosphorylation levels observed with EGF or LAP stimulation were not statistically significant, 
suggesting that engagement of αVβ6 to soluble LAP may not affect the overall dynamics of 
integrin-mediated adhesions in the cell (Figure 3.9). 
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Figure 3.8 Effect of EGF and LAP stimulation on EGFR, ERK1/2 and Akt activity. (A) Stimulation of MDA-
MB-468 cells with 10 ng/ml EGF; or 0.5 μg/ml LAP with DMSO vehicle control or 1 μM gefitinib (EGFR 
inhibitor). Western blots of phosphorylated and total levels of EGFR, ERK 1/2 and Akt. Quantification 
of phosphorylation relative to total protein levels with EGF (B) and LAP (C) stimulation.  EGF 
stimulation N=2, LAP Stimulation N=2, LAP + Gefitinib N=1. Error bars = standard deviation. Black bar 
= LAP Stimulation, white bar = LAP + gefitinib
Results I 
100 
 
 
 
Figure 3.9 Effect of EGF and LAP stimulation on paxillin, FAK and Src activity. (A) Stimulation of MDA-
MB-468 cells with 10 ng/ml EGF; or 0.5 μg/ml LAP with DMSO vehicle control or 1 μM gefitinib (EGFR 
inhibitor). Western blots of phosphorylated and total levels of paxillin, FAK and Src. Quantification of 
phosphorylation relative to total protein levels with EGF (B) and LAP (C) stimulation.  EGF stimulation 
Results I 
101 
 
N=2, LAP Stimulation N=2, LAP + gefitinib N=1. Error bars = standard deviation. Black bar = LAP 
Stimulation, white bar = LAP + gefitinib. 
3.3 Discussion 
The sub-cellular distribution of αVβ6 and EGFR was investigated in the TNBC cell line MDA-
MB-468, and points of co-localisation were identified between αVβ6 and EGFR at sites of 
αVβ6-mediated ECM engagement, and in intracellular structures reminiscent of endosomes. 
Ligand stimulation experiments were combined with co-staining of endosomal markers to 
identify the nature of the internal structures that αVβ6 and EGFR co-localised at, and if ligand 
stimulation altered the distribution and trafficking of αVβ6 and EGFR. Stimulation with EGF 
and LAP caused the internalisation of both receptors, which co-localised at EEA1 and HRS 
positive endosomes. EGFR co-localisation was observed with the lysosome during later 
stimulation timepoints, suggesting EGFR is degraded. Signalling crosstalk was investigated by 
examining the phosphorylation status of signalling effectors downstream of integrin and 
EGFR signalling. These data revealed LAP stimulation causes the phosphorylation of ERK, 
which could potentially be mediated either directly downstream of αVβ6 or indirectly via 
ligand-independent stimulation of EGFR. 
3.3.1 Cell line model 
The cell line MDA-MB-468 was selected as the primary model for study, due to its TNBC 
status, and high expression of αVβ6 and EGFR. The EGFR gene is amplified in MDA-MB-468 
cells (copy number 14, COSMIC database), therefore these cells represent a subset of TNBC 
that may be driven by EGFR amplification that could be more likely to respond to EGFR 
therapeutics (Chavez et al., 2010; Forbes et al., 2017). Cells can engage the ligand LAP via 
integrins αVβ6, αVβ1, αVβ8, αVβ3 and αVβ5 (Humphries et al., 2006; Worthington et al., 
2011). MDA-MB-468 cells are positive for αVβ6, and possibly αVβ1, and negative for αVβ3 
and αVβ5 expression. Expression of αVβ8 was not assessed, however has been reported 
(Meyer et al., 1998). The same research article also reports MDA-MB-468s are positive for 
αVβ5, which is in direct conflict our with flow cytometry data (Figure 3.1); however, 
highlighting differences in total and surface integrin expression, and potential variability in 
cell lines between laboratories and with passaging. The ligand LAP can therefore theoretically 
be engaged via αVβ6, αVβ1 and αVβ8 in MDA-MB-468s, meaning LAP is an αVβ6-selective 
but not αVβ6-specific ligand. However antibody-mediated functional blockade of αVβ6 in 
MDA-MB-468 cells reduces attachment to FN by 80%, indicating this is the primary integrin 
mediating FN binding (Singh et al., 2018). 
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3.3.2 Co-operation between αVβ6 and EGFR endocytosis 
Preliminary data suggested stimulation with either EGF or LAP ligand triggered endocytosis 
of both αVβ6 and EGFR concomitantly. Different dynamics were observed for each receptor’s 
endocytosis with EGF stimulation. EGFR co-localisation was observed with EEA1 prior to 
overlap with αVβ6 and persisted after αVβ6 had left EEA1 positive endosomes; indicating 
EGFR initially internalises before αVβ6 and continues endocytosing for longer. Cells 
overexpressing EGFR have slower rates of EGFR turnover, likely due to saturation of 
internalisation and degradation processes in trafficking (Sorkin and Goh, 2009).  Saturation 
of clathrin-mediated endocytosis can result in a switch to slower non-clathrin-mediated 
endocytosis (Sorkin and Goh, 2009). Thus, it is possible that initial EGFR endocytosis could be 
clathrin-mediated, followed by slower non-clathrin-mediated mechanisms. Surface EGFR 
could continue endocytosing throughout the time-course, as cells are maintained in the 
presence of EGF throughout the experiment. Unlike EGFR, αVβ6 is not overexpressed in 
MDA-MB-468s therefore internalisation may be from a smaller finite pool that is 
endocytosed faster. Receptor dynamics were also different for HRS co-localisation with LAP 
stimulation. EGFR remained co-localised with HRS for longer than αVβ6. This indicates EGFR 
remains in the MVB whereas αVβ6 trafficking progresses onwards. 
Under both ligand stimulations, EGFR appears to traffic to LAMP2 positive lysosomes 
however αVβ6 does not. Integrins are predominantly recycled, therefore it is likely that αVβ6 
is in recycling endosomes or returned to the plasma membrane (De Franceschi et al., 2015). 
Internalisation and recycling rates reported for integrins are consistent with the plasma 
membrane pool of integrins trafficking through the endosomal system and returning to the 
plasma membrane in 30 minutes (Caswell and Norman, 2006). Whilst we have not analysed 
recycling dynamics for αVβ6, it is conceivable that the internalised pool of αVβ6 could be 
recycled within the time-course of these experiments. Integrin αVβ6 may also traffic to the 
trans-golgi network, as recycling integrins can also progress via this compartment (Mana et 
al., 2016; Riggs et al., 2012). Trafficking integrins have also been reported to be degraded in 
a proteasomal-dependent manner, although this is not thought to be a predominant 
mechanism indicating it is an unlikely fate for αVβ6 (Liu et al., 2011b). A proportion of EGFR 
may also be recycled or degraded at the proteasome, however the canonical fate for EGFR is 
lysosomal degradation (Sorkin and von Zastrow, 2009). 
Preliminary immunofluorescence data indicated stimulation with EGF and LAP induced the 
internalisation of αVβ6 and EGFR. Biochemical internalisation assays confirmed EGF 
stimulation statistically significantly increases αVβ6 internalisation. However, conflictingly 
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stimulation with LAP did not affect the rate of αVβ6 internalisation measured in these assays. 
Soluble LAP has not previously been demonstrated to stimulate the internalisation of 
integrins and nothing is known about the likely magnitude of response. It is possible an effect 
would be seen at higher concentrations of LAP. Due to the nature of the assays, the 
biochemical approach measures an average global population of internalised receptor, 
whereas immunofluorescence identifies smaller internal pools and subcellular distributions. 
The effect of LAP on αVβ6 distribution could have been too subtle to be detected 
biochemically.  The rate of receptor internalisation could also be underestimated due to 
receptor recycling, which was not inhibited in these assays (Rainero et al., 2013). Differences 
between the experimental set-ups could also have affected the results, such as the thermal 
cycling of cells between 4°C and 37°C in the biochemical assay, which can affect the 
microtubule network and was not employed in the immunofluorescence experiments 
(Rainero et al., 2013). 
No effect was seen with either EGF or LAP on the rate of EGFR internalisation. This was 
unexpected as ligand-stimulated endocytosis is a well-defined mechanism for EGFR 
internalisation (Sorkin and Goh, 2008). The baseline unstimulated rate of EGFR 
internalisation was very high, potentially masking any differences with EGF or LAP stimulated 
conditions. This high baseline indicates EGFR is undergoing constitutive endo-exocytic cycling 
in the absence of ligand. EGFR can undergo constitutive endocytosis; however ligand-
stimulation is thought to be the predominant mechanism of EGFR internalisation (Goh and 
Sorkin, 2013). Basal phosphorylation of EGFR at Y1068 observed in MDA-MB-468 cells (Figure 
3.7) could potentially result in higher levels of constitutive endocytosis. The adaptor protein 
Grb2 which is recruited to active EGFR by binding to phosphorylated Y1068 and Y1086 is 
essential for EGF-stimulated EGFR internalisation (Huang and Sorkin, 2005). Basal 
phosphorylated Y1068 could recruit Grb2 and promote EGFR endocytosis. Conflicting 
evidence in the literature has shown a kinase dead EGFR mutant was internalised at the same 
rate as wild-type EGFR following EGF stimulation, leading to the conclusion that dimerisation 
of EGFR following EGF stimulation was more crucial than kinase domain activation for 
internalisation (Wang et al., 2005). Overexpression of EGFR in MDA-MB-468 cells could 
increase the chance of spontaneous dimer formation due to higher receptor concentration 
on the surface, which may promote constitutive endocytosis. 
Incubation of BT-20 cells with the clinical αVβ6 inhibitory antibody 264RAD caused the 
internalisation of αVβ6 and EGFR. This is the first demonstration of the effect of 264RAD on 
αVβ6 subcellular distribution. Xenograft studies show treatment with 264RAD decreases 
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αVβ6 protein level in the tumours, although the mechanism for this is unclear (Eberlein et 
al., 2013; Moore et al., 2014). It is likely due to the statistically significant decrease in tumour 
volume that the loss of αVβ6 protein levels is due to selective targeting of αVβ6-positive 
tumour cells. Stimulation of αVβ6 internalisation provides an additional hypothesis for the 
loss of αVβ6 protein levels, as this could potentially result in protein degradation if αVβ6 is 
sorted towards degradative pathways. Stimulation of EGFR internalisation with 264RAD 
could also result in decreased EGFR levels, especially as endocytosed EGFR is predominantly 
degraded. 
3.3.3 Signalling Crosstalk 
Preliminary data showed stimulation of MDA-MB-468 cells with LAP caused phosphorylation 
of ERK. This phosphorylation is likely mediated downstream of αVβ6 either directly, or 
indirectly via GFRs such as EGFR. Grb2 can be recruited to phosphorylated FAK at Y925, 
activating ERK directly downstream of integrin-mediated adhesions (Schlaepfer et al., 1994). 
Integrin-mediated activation of ERK has been postulated to be a more important mechanism 
if growth factor supply is limited (Giancotti and Ruoslahti, 1999). Integrins can also activate 
GFR signalling pathways indirectly, for example by promoting GFR activity or influencing GFR 
trafficking (Ivaska and Heino, 2011).  
Stimulation with LAP did not affect EGFR pY1068 or Akt S473 phosphorylation, indicating a 
mechanism specific to the Ras-MAPK signalling pathway. Incubation of cells with the EGFR 
inhibitor gefitinib did not statistically significantly prevent LAP-mediated ERK 
phosphorylation. This could suggest crosstalk between LAP stimulated αVβ6 and EGFR 
signalling is unlikely to directly affect EGFR. It is important to note however MDA-MB-468 
cells are resistant to gefitinib (IC50 = 6.8 µM) (Normanno et al., 2006), and treatment with 
gefitinib in our experiments did not suppress ERK phosphorylation, indicating PI3K-MAPK 
pathway activity. Unpublished data from Professor John Marshall, Barts Cancer Institute 
London, has demonstrated LAP-mediated ERK phosphorylation was reduced with 1 µM 
gefitinib in BT-20 cells indicating this mechanism could be via EGFR. Expression of αVβ6 is 
reported to be required for ERK phosphorylation, as siRNA-mediated knockdown reduced 
EGF stimulated ERK phosphorylation three-fold (Ahmed et al., 2002a). This strengthens the 
hypothesis that αVβ6-mediated ERK phosphorylation is due to crosstalk between αVβ6 and 
EGFR signalling pathways.  
No changes were observed in phosphorylation of paxillin, FAK or Src in response to EGF or 
LAP stimulation. Paxillin, FAK and Src become phosphorylated during adhesion formation and 
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can be dynamically regulated in adhesions (Robertson et al., 2015). Soluble LAP is a ligand for 
αVβ6 and therefore will engage αVβ6 at the cell surface initiating adhesions. A critical step 
in the progression from early nascent to more mature focal adhesions is the binding of talin 
and application of force, strengthening the adhesion and recruiting additional components 
(Wolfenson et al., 2013). The fact LAP is added as a soluble ligand means that force cannot 
be generated at these adhesions, as traction cannot be generated without anchoring of the 
ligand. Consequently paxillin, FAK and Src may not be recruited to these adhesions and 
phosphorylated, and therefore no changes would be observed. Additionally, most adhesions 
are likely to have been formed prior to stimulation, as cells were incubated to adhere and 
spread; therefore, small changes may not be detected. 
Trafficking and signalling crosstalk demonstrated between αVβ6 and EGFR is likely to regulate 
cellular processes controlled by αVβ6 and EGFR. Trafficking is an important mechanism by 
which receptor dynamics is regulated, which impacts processes mediated by their ligand 
engagement such as signalling and engagement of the ECM. Signalling crosstalk 
demonstrates αVβ6 influences signalling downstream of EGFR, which could for example 
promote the stimulation of cell proliferation mediated by the MAPK pathway. These 
processes are likely to have potential clinical relevance to cancer, as they contribute to the 
pro-invasive and pro-mitogenic functions of αVβ6 and EGFR, respectively. Localisation of 
EGFR at sites of αVβ6-mediated LAP engagement indicates EGFR is a component of αVβ6-
mediated adhesions. If so, other proteins associated with αVβ6 adhesions may have a role in 
mediating crosstalk between αVβ6 and EGFR, for example by facilitating their co-
internalisation in response to ligand engagement. Unbiased proteomic analysis of αVβ6-
mediated adhesions formed on the ligand LAP will aim to elucidate this. 
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4. The αVβ6-specific adhesome 
4.1 Introduction 
Integrin engagement of ECM ligands triggers recruitment of proteins to the integrin 
cytoplasmic domains. Integrins have no intrinsic catalytic activity or actin binding capacity 
and therefore rely on cytoplasmic adaptors and enzymatic proteins to exert their functions. 
Classically integrin-mediated adhesions can be sub-divided into nascent adhesions, focal 
complexes, focal adhesions and fibrillar adhesions (Wolfenson et al., 2013). These adhesions 
form sequentially and mature with the application of mechanical force. The canonical view 
of adhesion assembly is that integrin binding triggers rapid recruitment of paxillin and FAK, 
followed by talin and vinculin which provide a mechanical link to the actin cytoskeleton 
(Lawson and Schlaepfer, 2012). Integrin adhesion complexes (IACs) have been described as 
having three functionally distinct layers: 1) a membrane-proximal integrin signalling layer 
with integrin cytoplasmic domains, paxillin and FAK;  2) an intermediate force-transduction 
layer with talin and vinculin, and 3) a distal actin-regulatory layer with zyxin, VASP and α-
actinin (Kanchanawong et al., 2010). Talin spans all three layers, orientated with its head 
domain directly binding integrin cytoplasmic domains, and tail domain binding actin 
(Kanchanawong et al., 2010). Temporal changes during adhesion assembly and disassembly 
support the hierarchical distribution theory that the first proteins to be recruited are the last 
to be removed, with integrins remaining most stable throughout disassembly (Horton et al., 
2015a). 
IACs contain core structural and force-transducing proteins, and non-canonical proteins that 
are differentially recruited in response to environmental factors. Fluorescence recovery after 
photobleaching (FRAP) studies have demonstrated the dynamic exchange of proteins at 
adhesion sites (Carisey et al., 2013; Rossier et al., 2012). The core of adhesions complexes 
can be described as ‘meta-stable’ as it is robust, yet dynamic, as it undergoes turnover 
(Humphries et al., 2015). The integrin adhesome is defined as a set of proteins that localise 
to and regulate integrin-mediated adhesions (Humphries et al., 2015). Previously knowledge 
of the adhesome was based on the ‘literature-curated adhesome’, which estimated the 
network consisted of more than 200 proteins (Winograd-Katz et al., 2014). More recently 
adhesion isolation techniques combined with non-biased MS analyses have identified a more 
complex larger network of proteins (Horton et al., 2015a). 
Multiple proteomic datasets of enriched IACs have been integrated to identify a canonical 
(proteins identified in ≥ five of the seven datasets) and meta (proteins identified in ≥ one 
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dataset) adhesome (Horton et al., 2015a). The canonical adhesome is 60 proteins that are 
consistently recruited to IACs and are likely to represent core adhesion machinery. The non-
canonical meta-adhesome is 2,352 proteins that are more variably recruited. Proteins 
identified in few datasets are likely to be context specific, low-abundance or difficult to 
detect by MS.  Protein-protein interaction (PPI) network analysis revealed the consensus 
adhesome clustered into four signalling networks based on ILK–PINCH–kindlin, FAK–paxillin, 
talin–vinculin and α-actinin–zyxin–VASP (Horton et al., 2015a). 
Unbiased protocols were developed to analyse isolated IACs by MS to circumvent the bias of 
candidate-driven techniques such as immunoblotting immunoprecipitations (Humphries et 
al., 2015). This enabled global analysis of adhesion signalling networks and revealed 
complexity that exceeded candidate-driven approaches. These techniques yielded proteins 
previously known to be canonical components of IACs as expected, with additional new 
components not previously isolated or identified. Components could be sub-divided into 
those with known functions relating to adhesion biology, proteins with domains in common 
with characterised adhesion proteins, and those with previously unlinked roles (Humphries 
et al., 2015).  
Proteomic analysis and downstream validation have led to the discovery of novel 
components with previously unknown roles (Humphries et al., 2009). Proteomic analysis can 
also determine IAC compositional distinctions between different ECM ligands and 
heterodimers. Analysis of IACs formed via α5β1 or α4β1 revealed common and specific 
components, despite the shared β1 subunit (Humphries et al., 2009). Complexes specific to 
αV and β1 have also been analysed by generating pan-integrin-null cell lines and re-
expressing subunits (Schiller et al., 2013). 
The two main IAC isolation methods involve the use of ECM or antibody coated micro-beads 
or 2D surfaces. These protocols enrich for integrin-mediated adhesions with their local 
plasma membrane and cytosolic environments (Jones et al., 2015). The first method 
developed was micro-bead isolation (Humphries et al., 2009). Cells were incubated in 
suspension with magnetic micro-beads coated with ECM ligand or antibody. Adhesions were 
stabilised and the cell body was removed by sonication, followed by separation of the beads 
with bound adhesion complexes. Proteins were then eluted from the beads. This method had 
disadvantages as some canonical adhesion components were absent from the isolates, and 
some cell types routinely engulfed the beads during their incubation (Jones et al., 2015). This 
lead to the development of the IAC enrichment protocol, from cells plated on 2D cell culture 
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surfaces coated with ECM ligands, this allows cells to form load-bearing adhesion structures 
prior to DTBP cross-linking (Figure 4.1). Cell bodies are then removed to isolate ventral 
membrane preparations enriched for IACs, either by hydrodynamic force or sonication. The 
remaining IACs adherent to the 2D-surface are collected by scraping (Jones et al., 2015). The 
hydrodynamic force method is advantageous for assessing temporal changes in adhesion 
complexes, such as with the addition of an external stimulus.  The sonication method is more 
time-consuming, but is easier to standardise, more stringent and results in fewer 
contaminants. 
IAC MS datasets differ between cell types, ligands and integrin heterodimers. This was 
highlighted in the meta-adhesome database, where over half of the proteins were unique to 
a single dataset (Horton et al., 2015a). Targeted approaches can elucidate IACs recruited to 
specific integrin subunits or heterodimers, which can give functional insight. Integrin αVβ6 is 
pro-invasive and linked to a poor prognosis in a range of cancers (Raab-Westphal et al., 2017). 
Despite this αVβ6 is a relatively under-studied integrin and little is known about its cancer-
associated functions and interactome. Thus αVβ6 IACs was studied in the TNBC cell line MDA-
MB-468s, as αVβ6 is linked to a poor prognosis in TNBC (Unpublished data, Louise Jones, 
Barts Cancer Institute, London), and TNBC is an aggressive form of breast cancer that 
particularly affects younger women (< 50 years) with no current targeted therapies (Jitariu 
et al., 2017). The implication of αVβ6 as a potential therapeutic target for TNBC is novel and 
driven by our unpublished data in collaboration with the Marshall and Jones labs. The αVβ6-
associated IAC was characterised to give insight into proteins that were differentially 
recruited to αVβ6 IACs, which provided insight into its functions and mechanisms by which 
αVβ6 promotes cell invasion. 
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Figure 4.1 Schematic of integrin associated complex adhesion isolation protocol. Cells are allowed to 
spread and adhere onto plates coated with an ECM ligand. Protein interactions are then stabilised with 
the cell permeable crosslinker DTBP.  The crosslinker is then quenched and extraction buffer is added 
to the cells. Sonication is used to remove the cell body, leaving isolated adhesion complexes, which 
are then harvested by scarping. Composition of the samples can then be analysed by western blotting 
or LC MS/MS. 
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4.2 Results 
4.2.1 αVβ6 adhesions 
Three ECM ligands were used for pairwise comparisons to elucidate proteins selectively 
recruited to αVβ6-mediated IACs. IACs were isolated from MDA-MB-468 cells plated on 2D 
plastic coated with either FN, LAP or Collagen I ECM ligands. Collagen I was used as a negative 
control, as this cannot be engaged by αVβ6. FN and LAP ligands will be used to compare a 
mixed integrin environment of RGD and LDV binding integrins including αVβ6, and an αVβ6-
selective environment of LAP binding integrins, respectively.  
Initial validation of isolated IAC samples, prior to MS analysis, was achieved by 
immunoblotting for constituents of the samples. Focal adhesion components were probed 
for to confirm their presence, and negative controls that localise to other sub-cellular 
compartments were used to indicate their enrichment in IACs relative to the TCL.  
LAP-associated IACs were enriched in integrin β6, αV, vinculin and talin (Figure 4.2). Integrin 
β6 was enriched on LAP compared to FN, and absent on collagen, confirming LAP is β6- 
selective. Integrin β1 was detected in the TCL but not in the IAC samples. While Src was not 
detected by immunoblotting in the experiment presented in figure 4.2, Src was identified in 
all IACs from replicates 2 and 3 (Figure S6 and S7). The negative controls GAPDH 
(cytoplasmic), BAK (mitochondrial) HSP70 and HSP90 (endoplasmic reticulum) were absent 
or substantially lower than the TCL in the IAC samples, indicating purity of the isolation.  
Interestingly, EGFR was observed specifically on LAP isolated IACs (Figure 4.2). EGFR was 
probed for as previous data demonstrated colocalisation of EGFR with αVβ6 at points of 
matrix engagement (Figure 3.2), and EGF stimulation induced endocytosis of αVβ6, indicating 
EGFR may have a role in αVβ6 adhesion dynamics (Figure 3.5).  
Canonical adhesion components appeared most abundant in the LAP condition, this is 
possibly due to enrichment, however could also be due to a higher concentration of the 
sample. Protein concentration of the IAC samples cannot be estimated as the composition of 
the reducing sample buffer used to harvest the samples does not permit measurement by 
standard methods such as the BCA or Bradford assays (Jones et al., 2015). This was not an 
issue however for proteomic analyses, as total peptide abundance is considered during data 
normalisation. 
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Figure 4.2 Validation of integrin-associated complex enrichment. Western blotting in total cell lysate 
(TCL) and isolated integrin-associated complexes (IAC) for the adhesome components integrin β6, β1, 
vinculin, talin, Src (GD11), EGFR (sc-03), and negative control proteins GAPDH, HSP70, HSP90 and BAK 
from other subcellular compartments. (A) Representative blots of N1 that was analysed subsequently 
by mass spectrometry. Arrow indicates detection of β1 integrin, asterisk indicates detection of vinculin 
from previous probe. (B) β6, EGFR and αv from replicate N3 demonstrating αv recruitment to FN and 
LAP IACs. Full N3 panel in figure S7.
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4.2.2 Dataset quality and trends 
IAC samples were processed and analysed by MS to identify a αVβ6-associated network in an 
unbiased way. Reproducibility across the dataset between three biological replicates was 
assessed using pairwise scatter plots (Figure 4.3). Pearson correlation coefficient values for 
the normalized spectral abundance factor (NSAF) values were all ≥ 0.85, indicating good 
reproducibility between biological replicates. 
 
Figure 4.3: Scatter plots with regression lines. Pairwise comparison of log 10 transformed protein 
abundance normalized spectral abundance factor (NSAF) values between replicates for fibronectin, 
LAP and collagen ligand samples. Pearsson correlation coefficient value is indicated in the top left of 
each graph. 
Unique proteins were not included in the scatterplot analysis, but were included in Venn 
diagram representations (Figure 4.4 A). The first biological replicate identified the greatest 
number of proteins, which is reflected in the fact it has the most unique proteins. Out of the 
total number of proteins identified (790), 505 were common between all replicates, 
indicating reasonable consistency.  Venn diagrams were also constructed to indicate the 
shared and unique proteins identified on each ligand (Figure 4.4 B). A similar number of 
proteins were identified on each ligand, indicating a similar level of total protein isolated. The 
majority of proteins (581) were shared across all ligands, which is a similar order of 
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magnitude to other published proteomic datasets analysing different cell types and integrin 
heterodimers (Horton et al., 2015a; Schiller et al., 2013). 
 
Figure 4.4 Venn Diagrams demonstrating the degree of shared and unique proteins between replicates 
(A) and ligands (B). Replicates indicate the total number of proteins pooled from all three ligands from 
each biological replicate. Ligands indicate the total number of proteins isolated from adhesions on 
each ligand from all three biological replicates. Total proteins identified = 790. 
Thresholds for protein identification were applied to the dataset. The peptide threshold was 
> 4 peptide counts and identified in ≥ 2 biological replicate. Thresholds used in previous 
adhesome studies for IAC MS analysis are typically ≥ 4 spectral counts and/or ≥ 2 unique 
peptides, which is a comparative level of stringency to our thresholds (Horton et al., 2015a). 
Proteins which were unreviewed in the UniProtKB database were also removed as these are 
computer-annotated entries derived from the translation of coding sequences (Consortium, 
2011). Pairwise analysis of protein-normalised intensity values (intensity values normalised 
to total protein amount) were made between LAP and Collagen, and LAP and FN (Figure 4.5). 
Most proteins were < two-fold different between ligands (57.5% LAP/collagen, 64.5% 
LAP/FN); indicating the majority are not differentially recruited to different integrin-
mediated IACs. Fewer proteins were ≥ two-fold different between LAP/FN than LAP/collagen, 
indicating the IACs are more similar between LAP and FN than LAP and collagen (Figure 4.5 
A). This was expected as αVβ6 binds both LAP and FN, there are more common integrin 
subunits that are bind LAP and non-LAP RGD ligand binding, than collagen. A greater number 
of proteins are enriched on LAP (122 proteins) compared to FN (33 proteins) (Figure 4.5 B). 
This is in agreement with data suggesting αVβ6 is the predominant integrin engaged on FN 
(Singh et al., 2018), as the majority of proteins isolated from FN IACs are likely to be present 
and enriched on LAP as this represents an αVβ6-selective environment. 
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Figure 4.5 Fold change of proteins between ligand conditions. Low abundance (fewer than 5 peptides 
and/or unique to one N) and unreviewed UniProt proteins were removed from the dataset, yielding a 
total of 428 proteins. Graphs show ratios of normalised intensity values for log2 (A) [LAP/Collagen] 
and (B) [LAP Vs FN], mean ± SEM, N = 3 for each protein. Light blue shading corresponds to ≤ two-fold 
change.  (A) LAP Vs Collagen, 428 proteins in total, 57.5% of dataset (93 and 89 proteins increased and 
decreased, respectively). (B) LAP Vs FN, 422 proteins in total, 64.7% of dataset (122 and 33 proteins 
increased and decreased, respectively). 
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4.2.3 Comparison to the literature-curated adhesome 
The un-thresholded dataset (unreviewed proteins removed, without peptide threshold) was 
compared with the curated consensus- and meta-adhesome to determine which proteins 
from these datasets were identified (Horton et al., 2015a). Coverage of both the consensus 
(35%, 21 proteins) and meta-adhesome (20%, 468 proteins) was achieved (Figure 4.6). The 
coverage of the consensus adhesome is comparatively low, as these proteins were detected 
in ≥ five of the seven MS datasets used to curate the adhesome, and thus represent 
canonically recruited proteins. This divergence is interesting as it could represent novel IAC 
composition in αVβ6-mediated adhesions, TNBC cells, and adhesions formed on LAP ligands; 
all of which were previously unknown.  
The consensus adhesome contains four clustered modules based on known interactions and 
signalling axes (Horton et al., 2015a). Our dataset contains all the high evidence direct 
integrin interactors in the networks (α-actinin, talin, tensin, kindlin and filamin) (Horton et 
al., 2015a) (See figure S8 for a visual representation). However, except for four proteins 
(TGM2, ANXA1, IQGAP and VCL), no other connected network proteins were detected. Of 
the reported consensus adhesome, 16 proteins were unconnected to the main network and 
had no known adhesive functions. Eleven of these were present in our dataset (ALYREF, 
BRIX1, DDX18, DDX27, DIMT1, DNAJB1, FEN1, H1FX, POLDIP3, RPL23A and SYNCRIP), all of 
which have roles in DNA or RNA regulation.  
Whilst protein translation typically occurs in the endoplasmic reticulum or cytosol, proteins 
with roles in translation can localise to different subcellular structures. This can facilitate 
spatial compartmentalisation of translation that may be energetically favourable (Humphries 
et al., 2015). Local translation has also been demonstrated as a mechanism of controlling 
protein localisation to cell protrusions in migration (Mardakheh et al., 2015). Questions 
remain in the field about the relevance of these proteins at adhesions despite growing 
evidence, as many RNA binding proteins are common contaminants (Humphries et al., 2015; 
Mellacheruvu et al., 2013).  
  
Results II 
116 
 
 
Figure 4.6 Representation of consensus and meta adhesome dataset coverage. 35% of the consensus 
adhesome (21 proteins), inner ring; 20% of the meta adhesome (468 proteins), middle ring. Proteins 
in the outer ring were not reported in the consensus or meta adhesome (219 proteins). Total 
number of proteins = 726. Nodes represent proteins and edges are known interactions. Node colour 
red to blue gradient = log2 fold enrichment on LAP versus collagen. Green = FN specific proteins. (B) 
Percent of the IAC dataset represented by the consensus adhesome (3%) and meta-adhesome (62%). 
(C) Percent of the consensus adhesome (35%) and meta-adhesome (20%) identified in the IAC 
dataset. 
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30% of the dataset was not represented in either the consensus or meta-adhesome. 
Considerable divergence between this dataset and the curated adhesome is likely to be due 
to differences in experimental conditions. Five out of the seven datasets that comprised the 
adhesome were isolated from fibroblasts, and none used the ligands collagen or LAP (Horton 
et al., 2015a). Fibroblasts do not normally express αVβ6, so it is unlikely any proteins 
specifically recruited to αVβ6 IACs were identified. Adhesions formed on collagen and LAP 
will recruit different combinations of integrin heterodimers and therefore different IACs that 
consequently may recruit different novel signalling proteins.  
Our dataset was also compared to the literature-curated adhesome database from 
www.adhesome.org, which is divided into intrinsic and associated proteins (Winograd-Katz 
et al., 2014; Zaidel-Bar et al., 2007) (Table 4.1). Our dataset had 8% (19 proteins) of the total 
literature-curated adhesome database, consisting of 11% (16 proteins) of the intrinsic and 
4% (3 proteins) of the associated proteins. Our database has a lower percentage coverage of 
the associated proteins, as these are less robustly recruited to IACs. Whereas our dataset has 
a higher percentage coverage of the consensus adhesome, which reflects the similarity in the 
protocols of isolation and identification.   
Literature-curated Adhesome (150) Both Consensus Adhesome (60)  
CFL1 
KEAP1 
 
 
CORO1B 
MACF1 
CORO2A 
MYH9 
CTTN 
NEXN 
ENAH 
SVIL 
FLNA ACTN1 
 
LASP1 
 
VASP 
 
 ACTN4 
FLNC 
PDLIM5 
TNS3 
ANXA1 
IQGAP1 
PDLIM7 
CALD1 
LIMD1 
PLS3 
CNN2 
PALLD 
RSU1 
FHL3 
PDLIM1 
SIPA1 
A
ctin
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n
 
ACTB 
EZR 
GRB7 
LPXN 
NUDT16L1 
SDCBP 
TENC1 
BCAR1 
FERMT1 
HAX1 
MSN 
OSTF1 
SH2B1 
TGFB1I1 
CASS4 
FERMT3 
ITGB1BP1 
NCK2 
PALLD 
SH3KBP1 
TNS1 
CAV1 
GAB1 
JUB 
NDEL1 
PARVB 
SMPX 
ZFYVE21 
CRK 
GNB2L1 
LDB3 
NEDD9 
PPFIA1 
SORBS2 
CRKL 
GRB2 
LIMS2 
NF2 
RDX 
SYNM 
FHL2 
LPP 
TES 
ZYX 
FBLIM1 
PARVA 
TLN1 
 
FERMT2 
PXN 
TRIP6 
LIMS1 
SORBS3 
VCL 
     
A
d
ap
to
rs 
CD151 
ITGA4 
ITGAE 
ITGB4 
LRP1 
ITGA1 
ITGA6 
ITGAL 
ITGB5 
NRP1 
ITGA10 
ITGA7 
ITGAM 
ITGB6 
NRP2 
 
ITGA11 
ITGA8 
ITGAW 
ITGB7 
PVR 
ITGA2 
ITGA9 
ITGAX 
ITGB8 
SDC4 
ITGA3 
ITGAD 
ITGB2 
KTN1 
SLC3A2 
ITGA5 ITGAV ITGB1 ITGB3      A
d
h
esio
n
 R
e
ce
p
to
r 
AGAP2 
DDEF1 
GIT1 
ARHGAP24 
DEF6 
GRLF1 
ARHGAP26 
DLC1 
RASA1 
ARHGEF6 
DNM2 
RHOU 
ASAP2 
DOCK1 
STARD13 
ASAP3 
ELMO1 
ARHGEF7 GIT2        G
TP
ase 
ABL1 
SRC 
PAK1 PDPK1 PEAK1 PRKCA PTK2B CSK ILK PTK2       K
in
ase 
INPP5D 
PTPN12 
INPPL1 
PTPN6 
PPM1F 
PTPRA 
PPM1M 
PTPRF 
PPP2CA PTPN11          Ph
o
sp
h
atase 
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Literature-curated Adhesome (150) Both Consensus Adhesome (60)  
ITGB3BP RAVER1 STAT3        ALYREF 
DNAJB1 
MRTO4 
BRIX1 
FAU 
POLDIP3 
DDX18  
FEN1 
PPIB 
 
DDX27 
H1FX 
RPL23A 
DIMT1 
HP1BP3 
SYNCRIP 
D
N
A
 o
r R
N
A
 
re
gu
latio
n
 
CALR 
TGFB1I1 
PDE4D 
TRPM7 
PKD1 PLCG1 PRNP SPTLC1     P4HB TGM2    
V
ario
u
s 
Table 4.1: Dataset mapping onto the literature-curated and MS derived consensus adhesome. The 
literature-curated adhesome consists of 232 proteins from the database at www.adhesome.org.  Only 
‘intrinsic proteins’ rather than ‘associated proteins’ were used in these analyses. The consensus 
adhesome refers to the curated MS dataset of 60 proteins, defined by Horton et al. Proteins are 
grouped according to their annotation in the www.adhesome.org database. The group ‘GTPase’ 
contains GTPases and regulators, and the group ‘DNA or RNA’ includes all proteins with functions 
associated with DNA and RNA. The following proteins were listed under ‘various’ as their groups were 
formed of ≤ two proteins: PDE4D, PKD1, TRPM7, CALR, PLCG1, SPTLC1, PRNP, TGFB1I1, P4HB, TGM2. 
Of these, only TGM2 was present in our dataset. 19/232 (8.2%) of the total adhesome dataset, 16/150 
(10.7%) of the intrinsic proteins, 3/82 (3.7%) associated proteins were present in our dataset. 21/60 
(35%) of the consensus adhesome proteins were present in our dataset. Proteins in our dataset are 
shown in red. Proteins that were ≥ two-fold enriched on the ligand LAP are shown in bold and 
underlined. 
4.2.4 Global analysis 
To characterise the αVβ6-associated adhesome by identifying compositional changes in IAC 
proteomes formed on different ligands, fold change of protein detection was compared 
between LAP and collagen, and LAP and FN conditions. Protein-protein interaction (PPI) 
networks were constructed in Cytoscape (version 3.6.1) and interactions were mapped using 
the Protein Interaction Network Analysis (PINA) interactome database (release date 
21/05/2014) (Wu et al., 2009) supplemented with a literature curated database of IAC 
proteins (Robertson et al., 2015; Zaidel-Bar et al., 2007). Three proteins could not be mapped 
(E9PAV3, NACA; Q9BQ48, MRPL34; E9PRG8, c11orf98) as these were not present in the PPI 
with matrisome component database. Networks were constructed for proteins that were ≥ 
1.5, 2 and 5-fold different. On LAP versus collagen 183 proteins were ≥ 2-fold different (Figure 
4.7), 256 were ≥ 1.5-fold different (Figure S9) and 113 were ≥ 5-fold different (Figure S10). 
On LAP versus FN 154 proteins were ≥ 2-fold different (Figure 4.8), 201 were ≥ 1.5-fold 
different (Figure S11) and 110 were ≥ 5-fold different (Figure S12). A ≥ two-fold change 
threshold was chosen for analysis as it has been used consistently in the literature and 
identifies differences without compromising network connectivity (Horton et al., 2016b). 
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Figure 4.7 ≥ two-fold different proteins on LAP versus collagen.  Total number of proteins = 183. Nodes 
represent proteins and edges are known interactions. Node colour red to blue gradient = log2 fold 
enrichment LAP/collagen. 
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Figure 4.8: ≥ two-fold different proteins on LAP versus fibronectin.  Total number of proteins = 154. 
Nodes represent proteins and edges are known interactions. Node colour red to blue gradient = log2 
fold enrichment LAP/FN. 
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To provide additional stringency to the two-fold change threshold, statistical significance of 
protein NSAF value between ligands was assessed. Proteins that were statistically 
significantly different between ligands (p=<0.05) were mapped according to log2 fold 
enrichment to LAP (LAP/FN, LAP/collagen) (Figure 4.9). Proteins with p values < 0.01 are 
presented with individual labelling in supplementary figure S13. De-enrichment of proteins 
on LAP relative to FN or collagen, suggests exclusion from αVβ6-mediated IACs. Proteins 
significantly enriched on LAP in either or both comparisons indicate these are likely to be 
enriched in αVβ6-mediated IACs. 
 
Figure 4.9: Statistically significantly different proteins between ligands. Analysis of variance (ANOVA) 
between LAP, FN and collagen ligands normalized spectral abundance factor (NSAF) values. Statistical 
analysis was performed in Scaffold (version 4). Statistically significantly different proteins (p=<0.05) 
were mapped by log2 fold enrichment of LAP/ FN and LAP/collagen. Light blue shading corresponds 
to ≤ two-fold change. Black and white circles correspond to a significance value of p=<0.01 and <0.05, 
respectively. Gene names of key proteins are indicated in bold or regular text for p=<0.01 and p=<0.05, 
respectively. Blue arrow head indicates datapoint for TLN1. 
 
A protein-protein interaction network was constructed for statistically significantly different 
proteins that were enriched on both LAP/FN and LAP/FN, LAP/FN only and LAP/Collagen only 
(represented by the top right, top left and bottom right quadrants in Figure 4.9), arranged in 
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a hierarchical ring network (Figure 4.10). Of these proteins, 48% were unconnected by 
interaction to any others in the network, however the remaining clustered together in an 
interconnected ring. As expected, integrin β6 was clustered interacting with integrin αV, 
TGFβ1 and talin, forming the core of an αVβ6 adhesion. Peptide analysis revealed that TGFβ 
identification corresponded to the uncleaved precursor form of TGFβ that is bound to LAP. 
Therefore, here TGFβ represents the experimental ligand LAP used during the IAC isolation.  
 
Figure 4.10: Interaction network of proteins statistically significantly different between ligands and 
enriched on LAP.  Proteins arranged in a hierarchical ring network. Nodes represent proteins, and 
edges are known interactions. Node colour red to blue gradient = log2 fold enrichment LAP/collagen. 
Proteins that are enriched on collagen compared to LAP (represented in blue) are positively enriched 
on LAP compared to FN. 
Functional enrichment analysis was performed on proteins statistically significantly different 
and enriched on LAP. Over-representation of gene ontology (GO) term analysis was 
performed with KEGG (Kyoto Encyclopedia of Genes and Genomes) and Reactome pathway 
terms. GO term grouping was used to combine related terms into groups. KEGG term analysis 
identified enrichment of proteins associated with ErbB signalling, cytokine-cytokine receptor 
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interactions, Hippo pathway signalling, arrhythmogenic right ventricular cardiomyopathy 
(ARVC), MAPK signalling, fatty acid biosynthesis and endocytosis (Figure 4.11, Table 4.2).  
This identifies EGFR signalling as a key component of αVβ6 IACs, as ErbB signalling was the 
highest represented term. Interestingly, based on these analyses, ErbB signalling is more 
over-represented than adhesion signalling related terms, indicating it is highly prominent. 
Over-representation of Hippo pathway signalling, and fatty acid biosynthesis also suggests a 
potential role for αVβ6 in these processes. Reactome pathway analysis also identified ErbB 
signalling as an overrepresented term, represented by the RAF/MAPK cascade group (Figure 
4.12). 
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Figure 4.11: ClueGO KEGG Pathway term hierarchical clustering. (A) ClueGO hierarchical layout of 
represented KEGG terms. Node colour corresponds to grouping, with the lead term in corresponding 
coloured text.  Nodes with split colours belong to multiple groups. Nodes represent individual KEGG 
pathway terms. (B) Pie-chart organised by the % of genes per term. Analysis parameters: minimum 1 
gene per cluster, GO term/pathway network connectivity (Kappa score) =1; Statistical test 
Enrichment/Depletion (Two-sided hypergeometric test), Bonferroni p value correction, no p value 
threshold applied; GO term grouping based on kappa score, 50% of genes for group merge, 50% terms 
for group merge. Leading group term based on % gene/term. 
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Figure 4.12: ClueGO Reactome Pathway term hierarchical clustering.  (A) ClueGO hierarchical layout 
of represented KEGG terms. Node colour corresponds to grouping, with the lead term in 
corresponding coloured text.  Nodes with split colours belong to multiple groups. Nodes represent 
individual KEGG pathway terms. (B) Pie-chart organised by the % of genes per term. Analysis 
parameters: minimum 1 gene per cluster, GO term/pathway network connectivity (Kappa score) =1; 
Statistical test Enrichment/Depletion (Two-sided hypergeometric test), Bonferroni p value correction, 
p value threshold <0.05 applied; GO term grouping based on kappa score, 50% of genes for group 
merge, 50% terms for group merge. Leading group term based on %gene/term. 
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Leading Group 
Term 
Unique ID Group p 
value 
Bonferroni Group Genes All Term genes 
ErbB signalling 
pathway 
KEGG:04012 0.011 0.278 EGFR, ITGAV, 
SLC44A2, SMARCC2, 
TGFB1, TUBB2B. 
EGFR, PAK4 
Cytokine-
cytokine receptor 
interaction 
KEGG:04060 0.033 0.789 EGFR, RAB5C, 
TGFB1, TLN1 
EGFR, FASN, TGFB1 
Hippo signalling 
pathway 
KEGG:04390 0.503 1.000 CFL1, EGFR, FASN, 
ITGAV, ITGB6, 
KIF5B, PFN1, 
PPP2CA, PPP2R1A, 
TGFB1, TLN1, 
YWHAB, YWHAH, 
YWHAZ 
ACTB, PPP1CA, 
PPP2CA, PPP2R1A, 
PRKCI, TGFB1, 
YWHAB, YWHAH, 
YWHAQ, YWHAZ 
Arrhythmogenic 
right ventricular 
cardiomyopathy 
(ARVC) 
KEGG:05412 0.347 1.000 CFL1, DSG2, DSP, 
EGFR, ITGAV, ITGB6, 
PFN1, PPP2CA, 
PPP2R1A, TGFB1, 
TLN1 
ACTB, DSP, ITGA2, 
ITGAV, ITGB6, JUP, 
LMNA 
MAPK signalling 
pathway 
KEGG:04010 0.451 1.000 EGFR, ITGAV, ITGB6, 
SMARCC2, TGFB1, 
TLN1 
CDC42, EGFR, FASN, 
FLNA, FLNB, FLNC, 
GNG12, HSPA1A, 
HSPA8, HSPB1, RAC1, 
RAC2, RAP1A, TGFB1, 
TP53 
Fatty acid 
biosynthesis 
KEGG:00061 1.000 1.000 ACSL1, FASN ACSL1, FASN 
Endocytosis KEGG:04144 0.608 1.000 AP2A1, EGFR, KIF5B, 
RAB11A, RAB5C 
AP2A1, ARF6, ARPC3, 
ARPC4, CAPZA1, 
CDC42, CHMP4B, 
CHMP5, CHMP6, CLTC, 
EGFR, HSPA1A, HSPA8, 
KIF5B, PRKCI, RAB11A, 
RAB5C, RAB8A, RHOA 
Table 4.2: KEGG GO Term analysis. Top group leading terms and their unique GO term ID. Statistical p 
values for each group, and the Bonferroni step-down corrected p value. Group genes lists all the genes 
within the group. All term genes list all genes that are associated with the group leading term, that are 
present in the entire MS dataset.  
4.2.5 Key subnetworks 
Having identified the GO terms over-represented by proteins statistically significantly 
enriched on LAP, proteomic analysis was widened to the entire dataset to identify 
functionally linked proteins that did not meet the criteria of statistical significance or 
enrichment on LAP. All proteins associated with the leading group KEGG term were identified 
in the dataset, regardless of enrichment profile (Table 4.2). Protein-protein interaction 
networks were constructed for these proteins combined with the list of genes associated 
with the KEGG term group, and their one-hop protein interactors present in the dataset. 
Clustering was performed on these networks using the Cytoscape plug-in ‘clusterMaker2’ 
using the Community Clustering (GLay) algorithm, to identify functionally related nodes. The 
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group ‘Cytokine-cytokine receptor interaction’ was not further analysed as the predominant 
proteins related to the term were EGFR and TGFβ1. TGFβ1 represents the experimental 
ligand LAP, and EGFR is well represented across the other over-represented groups including 
ErbB signalling and MAPK signalling, making this analysis redundant. Experimental ligands 
fibronectin and collagen where identified in the one-hop neighbourhood of the networks 
were discounted from clustering analysis. 
4.2.6 ErbB and MAPK Signalling 
ErbB signalling and the related term MAPK signalling were overrepresented in the LAP 
enriched dataset. Four clusters were identified for the ErbB signalling pathway, named by a 
key protein chosen by a high level of enrichment, and close functional link to the term (Figure 
4.13). The EGFR-centric cluster contains LanC-like protein 2 (LANCL2), AP-2 complex subunit 
alpha-1 (AP2A1) and catenin delta-1 (CTNND1). LANCL2 is commonly amplified with EGFR in 
breast cancer (Eley et al., 2002), and may confer sensitivity to chemotherapy (Park and James, 
2003). AP2A1 is a subunit of AP2 which is involved in clathrin-mediated endocytosis, which 
is the predominant mechanism of internalisation for EGFR (Goh et al., 2010). Delta-catenin 
inhibits EGFR degradation and promotes ERK1/2 signalling, potentially due to higher EGFR 
levels (He et al., 2016).  
The EGFR-associated cluster contains receptor of activated protein C kinase 1 (RACK1) and 
Arf6. The canonical function of RACK1 is to bind to and stabilise active PKC, promoting PKC-
mediated phosphorylation. RACK1 over-expression is associated with metastasis and poor 
clinical outcome, which has hypothesised to be due to an associated increase in EGFR, ErbB2 
and MMP protein level (Li et al., 2012). Arf6 is often overexpressed in breast cancer and is 
activated by EGFR signalling (Morishige et al., 2008). The other three clusters include the DUB 
Probable ubiquitin carboxyl-terminal hydrolase FAF-X (USP9X), the actin regulator cofilin 
(CFL), and the serine/threonine-protein kinase PAK 4. 
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Figure 4.13: ErbB signalling pathway term subnetwork clusters. Selected key clusters from proteins 
associated with the ErbB signalling pathway KEGG term group and their one-hop interactors. Dashed 
lines from the EGFR cluster represent sub-clusters from within the large cluster. Clusters are named 
according to key proteins. Inter-cluster interactions are not shown. Nodes represent proteins, and 
edges are known interactions. Node colour red to blue gradient = log2 fold enrichment LAP/collagen. 
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The MAPK signalling pathway is canonically activated downstream of EGFR, and therefore is 
linked to ErbB signalling. The main clusters identified within the MAPK signalling pathway 
term were EGFR, Ras family GTPases, and three Rho family GTPase actin regulatory clusters 
centred on CDC42, RhoA and Rac1 (Figure 4.14). IQGAP within the EGFR cluster is a scaffold 
protein that binds to MEK and ERK2 and regulates their activity (Roy et al., 2005). The Ras 
family GTPase cluster contains isoforms of Rap1 and Ral which together with the three Ras 
isoforms (HRAS, KRAS, NRAS) comprise the Ras family (Mott and Owen, 2015).  
The Rho family GTPases also have roles in MAPK signalling. Elevated levels of RhoA-GTP are 
observed in Ras-transformed cells which inhibits expression of the cell cycle inhibitor 
p21/Waf, promoting proliferation (Sahai et al., 2001). Filamin A is also within the RhoA cluster 
and can enhance MAPK signalling by binding to β-Arrestin scaffolding proteins, promoting 
the formation of a β-Arrestin-ERK complex and ERK activation (Scott et al., 2006). Rac1 and 
CDC42 can both bind and activate PAK1, PAK2 and PAK3 kinases, which phosphorylate Raf 
and MEK promoting their signal transduction to ERK (Schwartz, 2004).  
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Figure 4.14: MAPK signalling pathway term subnetwork clusters. Selected key clusters from proteins 
associated with the MAPK signalling pathway KEGG term group and their one-hop interactors. Dashed 
lines from the EGFR and CDC42 clusters represent sub-clusters from within the large cluster. Clusters 
are named according to key proteins. Inter-cluster interactions are not shown. Nodes represent 
proteins, and edges are known interactions. Node colour red to blue gradient = log2 fold enrichment 
LAP/collagen. 
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4.2.7 Adhesion components 
The leading group term ARVC refers to an inherited cardiac myopathy, characterised by 
defects in cell-cell adhesion proteins (Indik and Marcus, 2018). As a result, this group contains 
proteins involved in cell-cell and cell-ECM adhesion. Talin and vinculin are present in the 
same cluster amongst other predominantly cadherin binding proteins (Figure 4.15). Talin 
binding links integrin β-subunit cytoplasmic domains to actin. Vinculin strengthens this 
interaction by binding talin and actin. The three proteins most highly enriched on LAP 
proteins in this cluster are profilin, S100A11 and plakophilin-3.  Profilin binds to the barbed 
end of actin monomers, preventing actin polymerisation (Pollard, 2017). S100A11 and its 
one-hop interactor annexin A1 (ANXA1) are calcium regulated proteins that can bind 
cadherin. Interestingly an annexin A1 complex with S100A11 is involved in formation of 
intraluminal vesicles in the MVB that sequester internalised EGFR from the limiting 
membrane, promoting its lysosomal targeting and degradation (Poeter et al., 2013). 
Plakophilin-3 (PKP3) is predominantly a structural protein that stabilises desmosome cell-cell 
adhesions (Hatzfeld, 2007).  
Integrins αVβ6 and α2, which are enriched on LAP and collagen respectively, cluster together 
with the ECM proteins pro-TGFβ, CYR61 and thrombospondin-1 (THBS1). CYR61 is a 
matricellular protein secreted into the ECM that has a regulatory rather than structural role 
and can be engaged by select integrins via a non-canonical non-RGD binding site (Lau, 2011). 
CYR61 has opposing effects on tumourigenesis, promoting angiogenesis, tumour growth and 
invasion when bound to αVβ3; and promoting apoptosis and senescence when bound to 
α6β1 (Lau, 2011). 
Two clusters focus on actin binding proteins, with one centred around actin isoforms, and 
the other including filamins. The most strongly enriched on LAP proteins are TAGLN2, CFL1, 
CAP1, CAPN1 and PHB. Transglein-2 (TAGLN2) stabilises actin filaments and acts as both a 
tumour promoter and suppressor (Dvorakova et al., 2014). Cofilin preferentially severs old 
GDP-bound actin filaments, promoting actin turnover which is critical for polarised growth of 
the actin network (Bravo-Cordero et al., 2013). CAP1 is an actin regulator that binds and 
sequesters G-actin monomers and also facilitates cofilin activity (Bertling et al., 2004).  CAP1 
may also have a role in IACs, as CAP1 depletion results in increased FAK activity and cell 
spreading (Zhang et al., 2013). Calpain 1 (CAPN1) is a calcium-dependent protease that 
cleaves a range of substrates including focal adhesion and actin regulatory proteins, and can 
therefore affect cell adhesion and the cytoskeleton (Lebart and Benyamin, 2006). Prohibitin 
(PHB) is a DNA synthesis inhibitor that is reported to bind actin (Sripathi et al., 2016). 
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Actin cross-linking proteins are contained in both actin-related clusters. Spectrin alpha-chain, 
non-erythrocytic 1 (SPTAN1) and Spectrin beta-chain, non-erythrocytic 2 (SPTBN2) are the 
alpha and beta chains of spectrin, and filamin A (FLNA) and filamin B (FLNB) are isoforms of 
filamin. Although not represented in these clusters the actin cross-linking protein α-actinin-
4 is also enriched on LAP. Actin cross-linking proteins have two actin-binding domains and 
enabling them to link actin filaments. The distance between actin-binding domains varies 
considerably between actin cross-linking proteins (Pollard, 2016). Filamin has widely spaced 
actin-binding domains and forms a loose network of actin such as those in lamellipodia 
(Pollard, 2016). α-actinin has closely spaced actin-binding domains and forms bundles of 
actin such as those in filopodia (Sjoblom et al., 2008). Spectrin is a long flexible protein with 
distant actin-binding sites which forms a web-like actin network that it links to the plasma 
membrane to provide mechanical support (Machnicka et al., 2014). 
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Figure 4.15: Arrhythmogenic right ventricular cardiomyopathy (ARVC) term subnetwork clusters. 
Selected key clusters from proteins associated with the ARVC KEGG term group and their one-hop 
interactors. Dashed lines from the adhesion complex cluster represent sub-clusters from within the 
large cluster. Clusters are named according to key proteins. Inter-cluster interactions are not shown. 
Nodes represent proteins, and edges are known interactions. Node colour red to blue gradient = log2 
fold enrichment LAP/collagen. 
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4.2.8 Endocytosis 
Clustering of proteins associated with the endocytosis KEGG term identified related groups 
that were divided by function broadly into internalisation, trafficking, and actin regulation 
(Figure 4.16). The internalisation and proteasomal clusters contain Rab5c, AP2A1 (AP2 
complex subunit alpha-1) and CLTC (clathrin heavy chain 1), which all have roles in clathrin-
mediated endocytosis (Merrifield and Kaksonen, 2014). The adaptor protein AP2 forms the 
inner coat of clathrin-coated vesicles and is involved in cargo selection. Clathrin assembles to 
form the curved outer coat and is recruited by adaptors such as AP2 (Merrifield and 
Kaksonen, 2014). Clathrin-mediated endocytosis is the predominant mechanism of 
internalisation for both EGFR and integrin αVβ6 (Goh et al., 2010; Ramsay et al., 2007). Rab5 
has been implicated in EGFR and integrin endocytosis, although this has only been 
demonstrated for the Rab5a isoform (Barbieri et al., 2000; Pellinen et al., 2006). Rab5 has 
been shown to associate directly with integrins and promotes focal adhesion disassembly 
(Mendoza et al., 2013; Pellinen et al., 2006). KIF5B (kinesin-1 heavy chain) is a component of 
the motor protein kinesin-1, which transports cargo anterograde along microtubules, away 
from the cell body. KIF5B clusters with its one-hop interactors PSMA5 and PSMB6 which are 
alpha type-5 and beta type-6 subunits of the proteasome catalytic core (Figure 4.16, 
proteasomal cluster). Kinesin-1 has been shown to transport the proteasome for efficient 
degradation in neurons, therefore could be postulated to have a similar function at adhesion 
sites (Otero et al., 2014). 
The vesicle recycling regulator Arf6 was clustered with USP9X (Probable ubiquitin carboxyl-
terminal hydrolase FAF-X), GDI2 (Rab GDP dissociation inhibitor beta), Rab8a and Rab1b; and 
Rab11a clustered with Rap1A and RalA (Figure 4.16, trafficking cluster). These regulators 
have roles in receptor endocytosis and at additional steps in the trafficking pathways. Three 
ESCRT-III subunits CHMP6, CHMP5 and CHMP4B were also clustered together and enriched 
on LAP (CHMP5 AND CHMP4B were positively enriched on LAP/FN). ESCRT-III is 
conventionally associated with the MVB, however novel functions have been identified for 
ESCRT-III in the maintenance of membranes (Stoten and Carlton, 2018). 
Many actin regulators were also present in the endocytosis group clusters, including the 
Arp2/3 complex subunits ARPC3 and ARPC4; CAPZA1 (F-actin-capping protein subunit alpha-
1) and the ERM family proteins MSN (moesin) and EZR (ezrin); CFL1 (cofilin), Rac1, Rac2 and 
CDC42; and the Rho GEF ARHGEF2. Actin is required for endocytosis in the formation of the 
membrane invagination structures, and is also central to vesicle motility (Smythe and 
Ayscough, 2006). 
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Figure 4.16: Endocytosis term subnetwork clusters. Selected key clusters from proteins associated with 
the endocytosis KEGG term group and their one-hop interactors. Clusters with dashed outlines are 
sub-clusters derived from larger clusters that are represented in the corresponding colour in figure 
S14. Clusters are named according to a key function or protein. Inter-cluster interactions are not 
shown. Nodes represent proteins, and edges are known interactions. Node colour red to blue gradient 
= log2 fold enrichment LAP/collagen. 
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Psoriasin (S100A7) is represented in the actin nucleation cluster as positively enriched on 
collagen compared to LAP.  Psoriasin binds directly to the cytoplasmic domain of β6 and is 
required for αVβ6-mediated invasion (Morgan et al., 2011). The profile of psoriasin was 
inconsistent between IAC MS replicates however, as psoriasin was equal between LAP and 
collagen in replicate 1, and unique to FN and collagen in replicates 2 and 3, respectively. This 
indicates a potential issue with biological replicate consistency for psoriasin. Psoriasin 
binding to collagen engaging integrins is theoretically possible as this has not been 
investigated, however these integrins lack the cytoplasmic motif in integrin β6 that mediates 
psoriasin binding (Morgan et al., 2011). Alternatively, psoriasin may bind β6 in subcellular 
compartments distinct from IACs, in which case it would not be detected in these assays. 
4.2.9 Hippo Pathway Signalling 
The Hippo signalling pathway phosphorylates and inhibits the transcriptional activators YAP 
and TAZ, preventing their translocation to the nucleus and subsequent stimulation of 
proliferative and anti-apoptotic gene transcription (Badouel and McNeill, 2011). The key 
proteins identified in the Hippo pathway signalling cluster were two subunits of protein 
phosphatase 2 A (PP2A) (PPP2CA, catalytic subunit alpha isoform; PPP2R1A, PR65 subunit), 
14-3-3 proteins (YWHAB, YWAH, YWHAQ, YWHAZ; beta/alpha, eta, theta and zeta, 
respectively), and a subunit of protein phosphatase 1 (PP1) (PPP1CA, alpha catalytic subunit) 
(Figure 4.17). 
PP2A is a negative regulator of the Hippo pathway, and thus promotes the nuclear 
translocation of YAP and TAZ. PP2A dephosphorylates MST1/2 (Mammalian STE20-like 
protein kinase 1/2), inhibiting its downstream activity activating LATS1/2 (Serine/threonine-
protein kinase LATS1/2) which phosphorylates YAP/TAZ (Guo et al., 2011) (Ribeiro et al., 
2010). 14-3-3 proteins are also negative regulators of YAP/TAZ. Phosphorylation of YAP/TAZ 
creates a binding site for 14-3-3 proteins, which when bound constrain YAP/TAZ in the 
cytoplasm (Lei et al., 2008; Zhao et al., 2007). PP1 dephosphorylates YAP/TAZ and therefore 
promotes their activity (Liu et al., 2011a; Wang et al., 2011b).  
Although not represented in the clustering, the DUB USP9X is enriched in αVβ6-mediated 
IACs on LAP (Figure 4.10) and contributes to Hippo signalling pathway regulation. USP9X has 
been shown to deubiquitinate both YAP and LATS2, stabilising them by inhibiting ubiquitin-
mediated degradation (Li et al., 2018). USP9X can therefore be both a positive and negative 
regulator of YAP/TAZ activity.  
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Figure 4.17: Hippo signalling pathway term subnetwork clusters. Selected key clusters from proteins 
associated with the hippo signalling pathway KEGG term group and their one-hop interactors. Clusters 
with dashed outlines are sub-clusters derived from larger clusters that are represented in the 
corresponding colour in figure S15. Clusters are named according to key proteins. Inter-cluster 
interactions are not shown. Nodes represent proteins, and edges are known interactions. Node colour 
red to blue gradient = log2 fold enrichment LAP/collagen. 
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Mechanical force from the cellular microenvironment is another major regulator of YAP/TAZ  
(Dupont et al., 2011). Key elements of this regulatory mechanism are the ECM, cell-cell and 
cell-ECM contacts and cytoskeletal dynamics. Integrin-mediated adhesions transmit 
mechanical force intracellularly by generating acto-myosin contractility. To determine if any 
actin regulators are differentially recruited to αVβ6-mediated IACs formed on LAP, proteins 
associated with actin binding and actin regulatory GO terms were identified within our 
dataset, that were ≥ two-fold different on LAP (Table 4.3). The majority of these proteins 
were positively enriched on LAP (26/30) and were predominantly non-actin binding 
regulators or actin crosslinkers. Proteins that were negatively enriched on LAP were 
predominantly myosins; possibly suggesting downregulated actomyosin contractility.  
Name Gene  Function 
Log2 Fold Change >Two-Fold Change 
LAP vs 
FN 
LAP vs 
Coll 
FN vs 
Coll 
LAP vs 
FN 
LAP vs 
Coll 
FN vs 
Coll 
Alpha-actinin-4 ACTN4 Cross-linking 2.85 0.42 -2.43 TRUE FALSE TRUE 
Arf6 ARF6 Actin 
regulator 
-0.35 6.53 6.77 FALSE TRUE TRUE 
Actin-related protein 2/3 complex 
subunit 4 
ARPC4 Nucleation 
5.91 -4.18 -7.83 TRUE TRUE TRUE 
Adenylyl cyclase-associated protein CAP1  Stabilising 10.97 7.7 -10.97 TRUE TRUE TRUE 
F-actin-capping protein subunit alpha-1 CAPZA1 Stabilising 1.29 -0.47 -1.76 TRUE FALSE TRUE 
Cofilin-1 CFL1 Severing 1.85 5.25 3.99 TRUE TRUE TRUE 
Elongation factor 2  EEF2 
 
8.37 0.95 -7.86 TRUE FALSE TRUE 
EGFR EGFR 
 
8.66 9.27 1.83 TRUE TRUE TRUE 
Filamin-A FLNA Cross-linking 2.79 0.85 -1.94 TRUE FALSE TRUE 
Filamin-B FLNB Cross-linking 3.65 0.77 -2.88 TRUE FALSE TRUE 
Filamin-C FLNC Cross-linking 2.02 0.18 -1.83 TRUE FALSE TRUE 
Inverted Formin-2 INF2 Nucleation 8.2 8.07 0 TRUE TRUE FALSE 
Microtubule-actin cross-linking factor 1 MACF1 Cytoskeletal 
linker 
8.38 1.56 -7.67 TRUE TRUE TRUE 
Myristoylated alanine-rich C-kinase 
substrate 
MARCKS Cross-linking 
0.24 1.43 1.2 FALSE TRUE TRUE 
Unconventional myosin-XVIIIa MYO18A Motor 
protein 
7.79 -1.35 -7.89 TRUE TRUE TRUE 
Profilin-1 PFN1 Elongation 10.97 10.97 ND TRUE TRUE FALSE 
Pleckstrin homology-like domain family 
B member 2 
PHLDB2 Actin 
regulator 
10.97 10.97 ND TRUE TRUE FALSE 
Plectin PLEC Cytoskeletal 
linker 
6.73 2.83 -5.39 TRUE TRUE TRUE 
Liprin-alpha PPFIA1 Actin 
regulator 
10.97 10.97 ND TRUE TRUE FALSE 
RhoG RHOG Actin 
regulator 
1.15 1 -0.15 TRUE TRUE FALSE 
Spectrin alpha chain, non-erythrocytic 1 SPTAN1 Cross-linking 10.97 2.88 -10.97 TRUE TRUE TRUE 
Spectrin beta chain, non-erythrocytic 1 SPTBN1 Cross-linking 10.97 4.26 -10.97 TRUE TRUE TRUE 
Pro-TGFβ1 TGFB1 Actin 
regulator 
10.97 10.97 ND TRUE TRUE FALSE 
Talin TLN1 Focal 
Adhesion 
3.16 1.4 -1.76 TRUE TRUE TRUE 
Vinculin VCL Focal 
Adhesion 
10.97 0.95 -10.97 TRUE FALSE TRUE 
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Name Gene  Function 
Log2 Fold Change >Two-Fold Change 
LAP vs 
FN 
LAP vs 
Coll 
FN vs 
Coll 
LAP vs 
FN 
LAP vs 
Coll 
FN vs 
Coll 
14-3-3 Eta YWHAH 
 
4.73 1.14 -3.94 TRUE TRUE TRUE 
Myosin-9 MYH9 Motor 
protein 
0.19 -1.29 -1.48 FALSE TRUE TRUE 
Myosin-10 MYH10 Motor 
protein 
0.22 -1.6 -1.81 FALSE TRUE TRUE 
Myosin-14 MYH14 Motor 
protein 
0.42 -2.29 -2.71 FALSE TRUE TRUE 
Leucine-rich PPR motif-containing 
protein, mitochondrial  
LRPPRC 
 
ND -10.97 -10.97 FALSE TRUE TRUE 
Table 4.3: Actin binding/regulating proteins. Proteins associated with the GO MF term’ actin binding’ 
(GO:0003779) and GO BP term ‘regulation of actin cytoskeleton organisation’ (GO:0032956). All 
proteins are ≥ two-fold different on the ligand LAP in the dataset and satisfy peptide cut-off values. 
Function annotation is manually curated as the dominant canonical function. Proteins without 
function listed have complex or ill-defined functions relating to actin. All proteins are positively 
enriched on LAP, except row myosin-9,10,14 and LRPPRC, highlighted in red/white are negatively 
enriched on LAP. 
4.2.10 Fatty Acid Biosynthesis 
The key genes within the fatty acid biosynthesis cluster are fatty acid synthase (FASN) and 
long-chain-fatty-acid--CoA ligase 1 (ACSL1) (Figure 4.18). FASN synthesises the fatty acid 
palmitate from acetyl-CoA and malonyl-CoA (Buckley et al., 2017). Palmitate is added to 
cysteine residues of proteins, by a process known as palmitoylation. Palmitoylation affects 
12% of the human proteome, and enables the reversible association of proteins with 
membranes, and can also modulate the behaviour within membranes of integral membrane 
proteins (Daniotti et al., 2017). FASN mainly localises to the cytoplasm but can be recruited 
to lipid rafts in the plasma membrane in association with caveolin-1 (Di Vizio et al., 2008). 
FASN expression and activity is associated with a poor prognosis in various cancers including 
breast, as tumour cells become ‘addicted’ to de novo synthesis of fatty acids opposed to 
dietary uptake (Buckley et al., 2017). 
ACSL1 is involved in the cellular uptake and degradation of fatty acids preferentially 
palmitoleate, oleate and linoleate, to acetyl CoA in the mitochondria (Zhan et al., 2012). 
ACSL1 co-localisation with a fatty acid transporter has been observed at the plasma 
membrane, however ACSL1 localisation is thought to be predominantly mitochondrial 
(Gargiulo et al., 1999).  
Palmitoylation is important in regulating membrane localisation of proteins, therefore 
proteins in our dataset were assessed to see if they are palmitoylated suggesting functional 
relevance of this modification. Our dataset was compared to the SwissPalm database on 
protein palmitoylation (Database release: 2 (2018-02-18) (www.swisspalm.org) (Blanc et al., 
2015). Of the 734 reviewed proteins in our dataset, 505 were observed in at least one 
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palmitome, and 220 were observed in ≥ three (Supplementary table 2). Just over half (111 
proteins) of the proteins observed in ≥ three palmitomes were ≥ two-fold enriched on LAP, 
and of these half (49 proteins) were enriched on LAP relative to FN and collagen.  Fewer 
proteins were enriched on FN or collagen compared to LAP (70), and a similar number were 
unchanged (65). This indicates FASN which is enriched on LAP, may function to recruit 
palmitoylatable proteins to αVβ6 IACs, or may be locally regulating palmitoylation at sites of 
αVβ6 engagement. 
 
Figure 4.18: Fatty acid biosynthesis term subnetwork clusters. Clusters from proteins associated with 
the fatty acid biosynthesis KEGG term group and their one-hop interactors. Inter-cluster interactions 
are not shown. Nodes represent proteins, and edges are known interactions. Node colour red to blue 
gradient = log2 fold enrichment LAP/collagen. 
4.2.11 Candidate Validation 
Having identified over-represented functional clusters and enriched proteins, we wanted to 
determine if these were increased in LAP-isolated IACs by immunoblotting in addition to MS. 
Integrin β6, EGFR and liprin α1 were unique to LAP IACs by immunoblotting (Figure 4.19 A). 
Clathrin, Rab8A, α-actinin, ARHGEF2 and Rap1A were observed in IACs on all three ligands, 
however were strongest in LAP-dependent IACs. Rap1a is present in all IACs but is strongest 
in FN and weakest in collagen. The immunoblotting data confirms the MS data for β6, EGFR, 
liprin α1, Rab8A and GEF-H1 (Figure 4.19 B). Clathrin and α-actinin were detected at higher 
levels on collagen than LAP by MS which was not reflected by immunoblotting, however they 
were all enriched on LAP compared to FN. Rap1A was detected at similar levels on FN (86%) 
and LAP and at half the amount on collagen (48%) by MS. This was confirmed by 
immunoblotting that showed similar levels of Rap1A in FN and LAP, and less in collagen IACs. 
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Figure 4.19: Proteomic candidate Validation. (A) Candidates statistically significantly enriched on LAP 
were validated by western blotting to verify their presence and distribution profile across the three 
different IAC isolation ligands. (B) MS NSAF abundance values of the candidates expressed as a 
percentage of LAP, for FN (black) and Collagen (grey) isolated IACs. Error bars = SEM of three replicates. 
(C) Validation of IAC isolation enrichment. Arrows indicate band of interest where ambiguous. 
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4.3 Discussion 
Multiple signalling pathways have been identified that are over-represented at αVβ6 IACs 
and are likely to feed into αVβ6-mediated invasion and poor cancer prognosis. The LAP based 
IAC isolation approach successfully enriched for integrin β6 and isolated proteins likely to be 
associated with αVβ6 function. Integrin αVβ6 IAC composition diverges from the 
experimentally defined consensus adhesome and literature-curated adhesome. 
4.3.1 EGFR Signalling 
ErbB and MAPK signalling are over-represented in αVβ6 IACs, and many of the enriched 
proteins within these terms are positive regulators of EGFR signalling. This demonstrates 
αVβ6 adhesions are likely to be sites of collaborative EGFR signalling.  ErbB and MAPK 
signalling is most likely to be mediated by EGFR in MDA-MB-468s, as no other ErbB receptors 
were detected in IACs. MDA-MB-468s are negative for ErbB2 expression (Figure 3.1) and are 
reported to be ErbB4 negative but ErbB3 positive (Jeong et al., 2014). ErbB3 can 
heterodimerise with EGFR when its preferential partner ErbB2 is not present (Graus-Porta et 
al., 1997). EGFR is highly overexpressed in MDA-MB-468s, therefore EGFR ErbB3 
heterodimers if present are likely to account for a minority of the EGFR dimers (Forbes et al., 
2017). ErbB3  cannot signal as a homodimer due to its truncated catalytic domain (Citri et al., 
2003). 
Endocytosis of active EGFR is required for full EGFR, ERK and PI3K phosphorylation (Murphy 
et al., 2009; Vieira et al., 1996). The DUB USP9X increases the rate of EGFR endocytosis, 
however does not appear to affect the phosphorylation levels of Akt and the MAPK Raf in 
response to EGF, although only one relevant timepoint was assessed (Savio et al., 2016). 
USP9X is essential for TGFβ signalling however and is required for TGFβ-mediated cell 
migration (Dupont et al., 2009). USP9X could therefore promote the autocrine response to 
local integrin αVβ6-mediated activation of TGFβ. 
The small GTPase Arf6 is activated by EGFR via the Arf6 GEF GEP100 (Morishige et al., 2008). 
Arf6 is part of the Arf family of Ras superfamily of small GTPases, and localises to the plasma 
membrane and endosomes where it controls vesicle trafficking (D'Souza-Schorey and 
Chavrier, 2006). EGFR-mediated activation of Arf6 increases breast cancer cell motility and 
invasion by promoting recycling of integrin β1 via Arf6-mediated trafficking (Onodera et al., 
2012). Arf6 is also involved in the trafficking of αV integrins and promotes recycling of αVβ3 
(Morgan et al., 2013). 
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EGFR signalling can also influence activity of the actin-severing protein cofilin, which 
promotes actin turnover by preferentially severing GDP-bound actin filaments (Pollard, 
2017). EGFR activates cofilin by releasing it from its inhibitory interaction with PIP2 at the 
plasma membrane, by activating PLCγ which hydrolyses PIP2 (Mouneimne et al., 2004). 
Cofilin is active when dephosphorylated, therefore its activity is dictated by its 
phosphorylation status controlled by LIM kinase (LIMK) and slingshot (SHH) phosphatase. 
EGFR can also inhibit cofilin by signalling via PI3K which stimulates the activity of LIMK which 
phosphorylates cofilin resulting in inactivation (Wang et al., 2007). The kinase PAK4 can also 
negatively regulate cofilin activity by phosphorylating and inactivating the slingshot (SSH) 
phosphatase, reducing cofilin dephosphorylation (Soosairajah et al., 2005). PAK4 and many 
of the interactors it clusters with are enriched on collagen compared to LAP IACs, suggesting 
exclusion from αVβ6-mediated IACs. 
The MAPK signalling term contained Ras and Rho family GTPases. Ras is activated in response 
to EGFR signalling, and triggers the MAPK cascade resulting in sequential recruitment and 
phosphorylation of the kinases Raf (MAPKKK), Mek (MAPKK), and Erk (MAPK). Ras was not 
detected in IACs, however the Ras related proteins Rap1a and RalA were identified, that can 
positively influence the MAPK signalling pathway. Rap1a is similar to Ras however does not 
efficiently activate the same effectors, and instead has distinct functions predominantly 
relating to cell adhesion, such as integrin activation (Lee et al., 2009; Simanshu et al., 2017). 
Rap1a has been shown to activate the MAPK pathway by binding Raf and potentiating 
downstream ERK signalling (Takahashi et al., 2017).  
RalA also has distinct effectors such as Sec5 and filamin, allowing it to regulate processes 
such as exocytosis and actin organisation through these interactions (Simanshu et al., 2017). 
Stimuli that activate Ras such as EGF stimulation also activate RalA through a Ras-dependent 
manner, mediated by the RalGDS (Ral guanine nucleotide dissociation stimulator) family that 
can bridge Ras and Ral and activate Ral (Ferro and Trabalzini, 2010). RalGEFs and RalA have 
also been implicated as important for Ras-mediated tumourigenic growth (Lim et al., 2005). 
4.3.2 YAP/TAZ nuclear localisation 
Mechanical stimulation is an important mediator of YAP/TAZ nuclear translocation and can 
override the Hippo signalling pathway (Dupont et al., 2011). YAP/TAZ can be described as 
sensors and active mediators of mechanical cues. YAP/TAZ accumulate in the nucleus in 
response to mechanical inputs such as stiff ECM and cytoskeletal tension, and relay these 
signals by activating transcription of target genes (Piccolo et al., 2014). Integrin β6 and β8 
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have a unique ability to activate TGFβ by applying force to induce a conformational change 
in LAP, thus releasing active TGFβ from its inhibitory complex (Sheppard, 2005). Both 
integrins have evolutionarily conserved specialisations for this force application and support 
cytoskeletal tensile force transmission (Dong et al., 2017). In addition, αVβ6 expression has 
been shown to enhance the ability of cells to sense and apply mechanical force (Oria et al., 
2017). 
Adaptations to transmit force to an extracellular ligand may also have relevance to the 
intracellular transmission of force.  Unpublished data from our laboratory (Mark Morgan, 
University of Liverpool) has shown that inhibition of αVβ6, or stimulation with EGF, reduces 
YAP nuclear localisation in both 2D and 3D substrates of different rigidities. This 
demonstrates αVβ6 is a positive regulator of YAP nuclear localisation. These experiments 
suggest EGFR is a negative regulator of YAP/TAZ, however these data are consistent with 
EGF-mediated induction of αVβ6 endocytosis (Figure 3.5). Reduction of YAP nuclear 
localisation in response to αVβ6 inhibition is likely mediated by force transmission, as 
inhibition of αVβ6 results in lower force application in TFM (Tod et al., 2017) and EGF 
stimulation reduces αVβ6 -mediated force transmission in TFM (unpublished data from our 
laboratory, Stephanie Mo, University of Liverpool). 
Nuclear translocation of YAP/TAZ leads to the transcription of genes associated with a poor 
clinical outcome in a range of cancers including breast (Piccolo et al., 2014). YAP/TAZ 
expression may underlie some key hallmarks of cancer such as uncontrolled proliferation and 
evasion of apoptosis (Piccolo et al., 2014). YAP/TAZ activity correlates with histological grade 
and metastases of breast cancer (Cordenonsi et al., 2011) TAZ nuclear expression is strongly 
associated with TNBC in comparison to ER/PG receptor-positive and ErbB2-positive breast 
cancer, and correlates with poorer clinical outcomes of recurrence and overall survival (Diaz-
Martin et al., 2015). Integrin αVβ6 and EGFR-mediated positive regulation of YAP/TAZ nuclear 
localisation therefore has direct clinical relevance to TNBC.  
4.3.3 Receptor trafficking and adhesion turnover 
Proteins associated with receptor endocytosis and endosomal trafficking were identified in 
αVβ6-IACs. Both integrins and EGFR can signal from endosomes, therefore endocytosis is 
unlikely to result in immediate signal termination (Alanko et al., 2015; Vieira et al., 1996). 
Indeed, endocytosis is actually required for the complete signalling response downstream of 
integrins and EGFR (Alanko and Ivaska, 2016; Tomas et al., 2014). Integrin adhesion turnover 
is co-ordinated by integrin endocytosis, as adhesion disassembly involves integrin 
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internalisation. Efficient adhesion turnover is important for co-ordinated and persistent cell 
migration. The Rho GTPase RhoG and the scaffold protein liprin α1 are both statistically 
significantly enriched on LAP IACs and are involved in adhesion turnover. Activation of RhoG 
induces β1 integrin endocytosis and is required for persistent cell migration (Bass et al., 
2011). Interestingly EGF-mediated activation of RhoG also increases the rate of EGFR 
internalisation (Samson et al., 2010).  
Liprin α1 localises to focal adhesions and forms a complex with ELKS/Rab6-interacting/CAST 
family member 1 (ERC1), Pleckstrin homology-like domain family B member 1 (PHLDB1) and 
PHLDB2 (Astro et al., 2014) which are all strongly enriched on LAP-IACs (Figure 4.10) except 
PHLDB1 which was not identified. This complex promotes internalisation of integrin β1 which 
is required for adhesion turnover at the migratory leading edge and stabilises lamellipodial 
protrusions (Astro et al., 2014; Astro et al., 2016). Liprin α1 also drives recycling of active FN-
bound integrin α5β1, controlling its polarised localisation in endothelial cells (Mana et al., 
2016). Liprin α1 is amplified in 15% of breast cancers (Dancau et al., 2010), and is associated 
with a poor prognosis and the formation of metastases (Chiaretti et al., 2016). Liprin α1 is 
required for TNBC cell invasion through promoting cell migration, lamellipodia stability and 
ECM degradation (Astro et al., 2011). Localisation of the liprin α1-ERC1-PHLDB2 complex at 
αVβ6-IACs is therefore potentially relevant for αVβ6-mediated invasion. Endocytosis of αVβ6 
is required for αVβ6-mediated migration and invasion (Ramsay et al., 2007), and therefore is 
highly relevant to αVβ6-positive cancer prognoses.  
4.3.4 Palmitoylation 
Metabolic reprogramming is a hallmark of cancer that allows cells to grow and proliferate 
intensively (Jozwiak et al., 2014). FASN is normally expressed at very low levels in adult 
tissues, however is often upregulated in cancer, where cells favour de novo lipogenesis 
opposed to uptake (Buckley et al., 2017; Flavin et al., 2010). FASN expression is associated 
with a poor prognosis in a range of a cancers, including breast (Flavin et al., 2010). 
Inhibition or knockdown of FASN decreases cell proliferation and migration (Gong et al., 
2017; Sokolowska et al., 2017). Unpublished data from Claire Wells (Kings College London) 
shows FASN inhibition reduces cell invasion and area spreading, and increases adhesion to 
Matrigel®, which collectively indicate an adhesion disassembly defect. These effects were 
rescued with palmitate, demonstrating the availability of palmitate drives the phenotype. 
Further unpublished data from Claire Wells indicates the effects of FASN on cell-ECM 
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adhesions may be mediated by the non-canonical Rho GTPase RhoU, which is regulated by 
palmitoylation (Ory et al., 2007).  
The post-translational modification palmitoylation is important for the membrane 
localisation cytosolic proteins, and the movement of transmembrane proteins which 
promotes the formation of signalling clusters (Daniotti et al., 2017). Palmitoylation positively 
mediates membrane localisation of H-Ras and N-Ras isoforms, but not K-Ras which does not 
undergo this modification (Eisenberg et al., 2013). Palmitoylation is reversible and de-
palmitoylation redistributes N-Ras to the Golgi complex and decreases short-term plasma 
membrane ERK signalling (Eisenberg et al., 2011).  
These analyses of αVβ6-IACs have generated novel insight into the functions of αVβ6-
dependent and clinically-relevant pathways. EGFR-related signalling is highly represented at 
αVβ6-IACs, strengthening our hypothesis and data demonstrating that crosstalk with EGFR is 
an important consideration for αVβ6 biology. Endocytic and trafficking regulators identified 
are interesting mediators of crosstalk between αVβ6 and EGFR, as the activity of cell surface 
receptors is controlled by their trafficking. Recruitment of FASN to αVβ6-IACs suggests 
palmitoylation could influence the dynamics of αVβ6-mediated adhesions, which may 
influence their composition and therefore function. Identification of Hippo pathway 
regulators at αVβ6-IACs provided the rationale for experiments that have demonstrated 
αVβ6 is a positive regulator of YAP nuclear localisation which has direct clinical relevance. 
Further investigation of functionally important candidate proteins aims to further elucidate 
αVβ6 biology. 
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5. Eps8 is a convergence point integrating EGFR and integrin 
crosstalk 
5.1 Introduction 
Biologically significant crosstalk exists between integrins and GFRs, mediated by a diverse 
range of mechanisms affecting receptor expression levels, activity, signalling and trafficking 
(introduction section 1.9) (Ivaska and Heino, 2011). Integration of crosstalk can be very 
complex, therefore there is a drive to understand it and identify potential mediators. 
Previous work in our laboratory employed proteomic, ontological and network analyses to 
determine the effect of acute EGF stimulation on adhesion signalling networks. To facilitate 
identification of crosstalk mediators, Nikki Paul (Humphries/Streuli labs, University of 
Manchester) used the hydrodynamic force-mediated IAC isolation protocol (Jones et al., 
2015), coupled with MS, to identify changes in IAC composition following 5 mins EGF 
stimulation. Downstream network and ontological analyses revealed a substantial decrease 
in the abundance of adhesion regulatory proteins and co-ordinators of endocytosis within 5 
minutes of EGF stimulation (Figure 5.1A and data not shown). Together these data suggested 
a mechanism of EGF-induced receptor endocytosis and adhesion complex turnover. 
Combinatorial interrogation of the networks allowed a global and dynamic view of adhesion 
and GFR crosstalk to be assembled. By interrogating network topology, Eps8 (Epidermal 
growth factor receptor kinase substrate 8) was identified as a putative node integrating α5β1 
integrin and EGFR functions (Figure 5.1 B). Eps8 was identified in α5β1-positive IACs and Eps8 
levels at IACs decreased in response to EGF stimulation. Importantly, Eps8 is a direct 
interactor of both EGFR and integrin β1 (Figure 5.1 A, B) (Calderwood et al., 2003; Castagnino 
et al., 1995). In addition, Eps8 interactors including Abi1 (Abl interactor 1) and RN-tre 
(USP6NL) were also de-enriched at IACs in response to EGF (Figure 5.1 C).  
The related Eps8-family member, Eps8-like 2 (Eps8L2), was also identified in IACs and 
exhibited a similar level of de-enrichment, however, Eps8L2 was only identified in the 2-hop 
intersect of α5β1 integrin and EGFR interactors and was not as inter-connected within the 
network as Eps8. Based on the EGF-dependent localisation of Eps8 at adhesion sites, 
identification of endocytosis by gene ontological analysis as a key EGF-dependent biological 
process at IACs, and the regulatory functions of Eps8 (outlined below); Eps8, and to a limited 
extent Eps8L2, were identified as putative regulators of EGFR and integrin crosstalk for 
further study. 
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Eps8 has been identified as a putative regulator of crosstalk between EGFR and integrins. 
Eps8 was originally identified as a substrate for EGFR that enhanced mitogenic 
responsiveness (Fazioli et al., 1993). Eps8 can directly bind the juxtamembrane region of 
EGFR (Castagnino et al., 1995), and is tyrosine phosphorylated in response to EGF (Matoskova 
et al., 1995). Eps8 has four human isoforms Eps8-like 1 (Eps8L1), Eps8L2 and Eps8-like 3 
(Eps8L3) which are homologous and have a conserved C-terminal “effector” domain 
(Tocchetti et al., 2003). A lack of phenotype in the Eps8 -/- mouse indicates redundancy in 
the Eps8 family (Scita et al., 1999). Eps8, Eps8L1 and Eps8L2 can activate Sos1 and bind actin, 
and Eps8 and Eps8L2 have overlapping expression profiles (Offenhauser et al., 2004). Eps8 
coordinates multiple signalling pathways and functions differently depending on its 
interactions to co-ordinate actin dynamics, GTPase activity and receptor trafficking (Di Fiore 
and Scita, 2002). 
Eps8 can regulate actin dynamics in a complex with Abi1 and Sos1. Abi1 functions as a 
scaffold, linking Eps8 to the bifunctional Ras/Rac-GEF Sos1 (Lanzetti et al., 2000). Eps8 
association promotes Sos1 activity, and the tri-complex exhibits Rac-specific GEF activity 
(Scita et al., 1999). The Eps8-Abi1-Sos1 complex is regulated by RTK downstream signalling. 
PI3K is recruited to active RTKs and activated by Ras, to produce PIP3, which in turn activates 
Rac-GEFs including Sos1 (Vanhaesebroeck et al., 2001).  Tri-complex-dependent Rac1 activity 
induces the formation of membrane ruffles and lamellipodia (Scita et al., 1999). 
Eps8 binds to actin directly and has actin capping and bundling capabilities (Scita et al., 2001). 
Eps8 actin-binding is also involved in establishing appropriate localisation of the Eps8-Abi1-
Sos1 complex to sites of actin re-modelling (Scita et al., 2001). Eps8 binds to the fast-growing 
barbed end of actin filaments, preventing addition of actin monomers and filament 
elongation (Disanza et al., 2004). Actin capping limits filament length and promotes actin 
branching which results in stiffer mesh-like networks, and aids polarisation by localising actin 
polymerisation (Disanza et al., 2004). Eps8 can also bind and sequester monomeric actin, 
preventing its incorporation into filaments (Hertzog et al., 2010). Eps8 is additionally capable 
of binding to the side of actin filaments and bundling actin, likely by forming homodimers or 
heterodimers with the CDC42 regulated actin-bundler IRSp53 (Hertzog et al., 2010; Vaggi et 
al., 2011). 
Eps8 can inhibit endocytosis in a complex with the Rab5-GAP RN-tre (Lanzetti et al., 2000). 
Rab5 is involved in receptor endocytosis. EGF stimulation activates Rab5 and downmodulates 
the activity of RN-tre. Eps8 binding to RN-tre recruits the complex to EGFR, enabling RN-tre 
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to inactivate Rab5, inhibiting endocytosis. Eps8 binds RN-tre and Abi1 via the same SH3 
domain, therefore RN-tre and Abi1 compete for binding and can therefore divert Eps8 
function (Lanzetti et al., 2000). Eps8 binding to actin is mediated by a different site, however 
this cannot occur for the monomeric form of Eps8 and is positively influenced by Abi1 binding 
to Eps8 (Disanza et al., 2004; Hertzog et al., 2010). 
The EGF regulated recruitment of Eps8 to IACs, its interconnectivity within the proteomic 
network indicate Eps8 could have functional relevance in integrating growth factor-mediated 
adhesion responses. Eps8 will therefore be examined as a potential mediator of EGFR and 
integrin crosstalk. Eps8 regulates EGFR endocytosis, therefore adhesion turnover and 
integrin receptor internalisation will be investigated. The effect of the diverse functions of 
Eps8 on the actin cytoskeleton will also be assessed by measuring cell membrane dynamics. 
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Figure 5.1: Network analysis of adhesion receptor-growth factor receptor crosstalk identified Eps8 as 
a putative node of signal interaction. MS dataset of IACs isolated from Eph4 cells plated on collagen 
initially, then cultured overnight with cells secreting ECM resulting in a mixed matrix environment. 
IACs were isolated under serum-free conditions or after 5 minutes EGF stimulation.  Node colour red 
to blue gradient = log2 fold enrichment EGF/serum-free.  (A) One and two-hop interactors of EGFR 
and integrin β1. (B) EGFR, integrin β1 and their one-hop intersect common interactors. (C) One and 
two-hop interactions of Eps8 and Eps8L2. 
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5.2 Results  
5.2.1 Eps8 localises to focal adhesions 
To investigate subcellular distribution of Eps8, cells were co-stained with Eps8, the canonical 
adhesion complex protein talin and phalloidin to determine if Eps8 localises to focal 
adhesions and actin, respectively. The Im+ MEF fibroblast cell line was used in addition to 
Eph4 mammary epithelial cells, as fibroblasts form robust load-bearing adhesion structures. 
Co-localisation between Eps8 and talin was observed in both Eph4 and Im+ MEF cell lines 
(Figure 5.2, Mark Morgan, unpublished data), confirming the results of the MS. Eps8 co-
localisation with actin was observed in Eph4 but not Im+ MEF cells. The cytoskeletal 
organisation differs between the two cell lines, which may account for this difference. The 
distribution of Eps8L2 was also investigated, as it was also isolated from Eph4 IACs. Eps8 co-
localised with Eps8L2 to a degree, however Eps8L2 was notably absent from talin positive 
focal adhesion structures (Figure 5.2 B). This observation was consistent with the reduced 
connectivity of Eps8L2 in enriched IACs and suggested that Eps8 may have more direct 
adhesion regulatory functions than Eps8L2. 
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Figure 5.2: Eps8 localises to integrin-associated adhesion complexes. (A) Eps8 co-localises with talin in 
Eph4 and Im+ MEF cells. Scale bar = 10 μm for Eph4 and 20 μm for Im+ MEFs. (B) Eps8 co-localises 
with talin at focal adhesions whereas Eps8L2 does not in Im+ MEF cells. Lower panel are higher 
amplification image insets. Scale bar = 20 μm. All images are maximum z-slice projections. 
Representative cells from three replicates. 
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5.2.2 Eps8 constrains EGFR and α5β1 integrin internalisation 
Ontological analysis suggested that endocytosis was a key biological process differentially 
regulated at IACs by EGF stimulation. While the effect of Eps8 on internalisation of integrins 
has never been determined, Eps8, in complex with RN-tre is known to inhibit Rab5 and 
suppress endocytosis of EGFR (Lanzetti et al., 2000). The detection of both Eps8 and RN-tre 
in isolated IACs, and the role that RN-tre plays in Rab5-dependent heterodimer-specific 
integrin endocytosis (Lanzetti et al., 2007; Palamidessi et al., 2013) led us to analyse whether 
Eps8 and Eps8L2 regulate integrin and/or EGFR trafficking. The EGF-dependent de-
enrichment of α5β1 in IACs, and the connectivity of α5β1 to Eps8 and RN-tre in the proteomic 
networks indicates this complex may have a role in α5β1 endocytosis. To determine the 
effect of Eps8 on EGFR and integrin endocytosis, constitutive and EGF ligand-stimulated 
internalisation rates of EGFR and integrin α5β1 were assessed by biochemical endocytosis 
assays in control, Eps8 and Eps8L2 knockdown Im+ MEFs. 
Under unstimulated conditions control knockdown Im+ MEFs exhibited low levels of 
constitutive endocytosis of both α5β1 and EGFR (Figure 5.3, Mark Morgan, unpublished 
data). Stimulation with EGF statistically significantly increased the rate of EGFR endocytosis 
(7.5 minutes p= 0.004; 15 minutes p= 0.005), and trended towards an increase in α5β1 
endocytosis, suggesting a level of crosstalk between EGFR and integrin α5. However, in the 
absence of EGF-stimulation, knockdown of Eps8 increased the rate of constitutive 
endocytosis in comparison to control cells of both α5β1 (7.5 minutes p= 0.023, 15 minutes 
p= 0.033) and EGFR (7.5 minutes p = 0.001, 15 minutes p= 0.017), to levels comparable to 
EGF stimulation of control cells. Stimulation with EGF in Eps8 knock-down cells slightly 
increased the rate of α5β1 and EGFR endocytosis relative to unstimulated Eps8 knock-down 
cells, which was statistically significant at 7.5 minutes for EGFR internalisation rates (7.5 
minutes Eps8 KD EGF stimulated compared to Eps8 KD nil p= 0.003). By contrast, Eps8L2 
knockdown did not statistically significantly affect either constitutive or ligand stimulated of 
α5 or EGFR endocytosis (Figure 5.3 B). Together these data show that Eps8 functions to 
constrain the endocytosis of both α5β1 and EGFR. 
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Figure 5.3: Eps8 constrains integrin α5β1 and EGFR endocytosis. EGF Stimulation increases 
endocytosis of both α5β1 and EGFR. (A) Eps8 knock down increases unstimulated constitutive and 
EGF stimulated endocytosis of α5β1 and EGFR. (B) Eps8L2 knock down does not statistically 
significantly affect α5β1 or EGFR endocytosis. Biochemical internalisation assay in Im+ MEFs. N = 3, 
data points plotted as means with SEM error bars. Statistical test = two-tailed t-test assuming 
unequal variance. * = p< 0.05 in comparison to the control KD nil. * = p< 0.05 in comparison to the 
Eps8 KD nil. 
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5.2.3 Eps8 is involved in EGF-mediated adhesion disassembly 
Adhesion disassembly is closely linked to endocytosis, as dissociation of integrin-associated 
cytoskeletal components is required to permit assembly of endocytic complexes and 
internalisation of integrins and associated proteins from the cell membrane (Ezratty et al., 
2009). As Eps8 constrains integrin α5β1 and EGFR internalisation, we assessed whether Eps8 
has a role in regulating the disassembly or remodelling of adhesions. Adhesion complex 
organisation was therefore assessed by immunofluorescence under basal and EGF-
stimulated conditions with Eps8 knockdown. (Figure 5.4, Mark Morgan, unpublished data). 
Under steady-state serum-containing conditions, α5β1 distribution is similar in control and 
Eps8 knockdown cells, however after serum-starvation α5β1 is organised in fibrillar-like 
adhesion structures in control cells, whereas in Eps8 KD cells α5β1 adhesive structures are 
disorganised (Figure 5.4). In control knockdown cells, EGF stimulation causes rapid 
disassembly of α5β1 adhesion complexes which is most evident at 15 minutes, prior to re-
assembly that is initiated from 30 minutes. However, in Eps8 knockdown cells α5β1 
adhesions do not disassemble in response to acute EGF stimulation and remain disorganised. 
Together these data indicate Eps8 is required for the organisation and EGF-mediated 
disassembly of adhesion complexes, which is likely related to Eps8-mediated regulation of 
α5β1 endocytosis. 
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Figure 5.4: Eps8 regulates adhesion complex disassembly. Eps8 is required for maintenance of 
adhesion complex organisation, and EGF-dependent adhesion complex disassembly. TIF cells were 
serum starved then stimulated with 10 ng/ml EGF. Images are maximum z-slice projections. 
Representative cells from three replicates. Scale bar = 30 μm 
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5.2.4 Effect of Eps8 on EGFR and integrin signalling 
Eps8 has been linked to EGFR signalling, as overexpression of Eps8 increases cell proliferation 
in response to EGF (Fazioli et al., 1993). Eps8 may also affect EGFR and integrin signalling by 
affecting their trafficking and consequent surface bioavailability and subcellular distribution. 
To determine the role of Eps8 in EGFR and integrin signalling, phosphorylation of canonical 
downstream signalling effectors was assessed in response to EGF with Eps8 or Eps8L2 
knockdown. No statistically significant effect was observed on the phosphorylation of EGFR 
or its downstream targets ERK or Akt in response to EGF (Figure 5.5).  
The phosphorylation of paxillin, FAK and Src which are canonically phosphorylated at IACs 
was also largely unchanged with Eps8 or Eps8L2 knockdown (Figure 5.6).  Phosphorylation 
levels of Src at Y527 was statistically significantly lower in Eps8 knock-down cells compared 
to control knock-down cells at 5 minutes EGF stimulation (Eps8 KD mean= 0.14, SD= 0.04; 
control KD mean= 0.21, SD= 0.01; p= 0.04), and significantly higher in Eps8 knock-down cells 
compared to control knock-down cells at 60 minutes EGF stimulation (Eps8 KD mean= 0.28, 
SD= 0.05; control KD mean= 0.18, SD= 0.02; p= 0.03). This trend was not observed at any 
other timepoints and therefore is unlikely to have great biological significance. These data 
indicate Eps8 and Eps8L2 do not seem to have a direct role in regulating EGFR or α5β1 
signalling. 
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Figure 5.5: Eps8 knock down does not statistically significantly affect EGFR signalling. (A) Stimulation 
of Im+ MEF cells with 10 ng/ml EGF. Western blots of phosphorylated and total levels of EGFR, 
ERK1/2, Akt. Total EGFR is normalised to tubulin due to poor staining of total EGFR. Quantification of 
phosphorylation relative to total protein levels or tubulin normalised to unstimulated control in Eps8 
KD (B) or Eps8L2 KD cells (C). N=3, error bars = SEM. Black bar = control siRNA, grey bar = Eps8 or 
Eps8L2 KD condition. 
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Figure 5.6: Eps8 knock down does not statistically significantly affect integrin signalling. A) Stimulation 
of Im+ MEF cells with 10 ng/ml EGF. Western blots of phosphorylated and total levels of paxillin, Src 
and FAK. Quantification of phosphorylation relative to total protein levels normalised to unstimulated 
control in Eps8 KD (B) or Eps8L2 KD cells (C). N=3, error bars = SEM. Black bar = control siRNA, grey bar 
= Eps8 or Eps8L2 KD condition. *  = p < 0.05. 
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5.2.5 Effect of Eps8 on cell membrane protrusion 
Eps8 is required for efficient cell migration, and influences membrane protrusion by 
promoting Rac1 activity in complex with Abi1 and Sos1, and capping or bundling actin 
(Disanza et al., 2004; Disanza et al., 2006; Scita et al., 1999). Our data have identified a key 
role for Eps8 in the regulation of α5β1 and EGFR endocytosis and EGF-dependent adhesion 
turnover. Coordinated integrin endocytosis and recycling is required for the spatio-temporal 
control of integrin-mediated adhesions and cytoskeletal dynamics, which is essential for 
membrane protrusion and retraction in cell migration (Paul et al., 2015). We therefore 
assessed the role of Eps8 on EGF-dependent cytoskeletal dynamics. Membrane protrusion 
and retraction were quantitatively analysed in cells on CDMs under serum-starved and EGF-
stimulated conditions with Eps8 and Eps8L2 knockdown. 
Control cells were contractile under serum-starved conditions, and EGF stimulation induced 
a suppression of contractility (Figure 5.7). No changes were observed in the non-directional 
membrane motility data (Figure 5.7 B), demonstrating overall dynamics were unchanged and 
only directionality was influenced. By contrast, Eps8 knockdown cells were less contractile 
than unstimulated control cells and did not respond to EGF stimulation. Serum-starved 
Eps8L2 knockdown cells exhibited similar levels of contractility to control cells, and also 
respond positively to EGF stimulation (although to a lesser degree than control knockdown). 
Thus, Eps8 is required to sustain membrane contractility in the absence of EGF and for the 
EGF-mediated stimulation of protrusion; whereas Eps8L2 is not essential for a protrusive 
response to EGF as this is only partially ameliorated with Eps8L2 knockdown. Collectively our 
data show Eps8 is required to constrain cellular functions that are stimulated by EGF, when 
Eps8 is displaced from IACs.  
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Figure 5.7: Effect of Eps8 KD on membrane protrusion and contractility. LifeAct transfected Im+ MEF 
cells were imaged on cell-derived matrices for one hour prior and post stimulation with 10 ng/ml EGF.  
Imaging was resumed approximately 10 minutes after EGF stimulation. Cell membrane tracking 
analysis was performed using the QuimP (V 17.10.02) plug-in for Image J. Directed (A) and undirected 
(B) membrane protrusion speed (nm/s) for control (black), Eps8 KD (light grey) and Eps8L2 KD (dark 
grey) cells under serum-starved and EGF stimulated conditions. Positive and negative values indicate 
membrane protrusion and contraction, respectively. Data was not statistically significant (p<0.05) by 
a two-way t-test. N =3 for control and Eps8 KD, N = 2 for Eps8L2 KD. Error bars = SEM. (C) Cell tracks 
for representative single cells in which all cell outlines are overlaid and coloured according to frame 
number.  Corresponding movies are supplementary information on the accompanying CD. Scale bar = 
10 μm. 
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5.3 Discussion 
Eps8 has been identified as a novel mediator of GFR and integrin crosstalk, with previously 
undescribed roles in integrin regulation. Eps8 localises to integrin-mediated adhesion 
complexes and is required for α5β1-mediated adhesion structural organisation. EGF 
stimulation causes de-enrichment of Eps8 and α5β1 from IACs, and results in α5β1 adhesion 
disassembly. Eps8 does not alter immediate signalling from α5β1 or EGFR, however alters 
receptor dynamics by constraining them at the cell surface. Eps8 contributes to the 
regulation of cell contractility, which is normally released by EGF signalling. We propose that 
during tissue morphogenesis and repair, Eps8 functions to spatially and temporally constrain 
endocytosis, and engagement, of α5β1 and EGFR in order to precisely co-ordinate adhesion 
disassembly, cytoskeletal dynamics and cell migration. 
It is not yet known how Eps8 is recruited to α5β1-mediated IACs. However, Eps8 can bind 
EGFR directly and therefore could be recruited via this interaction (Castagnino et al., 1995), 
as EGFR is present in the same IACs (Figure 5.1). Eps8 could also theoretically bind α5β1, as 
the isolated PTB domain of Eps8 binds the NPxY motif of integrin β1, β3 and β5 (Calderwood 
et al., 2003). Importantly, the EGFR binding region of Eps8 is separate from its PTB binding 
domain, therefore Eps8 would have the potential to bind both receptors simultaneously (Di 
Fiore and Scita, 2002). Localisation of the Eps8 binding partner RN-tre has been 
demonstrated at integrin-mediated adhesions and therefore RN-tre could also have a role in 
recruiting Eps8 (Palamidessi et al., 2013). 
Adhesions formed via α5β1 are disorganised in Eps8 knockdown cells, and do not form 
fibrillar structures that are evident in control cells (Figure 5.4). Adhesion disorganisation is 
likely linked to the increased rate of constitutive α5β1 endocytosis, as this would disrupt 
adhesion maturation into fibrillar adhesions. Adhesion organisation would also be impacted 
by Eps8-dependent changes in actin dynamics, as actomyosin-dependent contractility is 
essential for the translocation of α5β1 during fibrillar adhesion formation (Wolanska and 
Morgan, 2015). Importantly, the disorganised α5β1 adhesion structures in Eps8 knockdown 
cells do not undergo EGF-mediated disassembly, indicating Eps8 is required to functionally 
link EGF responses and adhesion disassembly. 
Eps8-dependent regulation of α5β1 endocytosis and adhesion organisation is likely to 
directly influence the ECM, as α5β1 has a major role in FN fibrillogenesis and remodelling 
(Wolanska and Morgan, 2015). Endocytosed active FN-bound α5β1 is trafficked to the 
lysosome where FN is degraded, resulting in matrix turnover (Shi and Sottile, 2008; Sottile 
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and Chandler, 2005). Unlike FN, α5β1 is recycled from the lysosome and perinuclear recycling 
compartment to the plasma membrane (Arjonen et al., 2012; Dozynkiewicz et al., 2012). 
Changes in ECM composition and structure can directly influence cellular functions. 
Eps8 and Eps8L2 knockdown did not affect phosphorylation of signalling targets downstream 
of EGFR or integrins under basal or EGF-stimulated conditions (Figure 5.5 and 5.6). Eps8 is a 
positive regulator of EGF-mediated mitogenic signals (Fazioli et al., 1993), however Eps8 
knockdown has been shown to have no effect on the level of ERK phosphorylation in 
response to EGF (Lanzetti et al., 2000). This is in agreement with our results, which suggest 
that positive regulation of cell proliferation in response to EGF by Eps8 is not due to a direct 
influence on phosphorylation of downstream effectors. Eps8 suppresses constitutive, and to 
some extent EGF-stimulated, EGFR endocytosis, which if it impacted surface-levels and 
bioavailability of EGFR, could potentially affect its signalling. However, recycling rates of EGFR 
and α5β1 have not been assessed, which if balanced with endocytosis would result in no net 
change in surface receptor levels. 
Membrane protrusion/retraction analysis demonstrated Eps8 is required for cell contractility 
in the absence of EGF (Figure 5.7). Control cells responded to EGF by decreasing contractility. 
This could be mediated by Rac1 which is activated downstream of EGFR-PI3K signalling which 
promotes the activity of the Abi1-Eps8-Sos1 complex which acts as a Rac-GEF, stimulating 
the formation of membrane ruffle protrusions (Offenhauser et al., 2004). Protrusive activity 
in Eps8 knockdown cells is unchanged with EGF stimulation, indicating the Abi1-Eps8-Sos1 
complex is required for EGF-mediated changes in cell protrusion.  
Eps8L2 knockdown cells exhibit similar levels of basal contractility as control cells. Moreover, 
Eps8L2 knockdown cells respond to EGF stimulation in a similar manner to control cells but 
to a lesser extent. This suggests that Eps8L2 does not function to supress contractility in the 
absence of EGF stimulation. However, Eps8 and Eps8L2 display the greatest protein 
homology within the Eps8 family of proteins (Offenhauser et al., 2004), so an alternative 
possibility is that the function of Eps8L2 may be compensated for by Eps8. If this were the 
case, our data suggest that Eps8 could possibly compensate for Eps8L2 knockdown, but not 
vice versa. Considerable redundancy is thought to exist within the Eps8 family, due to the 
highly conserved protein structure and apparent lack of phenotype in the Eps8 knockout 
mouse (Offenhauser et al., 2004; Scita et al., 1999). Eps8 and Eps8L2 bind and activate Sos1 
with similar kinetics, and ectopic expression of Eps8L2 can restore membrane ruffles in 
response to EGF in Eps8 knockdown cells (Offenhauser et al., 2004). However, while Eps8 and 
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Eps8L2 share 60% homology within their SH3 domains (Offenhauser et al., 2004), little is 
known about the ability of Eps8L2 to associate with RN-tre, so it is possible that Eps8 and 
Eps8L2 have differential abilities to modulate receptor trafficking. 
Eps8 knockdown cells under unstimulated conditions are less contractile than the control. 
Eps8 stimulates Rac1 activity downstream of PI3K activity, however knockdown of Eps8 has 
no effect on basal Rac1 activity levels (Scita et al., 1999).  Unpublished data from our 
laboratory (Katarzyna Wolanska, University of Liverpool) also suggests Eps8 does not 
modulate Rac1 activity levels in MEFs. Therefore, it is likely that Eps8-dependent contractility 
is a function of the actin regulatory and/or receptor trafficking regulatory roles of Eps8.  
Eps8 can function as a barbed-end actin capping protein, inhibiting filament elongation 
(Disanza et al., 2004). Actin capping proteins limit actin filament length, promoting the 
formation of a branched actin network and preventing inappropriate actin polymerisation 
(Pollard and Cooper, 2009). Loss of Eps8-mediated actin capping could result in an increase 
in uncoordinated protrusions and a less established actin-network that could be less 
contractile. In addition, the higher rate of α5β1 internalisation following Eps8 knockdown 
could limit cell contractility, as there would be fewer load-bearing cell-ECM interactions with 
the capacity to establish robust stress fibres in order to apply mechanical force. In conclusion, 
we have shown the multifunctional roles of Eps8 are likely to contribute to the regulation of 
integrin biology in an EGFR-influenced manner. 
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6. Discussion 
We have shown that integrin αVβ6 and EGFR exhibit functionally-relevant crosstalk in TNBC 
cell lines. EGFR co-localises with points of αVβ6-mediated cell-ECM adhesions, which was 
indicated by both immunofluorescence and proteomic analysis of αVβ6-IACs. Integrin αVβ6 
and EGFR crosstalk may modulate trafficking dynamics, as preliminary data suggested 
stimulation of either receptor induces co-internalisation and co-trafficking of both. Crosstalk 
also influences receptor signalling, as preliminary data showed stimulation of αVβ6 induces 
the phosphorylation of ERK which is canonically downstream of EGFR signalling.  
Unbiased interrogation of αVβ6 IAC proteomic networks revealed the composition of αVβ6-
associated adhesions and identified endocytosis and ErbB signalling as over-represented 
terms, highlighting relevant candidate proteins that may potentially regulate αVβ6-EGFR 
crosstalk. Using different cellular systems, proteomic analysis of EGF-regulated IAC 
composition identified Eps8 as a novel regulator of α5β1 and EGFR crosstalk, with roles 
affecting receptor trafficking, adhesion organisation and membrane dynamics. The potential 
for the novel functions of Eps8, revealed by these analyses, to have wider implications for 
other integrins, including αVβ6, will be considered below. 
6.1 Co-trafficking of αVβ6 and EGFR co-ordinates functional receptor 
crosstalk 
Integrin αVβ6 and EGFR co-localise at cell-ECM adhesion sites. Immunofluorescence data and 
αVβ6-IAC composition analysis indicates αVβ6 and EGFR are proximal, however it is unknown 
if the two interact. Co-immunoprecipitation of integrins and GFRs including EGFR has been 
reported (Borges et al., 2000; Yu et al., 2000), however direct interactions have not been 
robustly proven.  
Indirect interactions between integrins and GFRs can be mediated by other transmembrane 
proteins, such as syndecans and tetraspanins (Afratis et al., 2017; Byron et al., 2010; Charrin 
et al., 2014). Syndecan-4 can simultaneously bind EGFR and α6β4 integrin to form a 
trimolecular complex which is required for EGF-mediated motility (Wang et al., 2015). 
Syndecan-1 is required for the interaction between insulin-like growth factor-1 (IGF-1) and 
αVβ3 and mediates their crosstalk (Beauvais and Rapraeger, 2010). Tetraspanins can bind 
both EGFR and integrins (Odintsova et al., 2003). The interaction between some tetraspanins 
and integrins can be positively regulated by palmitoylation (Yang et al., 2004), which could 
be especially relevant for αVβ6, as FASN which produces palmitate is recruited to αVβ6-IACs. 
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Some ECM molecules can also function as bridges between integrins and GFRs, such as 
tenascin-C which can be bound by both EGFR and αVβ3 (Jones et al., 1997b; Swindle et al., 
2001). Cytoplasmic interactions may also influence association between αVβ6 and EGFR. 
Eps8 could also potentially mediate an interaction between EGFR and integrins, as Eps8 can 
bind both EGFR and integrin β-subunit cytoplasmic domain NPxY motifs, via separate 
domains (Calderwood et al., 2003; Castagnino et al., 1995). Proximity without interaction is 
also possible, and could be mediated by aggregation of integrins causing GFR co-clustering  
(Yamada and Even-Ram, 2002). 
Stimulation of either EGFR or αVβ6 triggers the endocytosis of both receptors, which then 
co-traffic to HRS-positive endosomes. Co-internalisation of these receptors is likely to affect 
the functions of both receptors both their functions. EGF stimulation reduced αVβ6-
dependent force application (Stephanie Mo, University of Liverpool), which is likely to be 
caused by EGF-mediated internalisation of αVβ6 reducing surface αVβ6 levels and therefore 
αVβ6-mediated adhesions. Reduced αVβ6-mediated force application reduces TGFβ activity, 
as αVβ6 cannot efficiently apply mechanical force to LAP (Tod et al., 2017). Thus, it is likely 
that trafficking-mediated αVβ6 and EGFR directly impacts TGFβ activation. Perturbation of 
αVβ6 and EGFR during ligand-stimulated endocytosis is required to investigate the influence 
of receptor crosstalk on trafficking. The use of super-resolution microscopy and advanced 
imaging techniques including photoactivatable EGFR and αVβ6 constructs would provide 
better spatial and temporal resolution of receptor trafficking dynamics, to enable further 
elucidation of αVβ6 and EGFR co-trafficking. Perturbation of key trafficking regulators 
identified in chapter 4 such as liprin α1 and Arf6 would allow us to dissect the mechanisms 
controlling αVβ6 and EGFR trafficking crosstalk. 
The effect of EGF and LAP stimulation on receptor recycling and overall surface levels of EGFR 
and αVβ6 is currently unknown. Imbalance in the rate of endocytosis and recycling would 
result in changes in receptor surface bioavailability. EGFR traffics to the lysosome following 
LAP-mediated internalisation, where it is likely degraded which could reduce total EGFR 
protein levels. αVβ6 does not co-localise with lysosomal markers and therefore is likely to be 
recycled back to the plasma membrane. Whilst this has not been yet been tested 
experimentally, EGFR-αVβ6 crosstalk could induce changes in plasma membrane 
bioavailability of receptors, which would be likely to influence EGFR and αVβ6-mediated cell 
migration and invasion. Importantly, the clinical αVβ6 inhibitor 264RAD stimulated the 
internalisation of both αVβ6 and EGFR in TNBC cells. Therefore, the impact of αVβ6 and EGFR 
co-trafficking is potentially relevant clinically as it may modulate the effect of therapeutically 
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targeting αVβ6. If this were the case, the EGFR status of tumours could be an important 
consideration for treatment stratification. The potential for αVβ6 and EGFR crosstalk to 
influence the response to targeted molecular therapeutics are the subject of ongoing studies 
in the Morgan and Marshall Laboratories. 
6.2 αVβ6 promotes EGFR functions 
Preliminary data showed LAP stimulation induced ERK phosphorylation, which was only 
partially ameliorated by EGFR inhibition (gefitinib treatment) in MDA-MB-468 cells, 
indicating that the process could be a consequence of ligand-independent stimulation of 
EGFR signalling or that αVβ6 directly regulated MAPK activity. Unpublished phospho-
proteomics KSEA (Kinase Substrate Enrichment Analysis) data from our collaborators 
(Caroline Sproat, Marshall laboratory, Barts Cancer Institute; analysed by Mark Morgan, 
University of Liverpool), and candidate follow-up by immunoblotting, also demonstrates 
upregulation of MAPK signalling in response to LAP stimulation (Sproat, 2017). Moreover, in 
BT-20 TNBC cells, LAP-induced induction of MAPK signalling was inhibited by gefitinib, 
suggesting that αVβ6-dependent MAPK signalling is, at least in part, EGFR-dependent. 
Together these data, when considered with the fact that MDA-MB-468 cells are resistant to 
gefitinib (IC50 = 6.8 µM) (Normanno et al., 2006), suggest that LAP-induced endocytosis of 
αVβ6 triggers EGFR-dependent MAPK activation. However, it is important to note that αVβ6 
has been reported to bind, and activate ERK, so it is possible that LAP-stimulation could 
directly contribute to ERK activation (Ahmed et al., 2002a). This study did not consider 
however the potential of crosstalk mechanisms with GFRs. 
Positive regulation of ERK signalling by αVβ6-EGFR crosstalk is a potential mechanism by 
which αVβ6 expression may result in a poor prognosis in cancer, as ERK signalling elicits 
mitogenic responses which could be linked to hallmarks of cancer such as dysregulated 
proliferation and anoikis. EGFR is linked to a poor prognosis in a range of cancers, and the 
expression of αVβ6 could function to exacerbate this, resulting in a worse prognosis with co-
expression of the both receptors. 
Unpublished data from our collaborators (Kate Moore, John Marshall laboratory, Barts 
Cancer Institute) has demonstrated that αVβ6 mediates EGFR-dependent invasion. 
Knockdown of αVβ6 or EGFR in a panel of TNBC cells (MDA-MB-468, SUM-159, BT-20) 
statistically significantly decreases cell invasion, indicating invasion is αVβ6- and EGFR-
dependent. Moreover, under control conditions stimulation with EGF statistically 
significantly increases invasion, whereas knockdown of αVβ6 completely abrogates this 
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response, suggesting αVβ6 is required for EGFR-dependent invasion. Together these data 
indicate αVβ6 has an important function in promoting and mediating EGFR-dependent 
functions with potential consequences for tumour growth and invasion.  
6.3 Novel aspects of αVβ6 biology 
Integrin αVβ6 has been relatively under-studied compared to many other integrins, and little 
is known about its function. It is clear that αVβ6 is associated with a poor prognosis in a range 
of carcinomas, which is likely to be mediated at least in part by its pro-invasive functions. 
Integrin αVβ6 is known to stimulate invasion through upregulating the expression and 
activity of proteases such as MMPs, promoting cell migration, by activating TGFβ and by 
promoting TGFβ-mediated EMT (Margadant and Sonnenberg, 2010; Morgan et al., 2004; Tod 
et al., 2017).  
Characterisation of αVβ6-IACs validated initial co-localisation data and revealed potential 
mechanisms of αVβ6-EGFR crosstalk co-ordination. Analysis has identified putative roles for 
αVβ6 in EGFR signalling, endocytosis, regulation of YAP/TAZ nuclear localisation, 
palmitoylation and adhesion turnover. All these processes could potentially contribute to 
αVβ6-mediated invasion. Proteins recruited to αVβ6-IACs and identified as functionally 
relevant currently being investigated further regarding their role to αVβ6 function. 
The identification of Hippo pathway over-representation at αVβ6-IACs provided the rationale 
for experiments investigating the role of αVβ6 in YAP/TAZ nuclear localisation. Translocation 
of YAP/TAZ to the nucleus is mediated by mechanical force, which is influenced by ECM 
rigidity which is often elevated in breast cancer (Dupont, 2016). YAP/TAZ regulate gene 
transcription, therefore elevated nuclear localisation of YAP/TAZ can lead to transcriptional 
programming of breast cancer that leads to a worse prognosis (Diaz-Martin et al., 2015). 
Inhibition of αVβ6 reduced YAP nuclear shuttling across a range of substrate rigidities, in 2D 
and 3D (unpublished data, Mark Morgan, University of Liverpool). Inhibition of αVβ6 also 
decreased RhoA activity and myosin-light chain phosphorylation (unpublished data, Mark 
Morgan, University of Liverpool). Together, these data suggest that αVβ6 blockade 
suppresses force-transmission and dysregulates YAP localisation and transcriptional 
reprogramming. Importantly, EGF stimulation also reduced nuclear YAP localisation, which 
could be a consequence of triggering αVβ6 endocytosis and limiting αVβ6 levels at the cell-
matrix interface. Although, to date, we cannot discount that the effect of EGF on YAP 
distribution is independent of αVβ6 function. 
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IAC analysis identified endocytic regulators recruited to αVβ6 IACs including a liprin-α1-
associated sub-network, that are likely to regulate αVβ6 endocytosis and adhesion turnover 
and therefore contribute to a pro-invasive phenotype in a similar manner to Hax-1 which is 
required for αVβ6 endocytosis (Ramsay et al., 2007) (Astro et al., 2014). This is the first 
comprehensive unbiased analysis of αVβ6 signalling networks and it is anticipated that the 
dataset of proteins recruited to αVβ6-mediated IACs will be a useful resource for many labs 
attempting to understand of αVβ6 biology. 
6.4 Eps8 is a novel mediator of integrin and growth factor receptor 
crosstalk 
A novel role for Eps8 has been identified in the regulation of basal and EGF-stimulated 
integrin endocytosis, adhesion organisation and membrane dynamics. While these studies 
were performed in non-tumour cell lines (Eph4, Im+ MEF & TIF), these newly identified 
functions of Eps8 are also likely to contribute to the mechanism by which Eps8 promotes cell 
migration and a poor prognosis in cancer (Cattaneo et al., 2012; Chen et al., 2015; Disanza et 
al., 2004). To follow up on these studies, it would be interesting to investigate if Eps8 is 
involved in integrin regulation and trafficking in the absence of EGFR, or in the absence of 
EGFR-coupling/binding, to determine if EGFR-mediated crosstalk is an essential requirement.  
Eps8 is reported to bind integrin β1, β3 and β5 subunits via the NPxY motif which is conserved 
across all integrin β-subunits (Calderwood et al., 2003). Eps8 binding to β6, β8 and β4 has not 
been investigated but is theoretically possible. Eps8 regulates the function of αVβ6 (Tod et 
al., 2017) therefore it is conceivable Eps8 binding to β6 could be a mechanism for this. Eps8 
stimulates αVβ6-dependent migration and inhibits αVβ6 force-application and TGFβ 
activation (Tod et al., 2017). Over-expression of Eps8 in αVβ6-positive tumours could 
contribute to a worse prognosis if it enhanced αVβ6-mediated invasion. Pro-invasive 
functions of αVβ6 have been near impossible to separate from indirect effects mediated via 
TGFβ, so the perturbation of Eps8 could provide a relevant mechanism to explore direct 
activity of αVβ6. Differentiation between αVβ6 functions is therapeutically important in 
cancers where inhibition of αVβ6 is contraindicated as TGFβ can function as a tumour 
suppressor (Thomas et al., 2006).  
6.5 The future of αVβ6 cancer therapy 
Therapeutic targeting of αVβ6 holds exciting opportunities for the treatment of TNBC which 
is in desperate need of molecular targets. 25% of TNBCs have high levels of αVβ6, and 
treatment with the αVβ6 inhibitor statistically significantly reduces tumour growth in in vivo 
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xenografts (Unpublished data, Kate Moore, John Marshall lab, Barts Cancer Institute). 
Combination of 264RAD with the EGFR inhibitor gefitinib statistically significantly further 
decreased tumour growth in the same assays, indicating co-targeting of αVβ6 and EGFR could 
be of therapeutic benefit. 
Crosstalk between αVβ6 and EGFR is likely to directly impact the consequences of αVβ6 
therapeutic inhibition. Data from this study, and other work in the Morgan Lab, indicates a 
complex relationship where αVβ6 promotes EGFR signalling and is required for EGF-mediated 
invasion (Kate Moore, Marshall Lab), and EGF-mediated internalisation of αVβ6 inhibits 
αVβ6-mediated force-application and YAP nuclear translocation. Thus, one might speculate 
that therapeutic targeting of EGFR would be contraindicated in αVβ6 positive tumours. 
However, this conflicts with the overall outcome demonstrated in in vivo xenografts. 
However, there are limitations to the clinical relevance of xenograft models and in the longer 
term it will be necessary to determine the impact of αVβ6- and EGFR-targeting in genetically-
engineered mouse models, or patient-derived xenografts, of TNBC. It will also be important 
to assess the impact of αVβ6- and EGFR-dependent transcriptional control in TNBC patient 
tissue. 
Ultimately, the success of an αVβ6 therapeutic is likely to be highly-dependent on patient 
stratification. As an example, TGFβ can function as either a tumour suppressor or promoter 
in cancer. Inhibition of αVβ6 promoted tumour growth in a PDAC mouse model, however this 
adverse effect was abrogated in a Smad4-null version of the model (Hezel et al., 2012). Thus, 
mutations in Smad4, which is essential for TGFβ signalling, are likely to be good criteria for 
predicting αVβ6 therapy success. However, to fully predict patient responses to αVβ6-
targeting drugs, and combination therapies, it will be necessary to employ single-cell next 
generation sequencing with systems-level analyses to understand the impact of key 
regulatory mechanisms on the proteomic, phospho-proteomic and transcriptional 
landscapes of both tumour and stromal cells.
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Figure S1 A: EGF stimulation induces colocalisation of β6 and EGFR with EEA1. MDA-MB-468 cells, co-
stained for β6, EGFR (D38B1) and EEA1. Single z slice shown for a juxtamembrane section of the cell.  
EGF stimulation shown in minutes. EGFR is shown at 50 - 15000 and 100 - 2000 intensity arbitrary units 
for 0, 5 and 10-minute timepoints. Scale bar = 10 μm.  N= 2, n= 13 - 20 cells per timepoint. 
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Figure S1 B: EGF stimulation induces colocalisation of β6 and EGFR with EEA1. MDA-MB-468 cells, co-
stained for β6, EGFR (D38B1) and EEA1. Single z slice shown for a juxtamembrane section of the cell.  
EGF stimulation shown in minutes. EGFR is shown at 50- 15000 and 100 - 2000 intensity arbitrary units 
for 15, 30 and 60-minute timepoints. Scale bar = 10 μm. N= 2, n= 13 - 20 cells per timepoint. 
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Figure S.2 A: EGF stimulation induces colocalisation of EGFR with LAMP2. MDA-MB-468 cells, co-
stained for β6, EGFR (D38B1) and LAMP2. Cells were pre-incubated with the lysosomal and 
proteasomal inhibitors folimycin and epoxomicin, respectively. Single z-slice shown for a 
juxtamembrane section of the cell.  EGF stimulation shown in minutes. EGFR is shown at 100 - 19000 
and 100 - 2600 intensity arbitrary units for 0, 5 and 10-minute timepoints. Scale bar = 10 μm.  N=1, n= 
15 - 20 cells per timepoint.
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Figure S.2 B: EGF stimulation induces colocalisation of EGFR with LAMP2. MDA-MB-468 cells, co-
stained for β6, EGFR (D38B1) and LAMP2. Cells were pre-incubated with the lysosomal and 
proteasomal inhibitors folimycin and epoxomicin, respectively. Single z-slice shown for a 
juxtamembrane section of the cell.  EGF stimulation shown in minutes. EGFR is shown at 100 - 19000 
and 100 - 2600 intensity arbitrary units for 15, 30, 60 and 90 minutes. Scale bar = 10 μm. N=1, n= 15 - 
20 cells per timepoint. 
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Figure S.3 A: EGF stimulation induces colocalisation of β6 and EGFR with LAMP2. MDA-MB-468 cells, 
co-stained for β6, EGFR (D38B1) and LAMP2. DMSO vehicle control for Folimycin and epoxomicin 
lysosomal and proteasomal inhibitors. Single z-slice shown for a juxtamembrane section of the cell.  
EGF stimulation shown in minutes. EGFR is shown at 100 - 19000 and 100 - 2600 intensity arbitrary 
units for 0, 5 and 10-minute timepoints. Scale bar = 10 μm.  N=1, n= 8 - 24 cells per timepoint.
Appendix 
202 
 
 
Figure S.3 B: EGF stimulation induces colocalisation of β6 and EGFR with LAMP2. MDA-MB-468 cells, 
co-stained for β6, EGFR (D38B1) and LAMP2. DMSO vehicle control for Folimycin and epoxomicin 
lysosomal and proteasomal inhibitors. Single z-slice shown for a juxtamembrane section of the cell.  
EGF stimulation shown in minutes. EGFR is shown at 100 - 19000 and 100 - 2600 intensity arbitrary 
units for 15, 30, 60 and 90 minutes. Scale bar = 10 μm.  N=1, n= 8 - 24 cells per timepoint. 
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Figure S4 A: LAP stimulation induces colocalisation of β6 and EGFR with HRS. MDA-MB-468 cells, co-
stained for β6, EGFR (D38B1) and HRS.  Single z-slice shown for a juxtamembrane section of the cell.  
LAP stimulation shown in minutes. EGFR is shown at 100 - 14000 and 120 - 500 intensity arbitrary units 
for 0, 5 and 10-minute timepoints. Scale bar = 10 μm. N=2, n= 13 - 19 cells per condition. 
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Figure S4 B: LAP stimulation induces colocalisation of β6 and EGFR with HRS. MDA-MB-468 cells, co-
stained for β6, EGFR (D38B1) and HRS.  Single z-slice shown for a juxtamembrane section of the cell.  
LAP stimulation shown in minutes. EGFR is shown at 100 - 14000 and 120 - 500 intensity arbitrary units 
for 15, 30 and 60-minute timepoints. Scale bar = 10 μm. N=2, n= 13 - 19 cells per condition. 
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Figure S5 A: LAP stimulation induces colocalisation of EGFR with LAMP2. MDA-MB-468 cells, co-stained 
for β6, EGFR (D38B1) and LAMP2. DMSO vehicle control. Single z-slice shown for a juxtamembrane 
section of the cell.  LAP stimulation shown in minutes. EGFR is shown at 160 - 47000 and 160 - 3700 
intensity arbitrary units for 0, 10 and 15-minute timepoints. Scale bar = 10 μm.  N=1, n= 15-17 cells 
per condition 
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Figure S5 B: LAP stimulation induces colocalisation of EGFR with LAMP2. MDA-MB-468 cells, co-stained 
for β6, EGFR (D38B1) and LAMP2. DMSO vehicle control. Single z-slice shown for a juxtamembrane 
section of the cell.  LAP stimulation shown in minutes. EGFR is shown at 160 - 47000 and 160 - 3700 
intensity arbitrary units for 0, 10 and 15-minute timepoints. Scale bar = 10 μm.  N=1, n= 15-17 cells 
per condition. 
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Figure S6: Validation of integrin-associated complex enrichment. Western blotting in total cell lysate 
(TCL) and isolated integrin-associated complexes (IAC) for the adhesome components integrin β6, 
vinculin, talin, src (GD11), EGFR (sc-03), and negative control proteins GAPDH, HSP70, and BAK from 
other subcellular compartments. Blots of N2 that was analysed subsequently by mass spectrometry. 
 
 
Figure S7: Validation of integrin-associated complex enrichment. Western blotting in total cell lysate 
(TCL) and isolated integrin-associated complexes (IAC) for the adhesome components integrin β6, αv, 
vinculin, talin, Src (GD11), EGFR (sc-03), and negative control proteins GAPDH, HSP70, and BAK from 
other subcellular compartments. Blots of N3 that was analysed subsequently by mass spectrometry. 
 
  
Appendix 
208 
 
 
 
 
 
 
 
 
 
 
Figure S8: Representation of consensus adhesome proteins represented in the IAC dataset. Figure is 
adapted from Horton et al depicting a schematic of key signalling axes formed by the consensus 
adhesome proteins (Horton et al., 2015b). Proteins outlined with a red box indicate connected 
consensus adhesome proteins that were present in our IAC dataset. 
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Figure S9: ≥ 1.5-fold different proteins on LAP versus collagen.  Total number of proteins = 256. Nodes 
represent proteins and edges are known interactions. Node colour red to blue gradient = log2 fold 
enrichment LAP/collagen.
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Figure S10: ≥ 5-fold different proteins on LAP versus collagen.  Total number of proteins = 113. 
Nodes represent proteins and edges are known interactions. Node colour red to blue gradient = log2 
fold enrichment LAP/collagen. 
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Figure S11: ≥ 1.5-fold different proteins on LAP versus fibronectin. Total number of proteins = 201. 
Nodes represent proteins and edges are known interactions. Node colour red to blue gradient = log2 
fold enrichment LAP/FN. 
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Figure S12: ≥ 5-fold different proteins on LAP versus fibronectin. Total number of proteins = 110. Nodes 
represent proteins and edges are known interactions. Node colour red to blue gradient = log2 fold 
enrichment LAP/FN. 
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Figure S13: Statistically significantly different proteins between ligands. Analysis of variance (ANOVA) 
between LAP, FN and collagen ligands normalized spectral abundance factor (NSAF) values. Proteins 
are mapped by log2 fold enrichment of LAP/ FN and LAP/collagen. Statistical significance p=<0.01. 
Gene names colour co-ordinated with the corresponding data point symbol. 
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Figure S14: Endocytosis term large subnetwork clusters. Large clusters from which smaller clusters in 
figure 4.16 were derived. Clusters are colour matched, with a continuous outline for the large cluster, 
and dashed outline for the smaller derivative. Clusters are from proteins associated with the 
endocytosis KEGG term group and their one-hop interactors. Inter-cluster interactions are not shown. 
Nodes represent proteins, and edges are known interactions. Node colour red to blue gradient = log2 
fold enrichment LAP/collagen. 
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Figure S15: Hippo signalling pathway term large subnetwork clusters. Large clusters from which 
smaller clusters in figure 4.17 were derived. Clusters are colour matched, with a continuous outline 
for the large cluster, and dashed outline for the smaller derivative. Clusters are from proteins 
associated with the hippo signalling pathway KEGG term group and their one-hop interactors. Inter-
cluster interactions are not shown. Nodes represent proteins, and edges are known interactions. Node 
colour red to blue gradient = log2 fold enrichment LAP/collagen. 
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Figure S16: Knockdown levels of Eps8 and Eps8L2. Immunoblotting levels of Eps8, Eps8L2 and tubulin 
for replicate 1 (A), 2 (B) and 3 (C). Average percentage knockdown quoted for all EGF stimulation 
timepoints. (C) Replicate 3 half the amount of Eps8L2 sample protein was loaded (5 μg for kd, 10 μg 
for control samples). 
